Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
31000.0 | 2023-05-19 00:00:00 UTC | Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval | ABT | https://www.nasdaq.com/articles/abbotts-abt-assert-iq-cardiac-monitor-receives-fda-approval | nan | nan | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. This approval adds to Abbott's line-up of remote patient management and treatment tools that can support doctors more effectively.
The latest approval bolster Abbott’s cardiac rhythm management business.
More on Assert-IQ
Abbott's Assert-IQ ICM uses Bluetooth® technology to stay linked to a transmitter, typically the patient's own cell phone, where it continuously monitors heart rhythms and sends real-time results to the clinic's portal. Assert-IQ ICM models can also be remotely programmed, which enables doctors to change the associated device's settings, improve performance and reduce pointless warnings or transmissions — without needing the patient to come to the clinic.
The Assert-IQ ICM increased diagnostic capabilities to give doctors more clinically applicable knowledge about the patient's cardiovascular health and facilitate quicker clinical decisions.
Image Source: Zacks Investment Research
The Assert-IQ helps doctors monitor for at least six years by providing a lengthy battery life. That is especially useful when providing care for patients who are receiving therapy, have recently undergone cardiac ablation or may be at risk of developing new arrhythmias, such as AFib.
Benefits of Assert-IQ
When compared with other diagnostic techniques in the market for diagnosing abnormal cardiac rhythms, the Assert-IQ ICM marks a major improvement. Patients can go about their regular lives and engage in the activities they enjoy while the ICM performs its function. The device is tiny and implanted just beneath the skin. With the use of Assert-IQ ICM's sophisticated algorithms, doctors can choose a course of therapy for even difficult-to-find anomalies. It can be a very useful technique for managing cardiac arrhythmia diseases both temporarily and permanently.
More physicians are using ICM technology to remotely monitor their patients to better identify the underlying causes of symptoms that may have an impact on general health and the quality of life as the prevalence of irregular cardiac rhythms like atrial fibrillation rises. The Assert-IQ test by Abbott ICM provides doctors with a linked health tool so they can give their patients the best care possible and make more accurate and knowledgeable treatment decisions.
Industry Prospects
Per a report by Grand View Research, the global cardiac rhythm management devices market size was valued at USD 18.8 billion in 2022 and is estimated to expand at a CAGR of 5.50% by 2030. The growing prevalence of various cardiovascular diseases, such as arrhythmia and atrial fibrillation, are driving the market.
Recent Developments
In May 2023, Abbott unveiled several new programs within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. The latest additions to Abbott's Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in the business's own clinical trials during the initiative's first year.
In March 2023, Abbott’s latest addition to the Epic surgical valve platform, the Epi Max stented tissue valve, received FDA approval. The design of the device is optimized to improve valve blood flow and will be used to treat aortic regurgitation or stenosis.
Price Performance
In the past year, Abbott’s shares declined up 4.2% compared with the industry’s fall of 28.9%.
Zacks Rank & Other Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Addus Homecare Corporation ADUS, Merit Medical Systems, Inc. MMSI and Davita Inc DVA.
The Zacks Consensus Estimate for Addus Homecare’s 2023 earnings indicates 10.9% year-over-year growth. The Zacks Consensus Estimate for ADUS’s 2023 earnings has moved 0.5% north in the past 30 days.
Addus Homecare has a long-term estimated growth rate of 11.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical reported a first-quarter 2023 adjusted EPS of 64 cents, beating the Zacks Consensus Estimate by 16.4%. Revenues of $297.6 million surpassed the Zacks Consensus Estimate by 5.9%. It currently carries a Zacks Rank #2.
Merit Medical has a long-term estimated growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
DaVita, carrying a Zacks Rank #2 at present, has a long-term estimated growth rate of 14.6%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.3%.
DaVita has lost 1.9% compared with the industry’s 18% decline over the past year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Assert-IQ ICM models can also be remotely programmed, which enables doctors to change the associated device's settings, improve performance and reduce pointless warnings or transmissions — without needing the patient to come to the clinic. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. The Assert-IQ ICM increased diagnostic capabilities to give doctors more clinically applicable knowledge about the patient's cardiovascular health and facilitate quicker clinical decisions. | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. More on Assert-IQ Abbott's Assert-IQ ICM uses Bluetooth® technology to stay linked to a transmitter, typically the patient's own cell phone, where it continuously monitors heart rhythms and sends real-time results to the clinic's portal. | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. The latest approval bolster Abbott’s cardiac rhythm management business. |
31001.0 | 2023-05-19 00:00:00 UTC | Abbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound? | ABT | https://www.nasdaq.com/articles/abbott-abt-down-1.7-since-last-earnings-report%3A-can-it-rebound | nan | nan | A month has gone by since the last earnings report for Abbott (ABT). Shares have lost about 1.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Abbott due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Abbott's Q1 Earnings and Revenues Beat Estimates
Abbott reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%.
The quarter’s adjustments include 28 cents of certain non-recurring items.
GAAP EPS came in at 75 cents, plunging 45.3% year on year.
First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 1.1%.
On an organic basis (excluding the impact of foreign exchange), sales rose 10.3% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics.
In the first quarter, Established Pharmaceuticals sales increased 3.7% on a reported basis (up 11.1% on an organic basis) to $1.19 billion. Organic sales in key emerging markets improved 8.3% year over year. According to Abbott, organic sales improvement was backed by growth in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management.
The Medical Devices business sales rose 8.5% year over year on a reported basis (up 12.4% on an organic basis) at $3.90 billion. Sales growth was led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer Amulet, Navitor, TriClip, Aveir and CardioMEMS.
Diabetes Care reported organic growth of 21% year over year, led by FreeStyle Libre, which contributed $1.2 billion in revenues in the reported quarter. Structural Heart sales rose 16.4% and Heart Failure sales improved 13.6% year over year organically. The Vascular business recorded an organic sales growth of 3.9%% in the quarter under review. Electrophysiology, Rhythm Management and Neuromodulation recorded organic growth of 8.8%, 4% and 11.2%, respectively, in the quarter under review.
Nutrition sales rose 3.8% year over year on a reported basis (up 10.3% on an organic basis) to $1.97 billion. Pediatric Nutrition sales registered an 18.4% growth on an organic basis.
Adult Nutrition sales improved 4.2% organically. Per the company, Adult Nutrition sales benefited from strong sales performance of Abbott's complete and balanced nutrition brand, Ensure, globally.
Diagnostics sales were down 48.9% year over year on a reported basis (down 47.1% on an organic basis) to $2.69 billion. Core Laboratory Diagnostics sales were up 5.1% organically. Molecular Diagnostics declined 64% on an organic basis. Rapid Diagnostics sales declined 64.5% on an organic basis, whereas Point of Care Diagnostics sales rose 5.7% organically.
Margins
Gross profit in the reported quarter fell 21.6% year over year to $5.42 billion. Gross margin contracted 251 basis points (bps) to 55.6%.
Selling, general and administrative expenses were down 0.9% year over year to $2.76 billion. Research and development expenses declined 6.2% year over year to $654 million.
The company reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Adjusted operating margin, too, contracted 827 bps to 20.5%.
2023 Guidance
Abbott provided its 2023 Earnings Per Share guidance.
Full-year adjusted earnings (excluding specified items of $1.25 per share) are expected to be in the range of $4.30 to $4.50. The current Zacks Consensus Estimate is pegged at $4.36.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high-single digits and COVID testing-related sales of around $1.5 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Abbott has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Abbott has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A month has gone by since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. | A month has gone by since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott's Q1 Earnings and Revenues Beat Estimates Abbott reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. | A month has gone by since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Medical Devices business sales rose 8.5% year over year on a reported basis (up 12.4% on an organic basis) at $3.90 billion. | A month has gone by since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott's Q1 Earnings and Revenues Beat Estimates Abbott reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. |
31002.0 | 2023-05-19 00:00:00 UTC | Abbott Announces FDA Approval For TactiFlex Ablation Catheter | ABT | https://www.nasdaq.com/articles/abbott-announces-fda-approval-for-tactiflex-ablation-catheter | nan | nan | (RTTNews) - Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology. Used to perform an ablation procedure to treat atrial fibrillation, the TactiFlex catheter can result in reduced procedure times and better safety when compared to the company's previous generation catheters.
The TactiFlex catheter is designed to be used with Abbott's EnSite X EP System, which allows physicians to identify areas in the heart that require ablation. The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall.
The TactiFlex catheter is approved for use in Europe, Japan, Africa and Australia.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology. The TactiFlex catheter is designed to be used with Abbott's EnSite X EP System, which allows physicians to identify areas in the heart that require ablation. The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall. | (RTTNews) - Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology. The TactiFlex catheter is designed to be used with Abbott's EnSite X EP System, which allows physicians to identify areas in the heart that require ablation. The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall. | (RTTNews) - Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology. Used to perform an ablation procedure to treat atrial fibrillation, the TactiFlex catheter can result in reduced procedure times and better safety when compared to the company's previous generation catheters. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology. Used to perform an ablation procedure to treat atrial fibrillation, the TactiFlex catheter can result in reduced procedure times and better safety when compared to the company's previous generation catheters. The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall. |
31003.0 | 2023-05-18 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABT | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-82 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Chevron Corporation (Symbol: CVX) $155.71 $190.39 22.27%
Nucor Corp. (Symbol: NUE) $139.64 $161.17 15.42%
Johnson & Johnson (Symbol: JNJ) $158.99 $183.31 15.30%
California Water Service Group (Symbol: CWT) $56.09 $64.67 15.29%
Abbott Laboratories (Symbol: ABT) $108.82 $124.44 14.35%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
Chevron Corporation (Symbol: CVX) 3.88% 22.27% 26.15%
Nucor Corp. (Symbol: NUE) 1.46% 15.42% 16.88%
Johnson & Johnson (Symbol: JNJ) 2.99% 15.30% 18.29%
California Water Service Group (Symbol: CWT) 1.85% 15.29% 17.14%
Abbott Laboratories (Symbol: ABT) 1.87% 14.35% 16.22%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
Chevron Corporation (Symbol: CVX) $5.44 $5.77 6.07%
Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60%
Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60%
California Water Service Group (Symbol: CWT) $0.96 $1.02 6.25%
Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on CWT — FREE
Get the latest Zacks research report on ABT — FREE
Dividend Growth Stocks: 25 Aristocrats »
Also see:
Institutional Holders of FVAC
SJB Options Chain
MDYV shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on CWT — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » Also see: Institutional Holders of FVAC SJB Options Chain MDYV shares outstanding history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Chevron Corporation (Symbol: CVX) $155.71 $190.39 22.27% Nucor Corp. (Symbol: NUE) $139.64 $161.17 15.42% Johnson & Johnson (Symbol: JNJ) $158.99 $183.31 15.30% California Water Service Group (Symbol: CWT) $56.09 $64.67 15.29% Abbott Laboratories (Symbol: ABT) $108.82 $124.44 14.35% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.88% 22.27% 26.15% Nucor Corp. (Symbol: NUE) 1.46% 15.42% 16.88% Johnson & Johnson (Symbol: JNJ) 2.99% 15.30% 18.29% California Water Service Group (Symbol: CWT) 1.85% 15.29% 17.14% Abbott Laboratories (Symbol: ABT) 1.87% 14.35% 16.22% Another consideration with dividend growth stocks is just how much the dividend is growing. | Chevron Corporation (Symbol: CVX) $155.71 $190.39 22.27% Nucor Corp. (Symbol: NUE) $139.64 $161.17 15.42% Johnson & Johnson (Symbol: JNJ) $158.99 $183.31 15.30% California Water Service Group (Symbol: CWT) $56.09 $64.67 15.29% Abbott Laboratories (Symbol: ABT) $108.82 $124.44 14.35% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.88% 22.27% 26.15% Nucor Corp. (Symbol: NUE) 1.46% 15.42% 16.88% Johnson & Johnson (Symbol: JNJ) 2.99% 15.30% 18.29% California Water Service Group (Symbol: CWT) 1.85% 15.29% 17.14% Abbott Laboratories (Symbol: ABT) 1.87% 14.35% 16.22% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.44 $5.77 6.07% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% California Water Service Group (Symbol: CWT) $0.96 $1.02 6.25% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% These five stocks are part of our full Dividend Aristocrats List. | Chevron Corporation (Symbol: CVX) $155.71 $190.39 22.27% Nucor Corp. (Symbol: NUE) $139.64 $161.17 15.42% Johnson & Johnson (Symbol: JNJ) $158.99 $183.31 15.30% California Water Service Group (Symbol: CWT) $56.09 $64.67 15.29% Abbott Laboratories (Symbol: ABT) $108.82 $124.44 14.35% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.88% 22.27% 26.15% Nucor Corp. (Symbol: NUE) 1.46% 15.42% 16.88% Johnson & Johnson (Symbol: JNJ) 2.99% 15.30% 18.29% California Water Service Group (Symbol: CWT) 1.85% 15.29% 17.14% Abbott Laboratories (Symbol: ABT) 1.87% 14.35% 16.22% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.44 $5.77 6.07% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% California Water Service Group (Symbol: CWT) $0.96 $1.02 6.25% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% These five stocks are part of our full Dividend Aristocrats List. | Chevron Corporation (Symbol: CVX) $155.71 $190.39 22.27% Nucor Corp. (Symbol: NUE) $139.64 $161.17 15.42% Johnson & Johnson (Symbol: JNJ) $158.99 $183.31 15.30% California Water Service Group (Symbol: CWT) $56.09 $64.67 15.29% Abbott Laboratories (Symbol: ABT) $108.82 $124.44 14.35% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.88% 22.27% 26.15% Nucor Corp. (Symbol: NUE) 1.46% 15.42% 16.88% Johnson & Johnson (Symbol: JNJ) 2.99% 15.30% 18.29% California Water Service Group (Symbol: CWT) 1.85% 15.29% 17.14% Abbott Laboratories (Symbol: ABT) 1.87% 14.35% 16.22% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.44 $5.77 6.07% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% California Water Service Group (Symbol: CWT) $0.96 $1.02 6.25% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% These five stocks are part of our full Dividend Aristocrats List. |
31004.0 | 2023-05-18 00:00:00 UTC | iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-core-sp-total-u.s.-stock-market-etf-experiences-big-inflow-2 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $96.0 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 455,200,000 to 456,250,000). Among the largest underlying components of ITOT, in trading today McDonald's Corp (Symbol: MCD) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average:
Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $96.36 as the 52 week high point — that compares with a last trade of $91.81. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
PANW Price Target
Top Ten Hedge Funds Holding REG
AGC Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ITOT, in trading today McDonald's Corp (Symbol: MCD) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of ITOT, in trading today McDonald's Corp (Symbol: MCD) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $96.36 as the 52 week high point — that compares with a last trade of $91.81. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of ITOT, in trading today McDonald's Corp (Symbol: MCD) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $96.0 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 455,200,000 to 456,250,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $96.36 as the 52 week high point — that compares with a last trade of $91.81. | Among the largest underlying components of ITOT, in trading today McDonald's Corp (Symbol: MCD) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $96.0 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 455,200,000 to 456,250,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $96.36 as the 52 week high point — that compares with a last trade of $91.81. |
31005.0 | 2023-05-18 00:00:00 UTC | Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor | ABT | https://www.nasdaq.com/articles/abbott-laboratories-says-fda-approves-assert-iq-insertable-cardiac-monitor | nan | nan | (RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely.
Using Bluetooth technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter - usually the person's own cell phone - where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal.
The Assert-IQ ICM also offers advanced diagnostic capabilities to provide physicians with more clinically relevant information about the cardiovascular health of the patient, allowing care providers to make clinical decisions faster.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely. Using Bluetooth technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter - usually the person's own cell phone - where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal. | (RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely. Using Bluetooth technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter - usually the person's own cell phone - where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal. | (RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. The Assert-IQ ICM also offers advanced diagnostic capabilities to provide physicians with more clinically relevant information about the cardiovascular health of the patient, allowing care providers to make clinical decisions faster. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely. Using Bluetooth technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter - usually the person's own cell phone - where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal. |
31006.0 | 2023-05-17 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-18 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31007.0 | 2023-05-17 00:00:00 UTC | Billionaire Paul Tudor Jones Pours Millions Into These 2 Stocks Amid Recession Fears | ABT | https://www.nasdaq.com/articles/billionaire-paul-tudor-jones-pours-millions-into-these-2-stocks-amid-recession-fears | nan | nan | The assumption among most financial prognosticators is that a recession is most likely on the way, and one prominent name agrees it’s all but inevitable. Legendary investor Paul Tudor Jones sees a recession coming and even has an idea of when it will hit.
The Tudor Investment Corp founder and billionaire expects a recession will come into play this fall, mainly as a result of the surge in debt and asset prices in recent years. Such activities are usually followed by an economic downturn.
"Historically, it's about a two year lag when that really really bites, and you go into recession," Tudor Jones explained. "That would be third quarter this year, there's a good chance that – based on our most recent financial episode – there's a really good chance that we're on the verge of looking like or actually going into recession."
That’s not to say it’s time to walk away from the stock market. In fact, Tudor Jones has been padding the portfolio with the equites he sees as well-equipped to deal with an upcoming recession – he’s been pouring millions into several. We ran a couple of new additions to his stock collection through the TipRanks database to also gauge Street sentiment toward these names. Here are the results.
Abbott Laboratories (ABT)
During periods of economic downturn, healthcare stocks are often regarded as defensive investments due to their resilience and stability in the face of recessionary pressures. This holds true for Abbott Laboratories.
Founded all the way back in 1888, Abbott is a multinational healthcare firm renowned for its extensive range of products and services in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. With a rich history, a global presence in more than 160 countries, approximately 115,000 employees, and a market capitalization of $189 billion, Abbott has earned a reputation for innovation and holds a significant position in the industry.
Investors gave the thumbs up to the company's latest quarterly results, despite the numbers showing a drop compared to the year-ago period. While revenue fell by 18.5% year-over-year to $9.7 billion, the figure just edged ahead of the consensus estimate. The company stated that the sales drop was due to an expected decline in COVID-19 testing-related sales compared to the previous year. On the bottom line, adjusted EPS declined by 40.5% from the same period a year ago to $1.03, but that figure exceeded the forecast by $0.05. Regarding the yearly outlook, the company maintained its forecast of adjusted EPS in the range of $4.30 to $4.50.
Tudor Jones must like what’s on offer here. He opened a new position in ABT during the first quarter, with the purchase of 139,628 shares. These are now worth $15.13 million.
The company also has a fan in Morgan Stanley analyst Cecilia Furlong. She says of the company: “Abbott possesses a strong balance sheet, supporting a faster organic growth profile in the base (ex-COVID Dx) business in 2023-2025, with 1Q results highlighting base business strength. Recent headwinds, including the infant formula recall, alongside macro pressures on supply and margins, continue to improve, and at current levels we remain constructive going forward on Abbott given its peer-leading organic growth profile (ex-COVID Dx), diversified business composition, continued core margin expansion opportunity post-COVID, and below-peer net leverage, creating optionality."
Quantifying this stance, Furlong rates ABT shares an Overweight (i.e. Buy) while her $133 price target suggests share will appreciation of ~23% for the year ahead. (To watch Furlong’s track record, click here)
Elsewhere on the Street, the stock garners an additional 11 Buys, and 1 Hold and Sell, each, for a Strong Buy consensus rating. Going by the $123.79 average target, the shares will climb 14% higher over the coming months. As an added bonus, the company also has a dividend which it has regularly increased over the years. The current payout stands at $0.51 and yields 1.78%. (See ABT stock forecast)
Johnson & Johnson (JNJ)
From one healthcare giant to an even bigger one. With a market-cap over $411 billion, Johnson & Johnson is one of the largest healthcare corporations in the world. The company operates through three business segments: pharmaceuticals, medical devices, and consumer health.
In the pharmaceutical sector, Johnson & Johnson develops and markets a diverse portfolio of prescription drugs, with a focus on areas such as oncology, immunology, neuroscience, and infectious diseases. The company's medical devices segment manufactures and sells a broad range of innovative medical equipment, including surgical instruments, orthopedic devices, cardiovascular products, and diagnostics. Additionally, Johnson & Johnson offers a variety of consumer healthcare products, such as over-the-counter medicines, baby care items, oral care products, and beauty and skincare brands.
The value proposition proved advantageous for the company in the most recently reported quarter, 1Q23. The company delivered revenue of $24.7 billion, reflecting a 5.6% year-over-year increase and surpassing the forecast by $1.09 billion. Moreover, the adjusted EPS of $2.68 exceeded the analysts' anticipated $2.50.
Even better, the company raised both its sales and earnings outlook for FY23. Additionally, the dividend got a boost, seeing a 5.3% increase to $1.19 per share. The payout currently provides a yield of 2.81%.
Tudor Jones enters the frame here with the purchase of 216,183 shares in Q1, a new position in JNJ that is now worth more than $34.23 million.
Jones is not the only one backing JNJ’s cause. Hailing a 'beat and raise' quarter, Cantor analyst Louise Chen sings the healthcare giant’s praises and believes the stock is undervalued.
"The strength and durability of JNJ's business segments remain underappreciated, in our view,” Chen said. “We continue to believe that upward earnings estimate revisions and multiple expansion to 15-20x 2023E EV/EBITDA now from ~13x, driven by above-market growth in its key franchises, should move JNJ shares higher."
These comments form the basis for Chen’s Overweight (i.e., Buy) rating, while her $215 Street-high price target implies shares will rise by 36% over the next year. (To watch Chen’s track record, click here)
Looking at the ratings breakdown, based on a total of 5 Buys and 12 Holds, the analyst consensus rates the stock a Moderate Buy. The forecast calls for one-year returns of 13.5%, considering the average target stands at $179.52. (See JNJ stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) During periods of economic downturn, healthcare stocks are often regarded as defensive investments due to their resilience and stability in the face of recessionary pressures. He opened a new position in ABT during the first quarter, with the purchase of 139,628 shares. Quantifying this stance, Furlong rates ABT shares an Overweight (i.e. Buy) while her $133 price target suggests share will appreciation of ~23% for the year ahead. | Abbott Laboratories (ABT) During periods of economic downturn, healthcare stocks are often regarded as defensive investments due to their resilience and stability in the face of recessionary pressures. (See ABT stock forecast) Johnson & Johnson (JNJ) From one healthcare giant to an even bigger one. He opened a new position in ABT during the first quarter, with the purchase of 139,628 shares. | Quantifying this stance, Furlong rates ABT shares an Overweight (i.e. Buy) while her $133 price target suggests share will appreciation of ~23% for the year ahead. Abbott Laboratories (ABT) During periods of economic downturn, healthcare stocks are often regarded as defensive investments due to their resilience and stability in the face of recessionary pressures. He opened a new position in ABT during the first quarter, with the purchase of 139,628 shares. | (See ABT stock forecast) Johnson & Johnson (JNJ) From one healthcare giant to an even bigger one. Abbott Laboratories (ABT) During periods of economic downturn, healthcare stocks are often regarded as defensive investments due to their resilience and stability in the face of recessionary pressures. He opened a new position in ABT during the first quarter, with the purchase of 139,628 shares. |
31008.0 | 2023-05-16 00:00:00 UTC | Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain | ABT | https://www.nasdaq.com/articles/abbott-says-fda-approves-spinal-cord-stimulation-devices-to-treat-chronic-back-pain | nan | nan | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain.
Abbott's DISTINCT study, which enrolled 270 participants who suffered for an average of 12.8 years with pain, is the largest randomized controlled trial for SCS in people with chronic back pain when surgery is not an option.
Results at six months for the first 200 patients demonstrated clear clinical evidence supporting BurstDR stimulation therapy as an effective treatment for chronic back pain and were sustained at the 12-month follow-up.
This new indication will span across the entirety of Abbott's SCS portfolio in the U.S., which includes the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform. All of Abbott's SCS therapies in the U.S. feature the company's proprietary, low-energy BurstDR waveform.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain. Results at six months for the first 200 patients demonstrated clear clinical evidence supporting BurstDR stimulation therapy as an effective treatment for chronic back pain and were sustained at the 12-month follow-up. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain. Results at six months for the first 200 patients demonstrated clear clinical evidence supporting BurstDR stimulation therapy as an effective treatment for chronic back pain and were sustained at the 12-month follow-up. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain. Abbott's DISTINCT study, which enrolled 270 participants who suffered for an average of 12.8 years with pain, is the largest randomized controlled trial for SCS in people with chronic back pain when surgery is not an option. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain. This new indication will span across the entirety of Abbott's SCS portfolio in the U.S., which includes the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform. |
31009.0 | 2023-05-16 00:00:00 UTC | Which Healthcare Stock Is A Better Pick: Abbott Or This Robotic Products Company? | ABT | https://www.nasdaq.com/articles/which-healthcare-stock-is-a-better-pick%3A-abbott-or-this-robotic-products-company | nan | nan | We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Although ISRG stock trades at a higher valuation of 16.5x trailing revenues, compared to just 4.6x for Abbott, this gap in valuation makes sense, in our view, given Intuitive Surgical’s superior revenue growth, profitability, and financial position, as discussed below.
Looking at stock returns, ISRG has outperformed ABT and the broader indices. While ISRG is up 14% this year, ABT is up 0.4%, and the S&P500 index is up 8%. There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer higher returns than ABT stock in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Abbott vs. Intuitive Surgical: Which Stock Is A Better Bet? Parts of the analysis are summarized below.
1. Intuitive Surgical’s Revenue Growth Is Better
Intuitive Surgical’s revenue growth has been slightly better, with a 12.4% average annual growth rate in the last three years, compared to 11.45 for Abbott.
A high demand for Covid-19 testing drove Abbott’s sales growth in recent years.
For Intuitive Surgical, revenue growth over the recent years has been driven by a rebound in procedure volume, which was adversely impacted in the initial phases of the pandemic due to the shelter-in-place restrictions.
Even if we look at the last twelve month period, Intuitive Surgical fares better with sales growth of 8.9% vs. -6.8% for Abbott.
With the worst of Covid-19 behind us, the demand for testing has been declining, weighing on Abbott’s diagnostics business in recent quarters.
On the other hand, Intuitive Surgical continues to expand its installed base, which results in the growth of recurring revenues for its consumables, bolstering its sales growth.
Our Abbott Revenue Comparison and Intuitive Surgical Revenue Comparison dashboards provide more insight into the companies’ sales.
Looking forward, Intuitive Surgical’s revenue is expected to grow much faster than Abbott’s over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 3% for Abbott, compared to a 14% CAGR for Intuitive Surgical, based on Trefis Machine Learning analysis.
Abbott will see a dip in sales in 2023 owing to its diagnostics business. For perspective, Abbott expects total Covid-19-related sales of $2.0 billion in 2023, compared to $8.4 billion last year. However, it should return to growth next year, and its other businesses, including Medical Devices and Established Pharmaceuticals, should continue to grow steadily. Intuitive Surgical will likely see the expansion of its installed base with more system placements.
Note that we have different methodologies for companies negatively impacted by Covid and those not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.
2. Intuitive Surgical Is More Profitable
Abbott’s operating margin has risen from 16.1% in 2019 to 20.4% in 2022, while Intuitive Surgical’s s operating margin declined from 30.7% to 25.2% over this period.
Looking at the last twelve month period, Intuitive Surgical’s operating margin of 24.2% fares better than 18.2% for Abbott.
The decline in operating margin for Intuitive Surgical can be attributed to its increased investments in R&D, which grew 1.5x faster than the company’s sales growth. The situation was the inverse for Abbott, with its sales rising 2x faster than its R&D and SG&A expenses.
Our Abbott Operating Income Comparison and Intuitive Surgical Operating Income Comparison dashboards have more details.
Intuitive Surgical’s free cash flow margin of 25.5% is higher than 20.9% for Abbott.
Looking at financial risk, Intuitive Surgical fares better with its 0.4% debt as a percentage of equity lower than 8.8% for Abbott, and its 50.4% cash as a percentage of assets higher than 12.9% for the latter, implying that Intuitive Surgical has a better debt position and more cash cushion.
3. The Net of It All
We see that Intuitive Surgical has demonstrated better revenue growth, is more profitable, and has a better debt position and cash cushion. This also explains its higher P/S multiple compared to Abbott.
Now, looking at prospects, using P/S as a base, due to high fluctuations in P/E and P/EBIT, we believe Intuitive Surgical is still the better choice of the two, despite its higher valuation.
If we compare the current valuation multiples to the historical averages, Intuitive Surgical fares better, with its stock currently trading at 16.5x trailing revenues vs. the last five-year average of 20.6x. In contrast, Abbott’s stock trades at 4.6x trailing revenues vs. the last five-year average of 5.4x.
Our Abbott (ABT) Valuation Ratios Comparison and Intuitive Surgical (ISRG) Valuation Ratios Comparison have more details.
The table below summarizes our revenue and return expectations for Abbott and Intuitive Surgical over the next three years and points to an expected return of 7% for Abbott over this period vs. a 43% expected return for Intuitive Surgical, based on Trefis Machine Learning analysis – Abbott vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers.
While ISRG may outperform ABT over the next three years, it is helpful to see how Abbott’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Xylem vs. Merck.
With higher inflation and the Fed raising interest rates, among other factors, ABT stock has risen just 0.4% this year. Can it drop from here? See how low Abbott stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns May 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ABT Return 0% 0% 187%
ISRG Return 1% 14% 331%
S&P 500 Return -1% 8% 84%
Trefis Multi-Strategy Portfolio -2% 7% 235%
[1] Month-to-date and year-to-date as of 5/12/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Looking at stock returns, ISRG has outperformed ABT and the broader indices. While ISRG is up 14% this year, ABT is up 0.4%, and the S&P500 index is up 8%. | Our Abbott (ABT) Valuation Ratios Comparison and Intuitive Surgical (ISRG) Valuation Ratios Comparison have more details. We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Looking at stock returns, ISRG has outperformed ABT and the broader indices. | We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Looking at stock returns, ISRG has outperformed ABT and the broader indices. While ISRG is up 14% this year, ABT is up 0.4%, and the S&P500 index is up 8%. | There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer higher returns than ABT stock in the next three years. We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Looking at stock returns, ISRG has outperformed ABT and the broader indices. |
31010.0 | 2023-05-15 00:00:00 UTC | Abbott Labs is sued over PediaSure height claims | ABT | https://www.nasdaq.com/articles/abbott-labs-is-sued-over-pediasure-height-claims | nan | nan | By Jonathan Stempel
NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height.
In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller.
The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.
Noriega dismissed PediaSure as "just a flavored sugar and milk-based drink that contains vitamins, which is not a cure for shortness." She said also that Abbott "knows from its own studies that its Clinically Proven Claim is false and misleading."
The lawsuit seeks unspecified damages for New Yorkers who were allegedly deceived into buying or overpaying for PediaSure.
Abbott did not immediately respond to requests for comment.
Lawyers for Noriega did not immediately respond to similar requests, including additional information about her grandson.
Abbott says PediaSure is intended for children ages two to 13, and has been clinically shown to help children "grow out of at-risk weight-for-height percentiles (5th-25th percentiles)" within eight weeks.
PediaSure is part of the Abbott Park, Illinois-based company's pediatric nutritional segment, which also includes Pedialyte and Similac.
U.S. sales from that unit fell 29% last year, in large part because of Abbott's recall of infant formula from a Michigan plant.
The case is Noriega v Abbott Laboratories, U.S. District Court, Southern District of New York, No. 23-04014.
For plaintiff: James Denlea, of Denlea & Carton; and Philip Smith, of Kravit Smith
For Abbott: Not known
(Reporting by Jonathan Stempel in New York; Editing by Bill Berkrot)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. PediaSure is part of the Abbott Park, Illinois-based company's pediatric nutritional segment, which also includes Pedialyte and Similac. | By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. Lawyers for Noriega did not immediately respond to similar requests, including additional information about her grandson. The case is Noriega v Abbott Laboratories, U.S. District Court, Southern District of New York, No. | By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. For plaintiff: James Denlea, of Denlea & Carton; and Philip Smith, of Kravit Smith For Abbott: Not known (Reporting by Jonathan Stempel in New York; Editing by Bill Berkrot) ((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks. The lawsuit seeks unspecified damages for New Yorkers who were allegedly deceived into buying or overpaying for PediaSure. |
31011.0 | 2023-05-15 00:00:00 UTC | Abbott's (ABT) New Pact to Advance Clinical Trials Diversity | ABT | https://www.nasdaq.com/articles/abbotts-abt-new-pact-to-advance-clinical-trials-diversity | nan | nan | Abbott Laboratories, Inc. ABT unveiled a number of new programmes within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. The latest additions to Abbott's Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in the business's own clinical trials during the initiative's first year.
Abbott's Diversity in Clinical Trials initiative aligns with the company's sustained focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation.
More on the Initiative
The latest initiatives include a new initiative with the Norton Healthcare Foundation to develop and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare, in Louisville, KY, a training course for clinical research coordinators in collaboration with Barnett International and a newly-established Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.
Abbott will collaborate with the Institute for Health Equity at Norton Healthcare through a new five-year commitment to develop research programme models that historically black colleges and universities (HBCUs) and clinics serving under-represented communities can use instead of designing and developing their own research programmes from scratch, which can be costly and resource-intensive.
To expand Abbott's focus on promoting diversity in the business's clinical trials and enhancing access to care for under-represented populations, the company established a Diversity in Research Office in addition to new external collaborations and initiatives.
Strategic Implications
To improve health equality, it is crucial to remove barriers to access clinical trials for underrepresented communities. Clinical trials are the source of new, inventive methods to combat diseases. To encourage even more diversity in our clinical trials and ensure that trials are given in more locations to reach underserved communities, Abbott has concentrated on removing barriers and putting in place new, long-lasting partnerships and programmes.
Image Source: Zacks Investment Research
As part of the programme, Abbott and Norton Healthcare will give community-based clinics a road map of best practises for setting up centres of excellence for clinical trial research. Grants will be available through the initiative to assist in the employment and training of research coordinators and data managers and direct the beginning of research programmes.
Industry Prospects
Per a report by Grand View Research, the global clinical trials market size was valued at $49.8 billion in 2022 and is expected to expand at a CAGR of 5.8% by 2030. Factors such as globalization of clinical trials, rapid technological evolution, and a rise in demand for CROs for conducting research activities are driving the market.
Recent Developments
In March 2023, Abbott’s latest addition to the Epic surgical valve platform, the Epi Max stented tissue valve, received FDA approval. The design of the device is optimized to improve valve blood flow and will be used to treat aortic regurgitation or stenosis.
In the same month, ABT announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. The studies revealed that the remote monitoring of patients with hemodynamic pressure sensing technology, such as its CardioMEMS HF System, can improve survival in heart failure patients with reduced ejection fraction.
Price Performance
In the past year, Abbott’s shares rose 0.7% against the industry’s fall of 27.8%.
Zacks Rank & Other Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AmerisourceBergen Corporation ABC, Merit Medical Systems, Inc. MMSI and Cardinal Health, Inc. CAH.
AmerisourceBergen, carrying a Zacks Rank of 2, reported second-quarter fiscal 2023 adjusted EPS of $3.50, beating the Zacks Consensus Estimate by 6.4%. Revenues of $ $63.46 billion outpaced the consensus mark by 4.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AmerisourceBergen has a long-term estimated growth rate of 8.9%. ABC’s earnings surpassed estimates in all the trailing four quarters, the average being 3.1%.
Merit Medical reported a first-quarter 2023 adjusted EPS of 64 cents, beating the Zacks Consensus Estimate by 16.4%. Revenues of $297.6 million surpassed the Zacks Consensus Estimate by 5.9%. It currently carries a Zacks Rank #2.
Merit Medical has a long-term estimated growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Cardinal Health reported a third-quarter fiscal 2023 adjusted EPS of $1.74, beating the Zacks Consensus Estimate by 17.6%. Revenues of $50.49 billion surpassed the Zacks Consensus Estimate by 1.7%. It currently carries a Zacks Rank #2.
Cardinal Health has a long-term estimated growth rate of 12.4%. CAH’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 12.3%.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories, Inc. ABT unveiled a number of new programmes within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. In the same month, ABT announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT unveiled a number of new programmes within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. In the same month, ABT announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT unveiled a number of new programmes within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. In the same month, ABT announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. | Abbott Laboratories, Inc. ABT unveiled a number of new programmes within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. In the same month, ABT announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31012.0 | 2023-05-13 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-17 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31013.0 | 2023-05-10 00:00:00 UTC | Noteworthy ETF Inflows: XLV, ABT, DHR, MDT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-xlv-abt-dhr-mdt | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $873.8 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 297,620,000 to 304,220,000). Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Danaher Corp (Symbol: DHR) is up about 0.4%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.51. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
ALXO Options Chain
Funds Holding SBV
Funds Holding XYN
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Danaher Corp (Symbol: DHR) is up about 0.4%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $873.8 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 297,620,000 to 304,220,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Danaher Corp (Symbol: DHR) is up about 0.4%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.51. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Danaher Corp (Symbol: DHR) is up about 0.4%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $873.8 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 297,620,000 to 304,220,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.51. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Danaher Corp (Symbol: DHR) is up about 0.4%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $873.8 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 297,620,000 to 304,220,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.51. |
31014.0 | 2023-05-10 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-16 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31015.0 | 2023-05-09 00:00:00 UTC | Here's Why You Should Retain Abbott (ABT) Stock For Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-retain-abbott-abt-stock-for-now-5 | nan | nan | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of continued growth in Medical Devices, EPD and Nutrition segments. Solid first-quarter 2023 performance buoys optimism. However, forex woes and lower sales impede growth.
In the past year, this Zacks Rank #3 (Hold) stock has gained 3.8% against 25% decline of the industry and a 3.1% rise of the S&P 500 composite.
This renowned provider of a diversified line of healthcare products has a market capitalization of $192.9 billion. The company projects a 5.1% growth for the next five years and expects to maintain its strong performance. Abbott’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 19.28%.
Let’s delve deeper.
Q1 Upsides: Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. Organic sales growth, excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals and Nutrition. Within EPD, sales increased 11% in the quarter. The upside can be attributed to strong performance in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. EPD successfully continued with its double-digit sales growth momentum for the last two years.
Core Diagnostics Grow Strong: Excluding COVID-testing sales, organic sales growth was led by mid to high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. In Core Lab Diagnostics, growth was led by strong performance in the United States and Europe, which was partially offset by soft market conditions in China early in the year. However, China is showing improved market demand over the last several weeks. Excluding China, Core Laboratory Diagnostics sales increased nearly 8% globally in the first quarter.
Image Source: Zacks Investment Research
Abbott successfully continued with the rollout of Alinity, the company’s innovative suite of diagnostic instruments and expand test menus across its platforms for immunoassay, clinical chemistry and molecular testing
Upbeat Guidance: Abbott expects full-year adjusted earnings (excluding specified items of $1.25 per share) to be in the range of $4.30-$4.50. The current Zacks Consensus Estimate is pegged at $4.36.
Abbott projects 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high-single digits and COVID testing-related sales of around $1.5 billion.
Downsides
Foreign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues from outside the United States. The strengthening of the Euro and some other developed market currencies have been hampering the company’s performance in the international markets.
Lower Sales: Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis. Total sales were affected by COVID-19 testing-related sales decline. Within Diagnostics, as forecasted, sales growth was negatively impacted by a significant decline in COVID testing sales compared with first quarter of 2022.
Estimate Trend
In the past 90 days, the Zacks Consensus Estimate for its earnings has been constant at $4.38.
The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $39.38 billion, suggesting a 9.8% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Edwards Lifesciences Corporation EW, Intuitive Surgical, Inc. ISRG and Johnson & Johnson JNJ.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), reported first-quarter 2023 adjusted earnings per share (EPS) of 62 cents, beating the Zacks Consensus Estimate by 1.6%. Revenues of $1.46 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences has a long-term estimated growth rate of 6.8%. EW’s earnings surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in the other, the average being 1.2%.
Intuitive Surgical, with a Zacks Rank #2, reported first-quarter 2023 adjusted EPS of $1.23, beating the Zacks Consensus Estimate by 3.4%. Revenues of $1.70 billion outpaced the consensus mark by 6.9%.
Intuitive Surgical has a long-term estimated growth rate of 13%. ISRG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 1.9%.
Johnson & Johnson reported first-quarter 2023 adjusted earnings of $2.68 per share, beating the Zacks Consensus Estimate by 6.8%. Revenues of $24.75 billion surpassed the Zacks Consensus Estimate by 5%. It currently carries a Zacks Rank #2.
Johnson & Johnson has a long-term estimated growth rate of 5.5%. JNJ’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.9%.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of continued growth in Medical Devices, EPD and Nutrition segments. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. The upside can be attributed to strong performance in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of continued growth in Medical Devices, EPD and Nutrition segments. Organic sales growth, excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals and Nutrition. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of continued growth in Medical Devices, EPD and Nutrition segments. Abbott projects 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high-single digits and COVID testing-related sales of around $1.5 billion. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of continued growth in Medical Devices, EPD and Nutrition segments. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. The company projects a 5.1% growth for the next five years and expects to maintain its strong performance. |
31016.0 | 2023-05-08 00:00:00 UTC | Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay | ABT | https://www.nasdaq.com/articles/abbott-abt-epd-business-grows-strong-macro-issues-stay | nan | nan | Abbott Laboratories’ ABT branded generics and international diabetes businesses should drive growth in the coming quarters. Yet, the business environment continues to be challenging. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Abbott has been outperforming the industry it belongs to. The stock has lost 0.8% compared with the industry’s 28.1% fall.
Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. Organic sales growth excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals and Nutrition. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China, and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. EPD successfully continued its double-digit sales growth momentum in the last two years.
Within Nutrition, sales increased more than 10%. In the United States, pediatric nutrition growth of more than 35% was driven by favorable year-ago comparable (lower sales in the first quarter of 2022 were due to a voluntary recall of certain infant formula products). Abbott continued to make good progress, increasing manufacturing production and recovering market share in this business. Internationally, total nutrition sales grew in mid-single digits overall. Sales in global adult nutrition also grew mid-single digits, driven by the strong performance of the company’s market-leading Ensure brand.
Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. Despite dull sales in China, Core Lab Diagnostics sales showed year-over-year improvement, led by strong performance in the United States and Europe.
Within Medical Devices, sales grew 12.5% globally on an organic basis, including mid-teens growth in the United States and double-digit growth internationally. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally.
Abbott currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales to be in the high-single digits for 2023.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis. Total sales were negatively impacted by COVID-19 testing-related sales decline. In Diagnostics, as forecast, sales growth was negatively impacted by a significant decrease in COVID testing sales compared with the first quarter of 2022. Worldwide COVID-19 testing sales were $730 million in the first quarter compared with $3.3 billion in the year-ago period. Further, in Core Lab Diagnostics, growth was partially offset by soft market conditions in China.
Challenging macroeconomic environment, adverse currency translation and stubborn inflationary situation severely impacted the company’s profitability in the first quarter. The ongoing inflation situation across the globe is adversely impacting input costs for Abbott.
Key Picks
Some better-ranked stocks in the broader medical space are Zimmer Biomet ZBH, Hologic, Inc. HOLX and Insulet PODD.
Zimmer Biomet, carrying a Zacks Rank #1 (Strong Buy) at present, has an earnings yield of 5.35% compared to the industry’s -2.55%. Zimmer Biomet’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 7.38%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Zimmer Biomet’s shares have increased 19.9% against the industry’s 25.2% decline in the past year.
Hologic, carrying a Zacks Rank #2 at present, has an earnings yield of 4.62% compared with the industry’s -7.01%. Shares of HOLX have risen 15.1% compared with the industry’s 9.8% rise over the past year.
HOLX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 27.3%.
Insulet, carrying a Zacks Rank #2 at present, has an estimated growth rate of 56.4% for 2024. Insulet’s shares have risen 71.7% against the industry’s 25.2% decline over the past year.
PODD’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 80.2%.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories’ ABT branded generics and international diabetes businesses should drive growth in the coming quarters. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China, and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories’ ABT branded generics and international diabetes businesses should drive growth in the coming quarters. Within Medical Devices, sales grew 12.5% globally on an organic basis, including mid-teens growth in the United States and double-digit growth internationally. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories’ ABT branded generics and international diabetes businesses should drive growth in the coming quarters. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis. | Abbott Laboratories’ ABT branded generics and international diabetes businesses should drive growth in the coming quarters. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zimmer Biomet, carrying a Zacks Rank #1 (Strong Buy) at present, has an earnings yield of 5.35% compared to the industry’s -2.55%. |
31017.0 | 2023-05-06 00:00:00 UTC | 3 Dividend Stock Warning Signs That Could Portend Trouble | ABT | https://www.nasdaq.com/articles/3-dividend-stock-warning-signs-that-could-portend-trouble | nan | nan | If one of your financial goals is to generate some passive income from dividend stocks, it behooves you to know when the companies in your portfolio are healthy, and when they're in deep danger. Likewise, when you're browsing for your next stock purchase, you'll have much better odds of finding a winner if you're using the right guidelines to separate the wheat from the chaff.
Income investors, beware: These three critical warning signs are often displayed by businesses that will soon be struggling to pay their dividends.
Image source: Getty Images.
1. High or rising payout ratios
The most obvious warning sign for a dividend stock is that its payout ratio is too high.
In most cases, "too high" means a payout ratio near or above 100%. Payout ratio is the percentage of a company's annual earnings that it uses to cover its dividend, so a figure above 100% is a big issue -- the business paid out more to shareholders than it generated in earnings. That's usually unsustainable. But depending on anticipated growth, ratios in the ballpark of 70% and up could be tough to maintain too.
While it's possible for an excessively high payout ratio to be a one-off occurrence after a particularly tough year or during a transitional period, investors should be particularly cautious about companies with payout ratios that have risen steadily over time.
Take a look at this chart depicting Walgreens Boots Alliance's (NASDAQ: WBA) payout ratio:
Data source: YCharts WBA Payout Ratio
As you can see, the situation is bad. A negative payout ratio only occurs when a company is losing money and paying out dividends at the same time. (Disbursing more than 100% of earnings requires there to be earnings to disburse in the first place.) Handing out checks to shareholders while the bottom line is in the red is an even dicier proposition than handing out unsustainably high dividends.
2. Dividend growth is slowing dramatically or has stopped altogether
When companies hike their dividend year after year for many years on end, it often reflects a degree of financial strength that portends further stability and perhaps even growth. Typically, a company's earnings need to be consistently growing to cover a steadily rising dividend, especially in the long run. But even annual dividend hikes of 1% or less still count as growth, so it's smart to look a bit deeper and consider the rate at which the payout is growing, assuming it is.
For example, over the past 10 years, Walgreens hiked its dividend by 75%, including most recently in 2022, when shareholders got a raise of 1.7%.
But look at this chart:
Data source: YCharts WBA Dividend Per Share (Annual YoY Growth)
The pattern that should jump out at you is that the company's dividend hikes have generally gotten smaller and smaller during the past 10 years. That's a red flag, and it suggests that the company is on a trajectory toward a point where it will probably cut the dividend at some point.
Nonetheless, it's important to note that not all companies have a regular dividend schedule, and many don't prioritize hiking their dividends consistently, preferring instead to hand off wads of excess cash to shareholders when it's available, and to dial back distributions when it's not. In those cases, you shouldn't judge a lack of dividend growth as harshly.
3. Management starts signaling differently
A final warning sign for dividend stocks is when management starts to discuss the dividend in a different light than in the past. Most of the time, companies that pay dividends and emphasize them as an important part of the appeal for investors make a big deal out of management's commitment to continue paying them, and perhaps even regularly hiking them. In some cases, management even offers rough guidance to investors about how much payout growth they should expect each year over a certain period.
For instance, Abbott Laboratories (NYSE: ABT) is quick to emphasize its track record of raising its dividend in all of its investor materials and earnings reports. Its streak of payout hikes is now at 51 years, making it a Dividend King. Management doesn't need to communicate much of anything for shareholders to know that more hikes are on the way. But for companies without such a long history, management will usually have a comment or two about how the dividend is a priority for capital allocation.
When a business with a history of making such promises or predictions suddenly clams up in its latest earnings report, it's a bad sign. While simply failing to reiterate its prior statements about its commitment to the dividend is not the same as indicating a cut, it's a silent message that priorities are shifting, or perhaps that past policies are no longer financially sustainable.
The same is not necessarily true for messaging surrounding other shareholder-friendly policies like share buybacks, however.
Corporate boards typically approve buybacks by earmarking large allotments of money to be spent on share repurchases over a given period. But during some periods, management may choose to use those funds for growth initiatives that they believe will deliver more value to shareholders than simply buying back stock. So don't get too spooked if the messaging about stock buybacks changes, as it could actually turn out to be good news.
10 stocks we like better than Walgreens Boots Alliance
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Walgreens Boots Alliance wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For instance, Abbott Laboratories (NYSE: ABT) is quick to emphasize its track record of raising its dividend in all of its investor materials and earnings reports. If one of your financial goals is to generate some passive income from dividend stocks, it behooves you to know when the companies in your portfolio are healthy, and when they're in deep danger. While simply failing to reiterate its prior statements about its commitment to the dividend is not the same as indicating a cut, it's a silent message that priorities are shifting, or perhaps that past policies are no longer financially sustainable. | For instance, Abbott Laboratories (NYSE: ABT) is quick to emphasize its track record of raising its dividend in all of its investor materials and earnings reports. Take a look at this chart depicting Walgreens Boots Alliance's (NASDAQ: WBA) payout ratio: Data source: YCharts WBA Payout Ratio As you can see, the situation is bad. Typically, a company's earnings need to be consistently growing to cover a steadily rising dividend, especially in the long run. | For instance, Abbott Laboratories (NYSE: ABT) is quick to emphasize its track record of raising its dividend in all of its investor materials and earnings reports. High or rising payout ratios The most obvious warning sign for a dividend stock is that its payout ratio is too high. 2. Dividend growth is slowing dramatically or has stopped altogether When companies hike their dividend year after year for many years on end, it often reflects a degree of financial strength that portends further stability and perhaps even growth. | For instance, Abbott Laboratories (NYSE: ABT) is quick to emphasize its track record of raising its dividend in all of its investor materials and earnings reports. Payout ratio is the percentage of a company's annual earnings that it uses to cover its dividend, so a figure above 100% is a big issue -- the business paid out more to shareholders than it generated in earnings. Typically, a company's earnings need to be consistently growing to cover a steadily rising dividend, especially in the long run. |
31018.0 | 2023-05-05 00:00:00 UTC | Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View | ABT | https://www.nasdaq.com/articles/cigna-ci-q1-earnings-surpass-estimates-ups-23-eps-view | nan | nan | The Cigna Group CI reported first-quarter 2023 adjusted earnings of $5.41 per share, which beat the Zacks Consensus Estimate by 3.4% but fell short of our estimate of earnings of $5.43 per share. The bottom line declined 10.7% year over year.
Adjusted revenues of $46,479 million improved 5% year over year in the quarter under review on the back of solid performances of Evernorth Health Services and Cigna Healthcare businesses. The top line outpaced the consensus mark by 2.1%.
The quarterly results also gained due to an expanding medical customer base and declining COVID costs.
The medical customer base of Cigna advanced 8% year over year to 19.5 million as of Mar 31, 2023. This was due to increased fee-based clients as well as higher Individual and Medicare Advantage customers. The reported figure surpassed the Zacks Consensus Estimate of 18.9 million and our estimate of 18.8 million.
Total benefits and expenses of $11,618 million escalated 15% year over year in the quarter under review. The adjusted selling, general and administrative (SG&A) expense ratio deteriorated 30 basis points (bps) year over year to 7.6%.
The Cigna Group Price, Consensus and EPS Surprise
The Cigna Group price-consensus-eps-surprise-chart | The Cigna Group Quote
Segmental Update
In February 2023, Cigna announced the rebranding of its segments. Evernorth, renamed Evernorth Health Services, performs the role of the pharmacy, care and benefits solutions provider of CI. Cigna Healthcare assumes the part of the health benefits provider of the company through which it will cater to customers and clients via the U.S. Commercial, U.S. Government and International Health businesses.
Evernorth Health Services: The segment reported adjusted revenues of $36,179 million in the first quarter, which rose 8% year over year. This can be attributed to solid organic growth in specialty pharmacy services and, care delivery and management solutions.
Adjusted operating income on a pretax basis inched up 1% year over year to $1,320 million and came higher than the Zacks Consensus Estimate of $1,244 million. The metric benefited on the back of specialty pharmacy revenues.
Cigna Healthcare: Adjusted revenues of the segment amounted to $12,718 million, which climbed 12% year over year in the quarter under review, thanks to the growing customer base in U.S. Government and U.S. Commercial businesses coupled with higher specialty contributions.
The segment’s adjusted operating income on a pretax basis came in at $1,115 million, which decreased 14% year over year but surpassed the consensus mark of $1,062 million. The metric was hurt due to an elevated adjusted expense ratio and reduced net investment income.
The segment’s medical care ratio (MCR) improved 20 bps year over year to 81.3% at the first-quarter end on the back of prudent pricing actions and favorable cost trends.
Financial Position (as of Mar 31, 2023)
Cigna exited the first quarter with cash and cash equivalents of $7,935 million, which advanced 33.9% from the figure at 2022 end. Total assets of $148 billion increased 2.8% from the 2022-end level.
Long-term debt amounted to $29,124 million, up 3.6% from the figure as of Dec 31, 2022. Short-term debt amounted to $3,418 million.
Shareholders’ equity of $44,502 million dipped 0.4% from the 2022-end level.
In the reported quarter, net cash provided by operating activities amounted to $5,028 million, which increased nearly three-fold year over year.
Debt-to-capitalization ratio deteriorated 130 bps year over year to 42.2% at the first-quarter end.
Share Repurchase Update
From Jan 1, 2023 till May 4, 2023, Cigna bought back 3.7 million shares of common stock worth around $1.1 billion.
2023 Guidance Updated
Concurrent with first-quarter results, management revised full-year guidance with respect to certain metrics.
Adjusted revenues are estimated at a minimum of $188 billion, up from the prior view of “at least $187 billion". The updated outlook indicates a minimum improvement of 4.1% from the 2022 figure.
Adjusted operating income is forecasted to be a minimum of $7,360 million in 2023, up from the previous guidance of “at least $7,330 million.”
Adjusted earnings per share are anticipated to be a minimum of $24.70, higher than the earlier view of “at least $24.60.” The revised outlook implies minimum growth of 6.1% from the 2022 figure.
CI projects total medical customer growth of a minimum of 1,300,000 this year, while the prior outlook called for the metric to grow “at least 1,200,000.”
MCR is expected within the 81.5-82.3% band for 2023, compared with the previous view of 81.5-82.5%. The adjusted SG&A expense ratio is anticipated at roughly 7.3%.
Adjusted operating income on a pretax basis for the Evernorth Health Services segment is forecasted at a minimum of $6,400 million. Meanwhile, the same for the Cigna Healthcare unit is estimated to be a minimum of $4,425 million, up from the prior view of "at least $4,400 million".
Operating cash flow is projected to be a minimum of $9,000 million. Earlier, capital expenditures were expected at around $1,400 million.
Long-Term Targets Reaffirmed
Cigna expects to achieve average annual adjusted earnings per share growth within 10-13% in the long term.
Over the 2022-2026 period, management expects CI to generate operating cash flows of roughly $50 billion.
Zacks Rank
Cigna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate.
Elevance Health’s first-quarter 2023 earnings of $9.46 per share beat the Zacks Consensus Estimate of earnings of $9.26 per share and our estimate of earnings of $9.22 per share. Additionally, the bottom line advanced 15.5% year over year. ELV’s operating revenues improved 10.6% year over year to $41,898 million in the quarter under review. The top line beat the consensus mark by 2.5% and came higher than our estimate of $40,766.5 million. Medical membership of Elevance Health, as of Mar 31, 2023, totaled 48.1 million, which rose 2.9% year over year in the first quarter.
HCA Healthcare’s first-quarter 2023 adjusted earnings of $4.93 per share surpassed the Zacks Consensus Estimate by 23.6%. Also, the bottom line climbed 19.7% year over year. HCA’s revenues advanced 4.3% year over year to $15.6 billion. The top line beat the consensus mark by 2% and our estimate of $15.2 billion. While same-facility equivalent admissions rose 7.5% year over year in the first quarter, same-facility admissions improved 4.4% year over year.
Abbott Laboratories reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%. First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 1.1%. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Adjusted operating margin also contracted 827 bps to 20.5%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Cigna Group (CI) : Free Stock Analysis Report
HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31019.0 | 2023-05-04 00:00:00 UTC | Becton Dickinson raises 2023 profit forecast as demand rebounds | ABT | https://www.nasdaq.com/articles/becton-dickinson-raises-2023-profit-forecast-as-demand-rebounds | nan | nan | May 4 (Reuters) - Becton Dickinson and Co BDX.N on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment.
The medical device maker joins peers Stryker Corp SYK.N and Abbott Laboratories ABT.N, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes.
The company's largest unit that sells devices to administer drugs and automate pharmacy system has reported sales of $2.36 billion, beating analysts' average estimate of $2.23 billion.
Interventional unit that offers surgical and critical care devices recorded sales of $1.19 billion, beating estimates of $1.12 billion.
Revenue in the life sciences segment, which sells diagnostic devices, fell 14.2% to $1.28 billion from a year earlier, as demand for its COVID-19 test kits slumped due to lower levels of infections.
Looking ahead, the New Jersey-based company expects nominal sales of its COVID-19 test kits, reducing its full-year forecast to $50 million from its prior forecast of about $50 million to $100 million.
Becton, Dickinson and Co, however, has raised its annual profit forecast for the second time.
On an adjusted basis, the company now expects to earn a profit of $12.10 to $12.32 per share this year, compared with its prior forecast of $12.07 to $12.32 per share.
Excluding special items, it reported a profit of $2.86 per share, topping analysts' average estimate of $2.74 per share, according to Refinitiv IBES data.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shweta Agarwal)
((Khushi.Mandowara@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The medical device maker joins peers Stryker Corp SYK.N and Abbott Laboratories ABT.N, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes. May 4 (Reuters) - Becton Dickinson and Co BDX.N on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment. Revenue in the life sciences segment, which sells diagnostic devices, fell 14.2% to $1.28 billion from a year earlier, as demand for its COVID-19 test kits slumped due to lower levels of infections. | The medical device maker joins peers Stryker Corp SYK.N and Abbott Laboratories ABT.N, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes. May 4 (Reuters) - Becton Dickinson and Co BDX.N on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment. The company's largest unit that sells devices to administer drugs and automate pharmacy system has reported sales of $2.36 billion, beating analysts' average estimate of $2.23 billion. | The medical device maker joins peers Stryker Corp SYK.N and Abbott Laboratories ABT.N, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes. May 4 (Reuters) - Becton Dickinson and Co BDX.N on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment. The company's largest unit that sells devices to administer drugs and automate pharmacy system has reported sales of $2.36 billion, beating analysts' average estimate of $2.23 billion. | The medical device maker joins peers Stryker Corp SYK.N and Abbott Laboratories ABT.N, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes. May 4 (Reuters) - Becton Dickinson and Co BDX.N on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment. The company's largest unit that sells devices to administer drugs and automate pharmacy system has reported sales of $2.36 billion, beating analysts' average estimate of $2.23 billion. |
31020.0 | 2023-05-04 00:00:00 UTC | The Zacks Analyst Blog Highlights Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-berkshire-hathaway-tesla-jpmorgan-chase-abbott | nan | nan | For Immediate Release
Chicago, IL – May 4, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. TSLA, JPMorgan Chase & Co. JPM, Abbott Laboratories ABT and Comcast Corp. CMCSA.
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Tesla and JPMorgan Chase
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Tesla, Inc. and JPMorgan Chase & Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Berkshire Hathaway shares have outperformed the Zacks Insurance - Property and Casualty industry over the past six months (+13.4% vs. +9.5%). The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts and indicates financial flexibility.
Berkshire Hathaway continuous insurance business growth fuels increase in float, drives earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
(You can read the full research report on Berkshire Hathaway here >>>)
Shares of Tesla have outperformed the Zacks Automotive - Domestic industry over the year-to-date period (+32.4% vs. -2.5%) on the back of strong momentum in its deliveries, particularly Models 3 and Y.
The Zacks analyst expects deliveries to see an annualized growth of around 38% in 2023. Production ramp-up at gigafactory 4 (in Berlin) and 5 (in Austin) and introduction of new models, including Semi and Cybertruck, are set to support long-term deliveries growth.
Additionally, Tesla’s energy generation and storage revenues outlook is promising. Falling debt levels is another positive. While inflation and economic concerns could pose near-term challenges, we expect Tesla to deliver outsized returns in the long run on the back of output ramp-up and introduction of new models.
(You can read the full research report on Tesla here >>>)
Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry over the past year (+12.3% vs. -13.5%). The company acquired failed First Republic Bank for $10.6 billion, which is expected to be accretive to earnings. The deal adds almost $173 billion in loans and will increase market share among wealthy clients.
Higher rates, global expansion initiatives and a steady loan demand will support net interest income (NII). Yet, the volatile nature of the capital markets business and higher mortgage rates are likely to make fee income growth challenging.
However, mounting expenses pose a major headwind, and we anticipate the same to rise 6.7% in 2023. Given the potential recession, provisions are likely to keep rising.
(You can read the full research report on JPMorgan Chase here >>>)
Other noteworthy reports we are featuring today include Abbott Laboratories and Comcast Corp.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Comcast Corporation (CMCSA) : Free Stock Analysis Report
Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. TSLA, JPMorgan Chase & Co. JPM, Abbott Laboratories ABT and Comcast Corp. CMCSA. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. While inflation and economic concerns could pose near-term challenges, we expect Tesla to deliver outsized returns in the long run on the back of output ramp-up and introduction of new models. | Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. TSLA, JPMorgan Chase & Co. JPM, Abbott Laboratories ABT and Comcast Corp. CMCSA. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Berkshire Hathaway, Tesla and JPMorgan Chase The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. TSLA, JPMorgan Chase & Co. JPM, Abbott Laboratories ABT and Comcast Corp. CMCSA. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Berkshire Hathaway, Tesla and JPMorgan Chase The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. TSLA, JPMorgan Chase & Co. JPM, Abbott Laboratories ABT and Comcast Corp. CMCSA. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Tesla, Inc. and JPMorgan Chase & Co. |
31021.0 | 2023-05-03 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-14 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31022.0 | 2023-05-03 00:00:00 UTC | Top Research Reports for Berkshire Hathaway, Tesla & JPMorgan Chase | ABT | https://www.nasdaq.com/articles/top-research-reports-for-berkshire-hathaway-tesla-jpmorgan-chase | nan | nan | Wednesday, May 3, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. (TSLA) and JPMorgan Chase & Co. (JPM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Berkshire Hathaway shares have outperformed the Zacks Insurance - Property and Casualty industry over the past six months (+13.4% vs. +9.5%). The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts and indicates the financial flexibility.
Berkshire Hathaway continuous insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
(You can read the full research report on Berkshire Hathaway here >>>)
Shares of Tesla have outperformed the Zacks Automotive - Domestic industry over the year-to-date period (+32.4% vs. -2.5%) on the back of strong momentum in its deliveries, particularly Models 3 and Y.
The Zacks analyst expects deliveries to see an annualized growth of around 38% in 2023. Production ramp-up at gigafactory 4 (in Berlin) and 5 (in Austin) and introduction of new models, including Semi and Cybertruck, are set to support long-term deliveries growth.
Additionally, Tesla’s energy generation and storage revenues outlook is promising. Falling debt levels is another positive. While inflation and economic concerns could pose near-term challenges, we expect Tesla to deliver outsized returns in the long run on the back of output ramp-up and introduction of new models.
(You can read the full research report on Tesla here >>>)
Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry over the past year (+12.3% vs. -13.5%). The company acquired failed First Republic Bank for $10.6 billion, which is expected to be accretive to earnings. The deal adds almost $173 billion in loans and will increase market share among wealthy clients.
Higher rates, global expansion initiatives and a steady loan demand will support net interest income (NII). Yet, the volatile nature of the capital markets business and higher mortgage rates are likely to make fee income growth challenging.
However, mounting expenses pose a major headwind, and we anticipate the same to rise 6.7% in 2023. Given the potential recession, provisions are likely to keep rising.
(You can read the full research report on JPMorgan Chase here >>>)
Other noteworthy reports we are featuring today include Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Comcast Corporation (CMCSA).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Berkshire (BRK.B) Poised to Grow on Solid Insurance Business
Tesla (TSLA) Rides High on Robust Model 3/Y Deliveries
Acquisitions, High Rates Aid JPMorgan (JPM), Fee Income Hurt
Featured Reports
Lilly (LLY) Potential New Products Key to Growth
The Zacks analyst is encouraged Lilly expects to launch four new medicines by 2023 end including Mounjaro (launched). Mounjaro's sales are already benefiting from strong demand trends
EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues
The Zacks analyst is upbeat about Abbott's Established Pharmaceuticals sales growth in key emerging markets on several therapeutic areas. Yet, stubborn global inflation has impacted profitability.
Wireless Subscriber Gain Drives Comcast's (CMCSA) Prospects
Per the Zacks Analyst, Comcast benefits from an expanding wireless subscriber base as well as strong adoption of Xfinity Mobile and Peacock.
Expanding LNG & Clean Energy Assets Aid TotalEnergies (TTE)
Per the Zacks analyst TotalEnergies's presence in entire LNG value chain and expansion of clean energy generation through joint venture and acquisition will boost its performance.
Mondelez (MDLZ) Gains on Solid Chocolate & Biscuit Categories
Per the Zacks analyst, Mondelez has been gaining on its focus on expanding the core chocolate & biscuit categories. Both these categories registered double-digit growth in the first quarter of 2023.
Focused Differentiation Aids Waste Management (WM), Debt High
Per the Zacks analyst, differentiation through capitalization of extensive assets ensures long-term profitable growth for Waste Management. A debt-heavy balance sheet remains a concern.
FUJIFILM (FUJIY) To Benefit From Strong Product Portfolio
Per the Zacks analyst, FUJIFILM's performance benefitted from strong revenue growth across all business segments. However, stiff competition is a major headwind.
New Upgrades
NVR Benefits from Solid Business Model & Stable Liquidity
Per the Zacks analyst, NVR has been benefiting from solid business model which focuses on maximizing liquidity and minimizing risk. Also, high liquidity adds to the tailwind.
Expanding Diagnosis & Treatment Portfolio Aids Philips (PHG)
Per the Zacks analyst, Philips continues to benefit from growing Diagnosis & Treatment business on the back of partnerships, expanding geographical coverage and innovative solutions.
AptarGroup (ATR) Rides on Solid Demand and Innovation
Per the Zacks analyst, AptarGroup will gain from demand in its end markets and innovative product rollouts. Efforts to expand geographic presence and product offerings through acquisitions bode well.
New Downgrades
Regulations & International Exposure Ail NRG Energy (NRG)
Per the Zacks analyst, NRG Energy's international operations exposes it to political and economic risks and adherence to extensive regulations to will increase expenses and impact margins.
High Capital Spending to Hurt Helmerich & Payne (HP)
The Zacks analyst believes that Helmerich & Payne's estimated capital outlay for fiscal 2023 is on the higher side and might act as a drag on the bottom line.
Nabors (NBR) Weighed Down by Massive Debt Burden
The Zacks analyst believes that Nabors Industries' high debt-to-capitalization of 81.4% is a concern, as it restricts the company's financial freedom to tap into growth opportunities.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Comcast Corporation (CMCSA) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other noteworthy reports we are featuring today include Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Comcast Corporation (CMCSA). Mounjaro's sales are already benefiting from strong demand trends EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues The Zacks analyst is upbeat about Abbott's Established Pharmaceuticals sales growth in key emerging markets on several therapeutic areas. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Comcast Corporation (CMCSA). Mounjaro's sales are already benefiting from strong demand trends EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues The Zacks analyst is upbeat about Abbott's Established Pharmaceuticals sales growth in key emerging markets on several therapeutic areas. | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Comcast Corporation (CMCSA). Mounjaro's sales are already benefiting from strong demand trends EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues The Zacks analyst is upbeat about Abbott's Established Pharmaceuticals sales growth in key emerging markets on several therapeutic areas. | Other noteworthy reports we are featuring today include Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Comcast Corporation (CMCSA). Mounjaro's sales are already benefiting from strong demand trends EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues The Zacks analyst is upbeat about Abbott's Established Pharmaceuticals sales growth in key emerging markets on several therapeutic areas. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31023.0 | 2023-05-02 00:00:00 UTC | Acadia Healthcare (ACHC) Q1 Earnings Beat on Higher Patient Volumes | ABT | https://www.nasdaq.com/articles/acadia-healthcare-achc-q1-earnings-beat-on-higher-patient-volumes | nan | nan | Shares of Acadia Healthcare Company, Inc. ACHC declined 4.9% since it reported first-quarter 2023 results on Apr 26. Despite reporting better-than-expected earnings, investor sentiments might have been hurt by the significant rise in ACHC’s expense level. Nevertheless, the downside was partially offset by growing admissions as a result of sustained demand for its behavioral healthcare services.
ACHC reported first-quarter 2023 adjusted earnings of 75 cents per share, which outpaced the Zacks Consensus Estimate by 5.6% and our estimate of 70 cents per share. The bottom line advanced 11.9% year over year.
Total revenues climbed 14.2% year over year to $704.3 million in the quarter under review. The top line beat the consensus mark by 4.2% and our estimate of $690.6 million.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Acadia Healthcare Company, Inc. price-consensus-eps-surprise-chart | Acadia Healthcare Company, Inc. Quote
Q1 Operations
Total U.S. same-facility revenues of $694.9 million improved 13.3% year over year, thanks to a 6.4% rise in revenue per patient day and 6.5% growth in patient days. Admissions grew 8.6% year over year in the first quarter. However, the average length of stay declined 1.9% year over year.
In the overall U.S. facility, both revenue per patient day and patient days rose 6.9% year over year in the quarter under review. Admissions registered year-over-year growth of 10.4%. Yet, the average length of stay fell 3.2% year over year.
Adjusted EBITDA advanced 11.6% year over year to $151.3 million in the first quarter, higher than our estimate of $149.4 million. The adjusted EBITDA margin of 26.5% improved 20 basis points year over year.
Total expenses came in at $618.6 million, which escalated 15.1% year over year mainly due to higher salaries, wages and benefits, professional fees, depreciation and amortization and interest expenses. The figure also came higher than our estimate of $580.8 million.
Acadia Healthcare added 106 beds to its existing operations in the quarter under review.
Financial Update (as of Mar 31, 2023)
Acadia Healthcare exited the first quarter with cash and cash equivalents of $63.8 million, which dropped 34.6% from the figure at 2022 end. It had $485 million left under its $600 million revolving credit facility at the first-quarter end.
Total assets of $5,044.3 million inched up 1.1% from the 2022-end level.
Long-term debt amounted to $1,399.8 million, which increased 2.6% from the figure as of Dec 31, 2022. The current portion of the long-term debt was $21.3 million.
Total equity of $2,839.6 million inched up 1% from the 2022-end level. The net leverage ratio stood at around 2.2X at the first-quarter end.
In the reported quarter, net cash provided by operating activities of $44.4 million plunged 42.2% year over year.
2023 Outlook Reiterated
Revenues are anticipated to lie within $2.82-$2.88 billion, the midpoint of which indicates an improvement of 9.2% from the 2022 reported figure.
Acadia Healthcare is on track to add 300 beds to its existing facilities this year. It is also set to inaugurate a minimum of six comprehensive treatment centers in 2023.
Adjusted EBITDA is forecasted to stay between $635 million and $675 million, the midpoint of which suggests 6.5% growth from the 2022 figure.
Adjusted earnings per share is estimated in the $3.10-$3.40 band, the midpoint of which implies growth of 8% from the 2022 reported figure.
Interest expenses are predicted to be $80-$85 million for 2023, while the tax rate is expected within 25-26%.
Operating cash flows are anticipated to lie between $450 million and $500 million. Capital expenditures for expansion initiatives are estimated to stay between $350 million and $400 million, while the same for maintenance is projected to be $40-$50 million. IT capital expenditures are expected to stay in the $35-$45 million band.
Zacks Rank
Acadia Healthcare currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate.
Elevance Health’s first-quarter 2023 earnings of $9.46 per share beat the Zacks Consensus Estimate of $9.26 and our estimate of $9.22. Additionally, the bottom line advanced 15.5% year over year. ELV’s operating revenues improved 10.6% year over year to $41,898 million in the quarter under review. The top line beat the consensus mark by 2.5% and came higher than our estimate of $40,766.5 million. Medical membership of Elevance Health, as of Mar 31, 2023, totaled 48.1 million, which rose 2.9% year over year in the first quarter.
HCA Healthcare’s first-quarter 2023 adjusted earnings of $4.93 per share surpassed the Zacks Consensus Estimate by 23.6%. Also, the bottom line climbed 19.7% year over year. HCA’s revenues advanced 4.3% year over year to $15.6 billion. The top line beat the consensus mark by 2% and our estimate of $15.2 billion. While same-facility equivalent admissions rose 7.5% year over year in the first quarter, same-facility admissions improved 4.4% year over year.
Abbott Laboratories reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%. First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 1.1%. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Adjusted operating margin also contracted 827 bps to 20.5%.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report
Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. | ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31024.0 | 2023-05-02 00:00:00 UTC | Zimmer Biomet raises annual forecasts on knees and hips unit strength | ABT | https://www.nasdaq.com/articles/zimmer-biomet-raises-annual-forecasts-on-knees-and-hips-unit-strength | nan | nan | May 2 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States.
Shares of the Indiana-based medical device maker rose 3.72% to $144 before the bell, also buoyed by better-than-expected first-quarter results.
Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp SYK.N and larger rival Abbott Laboratories ABT.N, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures.
Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. Analysts on average were expecting a profit of $7.06 per share, according to Refinitiv data.
The company expects revenue to grow 5%-6% this year, compared with its previous forecast of 1.5%-3.5%.
"Investor focus is largely on Zimmer's ability to take a share in the knee and head market and the adoption of the company's new launches," BTIG analyst Ryan Zimmerman told Reuters before the results.
Analysts have highlighted that Zimmer's smart implant that was authorized by the U.S. health regulator in November for cementless knee replacement procedures will have a broad market opportunity.
The medical device maker's revenue rose 10% to $1.83 billion in the first quarter, beating analysts' average estimates of $1.70 billion.
Excluding items, the company made a profit of $1.89 per share for the quarter ended March 31, compared with analysts' estimates of $1.64 per share.
(Reporting by Sriparna Roy in Bengaluru; Editing by Subhranshu Sahu)
((Sriparna.Roy@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp SYK.N and larger rival Abbott Laboratories ABT.N, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. May 2 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States. "Investor focus is largely on Zimmer's ability to take a share in the knee and head market and the adoption of the company's new launches," BTIG analyst Ryan Zimmerman told Reuters before the results. | Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp SYK.N and larger rival Abbott Laboratories ABT.N, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. The medical device maker's revenue rose 10% to $1.83 billion in the first quarter, beating analysts' average estimates of $1.70 billion. | Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp SYK.N and larger rival Abbott Laboratories ABT.N, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. Excluding items, the company made a profit of $1.89 per share for the quarter ended March 31, compared with analysts' estimates of $1.64 per share. | Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp SYK.N and larger rival Abbott Laboratories ABT.N, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. The medical device maker's revenue rose 10% to $1.83 billion in the first quarter, beating analysts' average estimates of $1.70 billion. |
31025.0 | 2023-05-02 00:00:00 UTC | Is Dexcom a Good Stock to Buy Now? | ABT | https://www.nasdaq.com/articles/is-dexcom-a-good-stock-to-buy-now | nan | nan | If you're a long-term Dexcom (NASDAQ: DXCM) shareholder, congratulations. A $1,000 bet placed on this developer of blood sugar monitoring devices a decade ago is worth nearly $30,000 today.
Sadly, past performance doesn't guarantee future results. If anything, Dexcom's success to date makes continued growth at its previous pace extra challenging.
Shares of Dexcom recently dipped a couple of percentage points after the company shared results from the first three months of 2023. Is the stock's recent slip a sign that investors should avoid this former highflier or is it an opportunity to buy a great stock at a bargain price?
Let's weigh Dexcom's strengths against its weaknesses to see if it's still a smart buy.
Reasons to buy Dexcom stock now
Dexcom's stock price didn't respond well to management's latestearnings call but the investment bankers who were listening in were more than satisfied. At least half a dozen Wall Street analysts raised their price targets on Dexcom stock.
Dexcom's new consensus price target implies a potential gain of 16% over the next 12 months if the rest of the market sees its constant blood-glucose monitor (CGM) business in the same light. This isn't the rate of return investors are used to with this stock but there's a lot less risk now than there was 10 years ago.
In February, Dexcom launched its next-generation CGM device, called the G7, with help from a Super Bowl commercial. Shortly after that, a positive coverage decision for G7 from the Centers for Medicare and Medicaid Services (CMS) helped make the first weeks of its launch a success.
Total first-quarter sales in the U.S. grew 17% year over year and will likely accelerate later this year. According to management, nearly 1,000 healthcare providers who had never prescribed a Dexcom device started patients on the G7 during the first quarter.
In April, CMS expanded CGM coverage to diabetes patients using all types of insulin, plus non-insulin-using patients with a history of hypoglycemic events. Previously, millions of Americans with type 2 diabetes who use basal insulin weren't eligible for CGM coverage.
Their new eligibility could lead to a surge in demand from folks too young for Medicare, too. Private insurers don't necessarily need to follow CMS' lead but they usually do.
Reasons to remain cautious for now
Dexcom isn't the only company with a fancy new CGM on the market. The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom.
Abbott recently reported first-quarter FreeStyle Libre sales that reached $1.2 billion worldwide. This included a gain of nearly 50% year over year in the U.S. market.
Dexcom is expecting its first year with G7 in the U.S. to be somewhat muted. Management's revenue outlook for 2023 implies growth between 17% and 21% this year.
Dexcom's stock price has heaps of growth already baked in. The stock is trading at sky-high multiples of 149 times trailing earnings and 17.7 times sales.
A very risky bet
With expectations already high, investors who buy at recent prices have little to gain if the G7 device simply succeeds. The stock's valuation is so high right now that it will need to grow CGM sales faster than Abbott has to justify its valuation.
Dexcom's near-term expectations for G7 sales appear way below the explosive growth the stock market is expecting. It's probably best to watch the G7 launch from a safe distance until the stock's valuation returns to a sensible level.
10 stocks we like better than DexCom
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom. Dexcom's new consensus price target implies a potential gain of 16% over the next 12 months if the rest of the market sees its constant blood-glucose monitor (CGM) business in the same light. Shortly after that, a positive coverage decision for G7 from the Centers for Medicare and Medicaid Services (CMS) helped make the first weeks of its launch a success. | The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom. Reasons to buy Dexcom stock now Dexcom's stock price didn't respond well to management's latestearnings call but the investment bankers who were listening in were more than satisfied. In April, CMS expanded CGM coverage to diabetes patients using all types of insulin, plus non-insulin-using patients with a history of hypoglycemic events. | The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom. Reasons to buy Dexcom stock now Dexcom's stock price didn't respond well to management's latestearnings call but the investment bankers who were listening in were more than satisfied. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen. | The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom. Reasons to buy Dexcom stock now Dexcom's stock price didn't respond well to management's latestearnings call but the investment bankers who were listening in were more than satisfied. This isn't the rate of return investors are used to with this stock but there's a lot less risk now than there was 10 years ago. |
31026.0 | 2023-05-01 00:00:00 UTC | 3 Stocks to Buy Before They Soar to New Heights in 2023 | ABT | https://www.nasdaq.com/articles/3-stocks-to-buy-before-they-soar-to-new-heights-in-2023 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Many stocks are recovering from the losses they endured last year, with some looking ready to break out and test new highs. Many of the top stocks to buy in down markets have led the way higher in 2023. These strong performers have been propelled higher by solid earnings and improving sentiment among analysts and investors.
The key for retail investors is spotting the stocks on the cusp of soaring and buying before the price rockets upwards. This isn’t easy, especially as the stock market swings between gains and losses, and its near-term direction remains hard to pin down.
Concerns about a recession and uncertainty regarding when the U.S. Federal Reserve will stop raising interest rates continue to muddy the waters for professional and amateur investors alike. Of course, we at InvestorPlace want to help and offer the following three stocks to buy before they soar to new heights in 2023.
RL Ralph Lauren $116.13
ABT Abbott Laboratories $110.40
JPM JPMorgan Chase $140.73
Ralph Lauren (RL)
Source: Martin Good / Shutterstock.com
Fashion designer and clothing retailer Ralph Lauren (NYSE:RL) has found its way onto my list of top stocks to buy. This is a retailer that’s trending in the right direction, and could be on the cusp of a breakout.
Over the past six months, RL stock has gained 30%, including a 7% increase this year. The company’s share price has increased on solid earnings and analyst upgrades. In February, the fashion house reported an earnings beat on the top and bottom lines.
Citing strong fundamentals, Bank of America (NYSE:BAC) upgraded their rating on Ralph Lauren stock to a “buy” and gave the shares a $145 price target, 25% higher than where the stock is currently trading. In its upgrade, Bank of America noted Ralph Lauren’s growing revenue streams from various operating units. It applauded the company’s management team for keeping costs in line during the current inflationary period.
Abbott Laboratories (ABT)
Source: testing / Shutterstock.com
Abbot Laboratories (NYSE:ABT) finds itself on this list of stocks to buy due partly to the promising move ABT stock has made over the past six months. However, despite the voracity of this move higher, I think a bigger move could be on the horizon.
Incredibly, ABT stock recently jumped 8% in a single trading session after the company reported strong earnings, beating consensus estimates by four cents a share. The results were awe-inspiring as they showed Abbott Labs overcame a pronounced slowdown in sales of its Covid-19 tests.
Strong sales in Abbott’s medical devices unit drove the latest earnings beat, posting $3.9 billion in sales during the first quarter, up 9% from a year earlier. The company’s glucose-monitoring device, Freestyle Libre, is a bestseller, earning $1.2 billion in Q1 revenue. For the year to date, ABT stock has gained 2%, though it is trading 9% lower than where it was this time last year. A continued breakout could be in the cards for this stock.
JPMorgan Chase (JPM)
Source: Bjorn Bakstad / Shutterstock.com
Last on this list of stocks to buy is yet another company that has managed to defy expectations. JPMorgan Chase (NYSE:JPM) reported record first-quarter revenue of nearly $40 billion. Notably, these results came despite recent turmoil in the banking sector.
JPMorgan attributed the record results to higher interest rates charged on its various loans, announcing earnings of $4.32 per share versus the $3.41 expected among analysts, according to Refinitiv data.
JPMorgan Chase’s Q1 revenue came in at $39.34 billion versus a consensus forecast of $36.19 billion, which had been forecast among analysts covering the bank. JPMorgan’s results were robust, particularly considering the recent collapses of two regional lenders, Silicon Valley Bank, and Signature Bank. However, the failure of those regional banks may have helped JPMorgan as it reported an influx of new customers towards the end of Q1.
JPM stock shot up 6% immediately after its Q1 earnings were issued publicly. The stock has now gained 21% over the last six months.
On the date of publication, Joel Baglole held a long position in BAC. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia.
The post 3 Stocks to Buy Before They Soar to New Heights in 2023 appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Incredibly, ABT stock recently jumped 8% in a single trading session after the company reported strong earnings, beating consensus estimates by four cents a share. RL Ralph Lauren $116.13 ABT Abbott Laboratories $110.40 JPM JPMorgan Chase $140.73 Ralph Lauren (RL) Source: Martin Good / Shutterstock.com Fashion designer and clothing retailer Ralph Lauren (NYSE:RL) has found its way onto my list of top stocks to buy. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Abbot Laboratories (NYSE:ABT) finds itself on this list of stocks to buy due partly to the promising move ABT stock has made over the past six months. | RL Ralph Lauren $116.13 ABT Abbott Laboratories $110.40 JPM JPMorgan Chase $140.73 Ralph Lauren (RL) Source: Martin Good / Shutterstock.com Fashion designer and clothing retailer Ralph Lauren (NYSE:RL) has found its way onto my list of top stocks to buy. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Abbot Laboratories (NYSE:ABT) finds itself on this list of stocks to buy due partly to the promising move ABT stock has made over the past six months. Incredibly, ABT stock recently jumped 8% in a single trading session after the company reported strong earnings, beating consensus estimates by four cents a share. | RL Ralph Lauren $116.13 ABT Abbott Laboratories $110.40 JPM JPMorgan Chase $140.73 Ralph Lauren (RL) Source: Martin Good / Shutterstock.com Fashion designer and clothing retailer Ralph Lauren (NYSE:RL) has found its way onto my list of top stocks to buy. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Abbot Laboratories (NYSE:ABT) finds itself on this list of stocks to buy due partly to the promising move ABT stock has made over the past six months. Incredibly, ABT stock recently jumped 8% in a single trading session after the company reported strong earnings, beating consensus estimates by four cents a share. | RL Ralph Lauren $116.13 ABT Abbott Laboratories $110.40 JPM JPMorgan Chase $140.73 Ralph Lauren (RL) Source: Martin Good / Shutterstock.com Fashion designer and clothing retailer Ralph Lauren (NYSE:RL) has found its way onto my list of top stocks to buy. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Abbot Laboratories (NYSE:ABT) finds itself on this list of stocks to buy due partly to the promising move ABT stock has made over the past six months. Incredibly, ABT stock recently jumped 8% in a single trading session after the company reported strong earnings, beating consensus estimates by four cents a share. |
31027.0 | 2023-04-29 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-13 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31028.0 | 2023-04-28 00:00:00 UTC | Got $1,000? 2 Top Dividend Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/got-%241000-2-top-dividend-stocks-to-buy-now | nan | nan | If you're looking to grow your $1,000, you can do that by investing in stocks that probably will deliver share performance. But you can boost your opportunities for gains if you invest in stocks that also pay you just for investing in them: dividend stocks. Even better, scoop up companies that truly are committed to growing these payments.
Where to find these investment jewels? On the list of Dividend Kings. These are companies that have increased their dividends for at least 50 straight years. This shows rewarding shareholders is important to them. So, there's reason to believe they won't break their long streak of dividend increases. Let's check out two top Dividend Kings to buy now. With your $1,000, you can invest in a few shares of each.
1. Abbott Laboratories
First, let's talk about Abbott Laboratories' (NYSE: ABT) business and earnings. You may know of Abbott because of its enormous COVID-19 testing business. But even without those products, Abbott is impressive.
What I like about Abbott is its diversification, with medical devices, diagnostics, nutrition, and established pharmaceuticals businesses. This diversification means if one area sees a slowdown, another business may compensate.
Abbott has grown annual revenue, net income, and free cash flow considerably over the years. And as a healthcare business, even in tough economic times, Abbott's revenue continues to grow. Patients still need their diagnostic tests, surgeries, and medicines. Right now is the perfect time to look at Abbott's revenue growth. In the most recent quarter, the company posted double-digit organic revenue growth. This is if we exclude coronavirus testing revenue -- the fair thing to do since we're heading toward a post-pandemic situation.
Now let's talk dividend. Abbott pays an annual dividend of $2.04 at a dividend yield of 1.88%. The company's cash-dividend payout ratio shows it paid out 42% of free cash flow in dividends over the past year.
ABT Free Cash Flow data by YCharts.
Considering Abbott's growth in free cash flow, it's likely this top healthcare stock will continue boosting its dividend. This and Abbott's steady earnings growth make it a fantastic long-term stock for any portfolio.
2. Target
Like other retailers, Target (NYSE: TGT) has struggled through these days of higher inflation and economic woes. But there still are plenty of reasons to be positive about the stock.
First, Target is taking steps to manage the difficult times. For example, it's limiting inventory on discretionary items, which have seen lower demand. And at the same time, it plans on expanding collections in 10 of its high-growth owned brands this year.
Second, it's important to look at the big picture. Target has grown in leaps and bounds over the past few years, and that growth will benefit the company over the long term. The fourth quarter of last year represented the 23rd consecutive quarter of comparable sales growth. And since 2019, total revenue has increased by more than $30 billion.
Target also continues to grow market share across all merchandise categories. And the company wins in efficiency too, with stores fulfilling 95% of all sales, including online sales. The company continues to revamp stores and launch new stores designed to best suit their local communities. All of these elements should help Target succeed over time.
Meanwhile, you're sure to benefit from passive income. Target pays an annual dividend of $4.32, representing a yield of 2.74%. This is well above the average dividend yield for the retail industry.
All of this means Target has what it takes to deliver share-price performance over the long run, and this top retail company will pay you while you wait.
10 stocks we like better than Abbott Laboratories
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
Adria Cimino has positions in Target. The Motley Fool has positions in and recommends Abbott Laboratories and Target. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories First, let's talk about Abbott Laboratories' (NYSE: ABT) business and earnings. ABT Free Cash Flow data by YCharts. The company's cash-dividend payout ratio shows it paid out 42% of free cash flow in dividends over the past year. | Abbott Laboratories First, let's talk about Abbott Laboratories' (NYSE: ABT) business and earnings. ABT Free Cash Flow data by YCharts. Considering Abbott's growth in free cash flow, it's likely this top healthcare stock will continue boosting its dividend. | Abbott Laboratories First, let's talk about Abbott Laboratories' (NYSE: ABT) business and earnings. ABT Free Cash Flow data by YCharts. But you can boost your opportunities for gains if you invest in stocks that also pay you just for investing in them: dividend stocks. | Abbott Laboratories First, let's talk about Abbott Laboratories' (NYSE: ABT) business and earnings. ABT Free Cash Flow data by YCharts. Right now is the perfect time to look at Abbott's revenue growth. |
31029.0 | 2023-04-27 00:00:00 UTC | Why Abbott Laboratories Stock Looks Ridiculously Overpriced | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-stock-looks-ridiculously-overpriced | nan | nan | Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.
The business is improving, but at a modest pace
On April 19, Abbott released its first-quarter earnings numbers. Total revenue of $9.7 billion for the period ending March 31 was down 18% year over year, but that was largely due to the decline in its diagnostics business, where demand for COVID-19 tests has dropped off significantly -- sales in that segment were down close to 50%.
One positive is that the nutrition business was up 3.8% as the company recovers from headwinds last year due to recalls and manufacturing stoppages related to its baby formula products. The company says it has been making "good progress recovering market share" in its pediatric nutrition business.
But the downside is that the company's growth rate hasn't been all that impressive, as its pharmaceuticals business was up by just 3.7%. And while its medical device segment grew by 8.5%, that was with some incredibly strong numbers from its diabetes care business, where sales growth was 16.6%. The company's revenue from its glucose monitoring devices under the FreeStyle Libre brand totaled $1.2 billion and generated growth of 50% in the U.S.
Even despite some fast-growing products, Abbott's business hasn't been growing at a significant enough rate to justify the company's valuation. And the problem is that this has historically been a modestly growing business.
ABT Revenue (Quarterly YoY Growth) data by YCharts
The stock is trading at a rich valuation
This year, Abbott is projecting that its diluted earnings per share will fall within a range of $3.05 to $3.25. At the midpoint, $3.15, that would put it at a price-earnings ratio of 35 based on its current share price of around $111. That's a high multiple when you consider that the average healthcare stock trades at 23 times its trailing earnings and 18 times future estimated profits. So unless Abbott's price comes down significantly over the next 12 months, this could be an expensive stock to hold onto right now.
ABT PE Ratio data by YCharts
Its valuation has been creeping down amid the current bear market, and investors should remember that this valuation was achieved while the business benefited from strong demand for COVID tests. Now, with operations moving in a more normal range, profits won't be as high, which could make its valuation look even worse.
Is Abbott Labs stock a buy?
Abbott Laboratories is expecting high-single-digit growth this year (excluding COVID-19 tests), but that isn't enough of a reason to justify its rich valuation. For a company with such a tame growth rate, investors should be paying a more reasonable price for Abbott's stock.
That's why unless shares of Abbott drop significantly in the near future, investors are better off avoiding the stock right now. Even Abbott's modest dividend yield of 1.9% isn't enough of a reason to buy the stock as there is no shortage of high-yielding options out there to choose from today.
10 stocks we like better than Abbott Laboratories
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT Revenue (Quarterly YoY Growth) data by YCharts The stock is trading at a rich valuation This year, Abbott is projecting that its diluted earnings per share will fall within a range of $3.05 to $3.25. Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. ABT PE Ratio data by YCharts Its valuation has been creeping down amid the current bear market, and investors should remember that this valuation was achieved while the business benefited from strong demand for COVID tests. | ABT Revenue (Quarterly YoY Growth) data by YCharts The stock is trading at a rich valuation This year, Abbott is projecting that its diluted earnings per share will fall within a range of $3.05 to $3.25. Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. ABT PE Ratio data by YCharts Its valuation has been creeping down amid the current bear market, and investors should remember that this valuation was achieved while the business benefited from strong demand for COVID tests. | ABT Revenue (Quarterly YoY Growth) data by YCharts The stock is trading at a rich valuation This year, Abbott is projecting that its diluted earnings per share will fall within a range of $3.05 to $3.25. Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. ABT PE Ratio data by YCharts Its valuation has been creeping down amid the current bear market, and investors should remember that this valuation was achieved while the business benefited from strong demand for COVID tests. | Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. ABT Revenue (Quarterly YoY Growth) data by YCharts The stock is trading at a rich valuation This year, Abbott is projecting that its diluted earnings per share will fall within a range of $3.05 to $3.25. ABT PE Ratio data by YCharts Its valuation has been creeping down amid the current bear market, and investors should remember that this valuation was achieved while the business benefited from strong demand for COVID tests. |
31030.0 | 2023-04-27 00:00:00 UTC | Can Boston Scientific Set Another Net High? | ABT | https://www.nasdaq.com/articles/can-boston-scientific-set-another-net-high | nan | nan | Although the Q1 results sparked a round of profit-taking, Boston Scientific (NYSE: BSX) can set another new all-time high in 2023. The market has been trending higher on a combination of factors that result in up trending sentiment and analyst price targets that have yet to end. The factors driving the stock are the rebound in medical procedures, organic growth of healthcare services, innovation, acquisitions and results. The Q1 results may have made the market doubtful, but the news is unlikely to alter the trend in analysts' sentiment.
Marketbeat’s analyst tracking tools haven’t picked up any new coverage, but there were several updates just before the Q1 results were released. They include 4 increased price targets above the consensus price target. The consensus price target is trending higher and supporting the price action, although it assumes the market is fairly valued at its current levels. The takeaway is that recent sentiment sees this stock trading 10% to 15% above its current levels, and the price target may trend higher now that the Q1 results are in.
Boston Scientific: Strength Was Expected
Boston Scientific had an outstanding quarter, with top and bottom-line growth outpacing the analyst consensus. The problem is that even with the estimates rising, the market was expecting solid results, which is what it got. The $3.39 billion in revenue is up 11.9% compared to last year and beat the Marketbeat.com consensus by 720 basis points on an 11% increase in MedSurg sales and a 12.7% increase in Cardio sales. Revenue is up 14.9% on an operational basis which shows the strength of the core business. Organic growth is also up firmly at 14%.
The bottom line results are equally good with YOY growth and outperformance relative to the consensus. The $0.47 adjusted EPS is up about 20% YOY to outpace the topline growth and beat by 850 basis points. This led to an increase in guidance favorable to higher share prices over the longer term. The company expects revenue to grow by 8.5% to 10.5%, up from the prior view of 5% to 7%, and the EPS outlook is robust. The company expects FY and 2nd quarter EPS to match the consensus at the low end of the range; this should be enough to get a few analysts to raise their targets.
Boston Scientific Versus Peers
Boston Scientific is a growth-oriented company without dividends, which may turn off some investors. Others in the group offer yield and growth for the same value. Among those are Abbott Laboratories (NYSE: ABT), which also provides diversification and Medtronic (NYSE: MDT). Abbott Laboratories trades at the same 25X/26X multiple as BSX but pays a healthy 1.85% dividend yield. The distribution is also growing and backed up by a solid balance sheet. Medtronic has been lagging behind the medical device group and so offers value. It trades at only 17X earnings and pays an excellent 3.% yield. It just received early approval for the MiniMed 780G insulin pump, news that should show up in results as soon as the summer quarter.
The chart of Boston Scientific is bullish regardless of the dividend and the post-release action. The post-release action resulted in profit-taking, but support is strong at the short-term moving average and indicates a trend-following buy signal. Assuming the market follows through on this move, this stock should retest the all-time highs soon and possibly break to new ones.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among those are Abbott Laboratories (NYSE: ABT), which also provides diversification and Medtronic (NYSE: MDT). The factors driving the stock are the rebound in medical procedures, organic growth of healthcare services, innovation, acquisitions and results. The takeaway is that recent sentiment sees this stock trading 10% to 15% above its current levels, and the price target may trend higher now that the Q1 results are in. | Among those are Abbott Laboratories (NYSE: ABT), which also provides diversification and Medtronic (NYSE: MDT). Although the Q1 results sparked a round of profit-taking, Boston Scientific (NYSE: BSX) can set another new all-time high in 2023. The consensus price target is trending higher and supporting the price action, although it assumes the market is fairly valued at its current levels. | Among those are Abbott Laboratories (NYSE: ABT), which also provides diversification and Medtronic (NYSE: MDT). The market has been trending higher on a combination of factors that result in up trending sentiment and analyst price targets that have yet to end. The consensus price target is trending higher and supporting the price action, although it assumes the market is fairly valued at its current levels. | Among those are Abbott Laboratories (NYSE: ABT), which also provides diversification and Medtronic (NYSE: MDT). Although the Q1 results sparked a round of profit-taking, Boston Scientific (NYSE: BSX) can set another new all-time high in 2023. The market has been trending higher on a combination of factors that result in up trending sentiment and analyst price targets that have yet to end. |
31031.0 | 2023-04-27 00:00:00 UTC | The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-biorad-laboratories-henry-schein-insulet-abbott-and | nan | nan | For Immediate Release
Chicago, IL – April 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: BioRad Laboratories BIO, Henry Schein HSIC, Insulet PODD, Abbott ABT and LabCorp LH.
Here are highlights from Wednesday’s Analyst Blog:
3 MedTech Stocks Likely to Beat Q1 Earnings Estimates
So far, the first-quarter reporting cycle has displayed a year-over-year earnings deterioration for MedTech companies within the broader Medical sector. The handful of MedTech stocks that have released their earnings so far showed market share gain within their base businesses through the months of the first quarter compared with 2022. However, the ongoing macroeconomic headwind in the form of a record level of inflation put pressure on the bottom line.
Even if we consider the performance on a sequential basis, the first-quarter performance of the majority of the companies is likely to have declined. Replicating the market-wide trend, this sector’s first-quarter results are likely to be significantly dampened by the ongoing macroeconomic threat in the United States and outside.
Here we talk about three stocks, BioRad Laboratories, Henry Schein and Insulet that are expected to beat earnings estimates in the ongoing reporting cycle.
Two Major Q1 Trends
The first-quarter reporting cycle is expected to depict a year-over-year improvement in base sales volumes. This can be attributed to a significant reduction in COVID-led severity globally. There has been a significant rebound in non-COVID and elective legacy businesses of the MedTech companies. Meanwhile, the first-quarter results of the diagnostic testing companies are expected to reflect a year-over-year decline in testing demand.
However, a contrasting trend is also evident. Considering the deteriorating trade situation, with global inflationary pressure leading to an extremely tighter situation related to raw material and labor cost as well as freight charges, we expect first-quarter results to be disappointing in comparison to the year-ago period.
Through the first-quarter months, the companies, which are into international trade, are expected to have faced severe currency headwinds. During this period, the U.S. dollar strengthened compared to several foreign currencies, resulting in a slightly more unfavorable impact on sales compared to exchange rates at the time of the fourth-quarter earnings season.
In this regard, IMF, in April provided its World Economic Outlook Update. Going by the outlook, the baseline forecast is for growth to decelerate from 3.4% in 2022 to 2.8% in 2023, before settling at 3% in 2024. IMF expects developed economies to see an especially pronounced growth slowdown, from 2.7% in 2022 to 1.3% in 2023. This is expected to get reflected in the Q1 results of the MedTech companies in the form of logistical challenges and increasing unit cost in the first quarter, resulting in corporate profitability cuts.
Q1 Scorecard Thus Far
Per the latest Earnings Preview, quarterly results so far have been dull year over year, reflecting the ongoing macroeconomic headwinds and record level of inflationary pressure worldwide. Going by the sector’s scorecard, 8.8% of the companies in the Medical sector, constituting 27.5% of the sector’s market capitalization, reported earnings till Apr 19. Of these, 100% beat both earnings and revenue estimates. Earnings declined 2.4% year over year on 9.8% higher revenues.
Overall, first-quarter earnings of the Medical sector are expected to plunge 22.4% on 1% revenue growth. This compares with the fourth-quarter earnings decline of 6.7% on revenue growth of 4.9%.
Abbott is one of the few companies whose base-business performance registered a strong recovery rate.
In the first quarter, Abbott’s Established Pharmaceuticals sales increased 11.1% on an organic basis on sales improvement in countries like Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management. Diabetes Care reported organic growth of 21% year over year, led by FreeStyle Libre, which contributed $1.2 billion in revenues in the reported quarter.
However, rising costs and expenses in the face of record inflationary pressure put huge pressure on margins for the company.Adjusted operating margin contracted 827 bps to 20.5% in Q1.
LabCorp’s revenues in the first quarter fell 3.1% year over year. The decline in revenues can be attributed to a 3.6% fall in organic revenues and a 0.7% negative impact from foreign currency translation. The downside was partially offset by 1.2% growth from acquisitions net of divestitures. The drop in organic revenues was due to an 11.6% fall in contribution from COVID-19 PCR and antibody testing (COVID-19 testing).
LabCorp’s gross margin contracted 582 basis points (bps) to 25.8% in the first quarter. Adjusted operating margin contracted 857 bps from the year-ago quarter to 11.1%.
Zacks Methodology
Given the high degree of diversity in the Medtech industry, finding the right stocks with the potential to beat estimates might be quite a daunting task.
However, our proprietary Zacks methodology makes this fairly simple.
We are focusing on stocks that have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Our research shows that for stocks with this combination, the chances of an earnings surprise are as high as 70%.
Earnings ESP provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here we present three MedTech stocks that are expected to beat earnings estimates in this reporting cycle.
BioRad’s Life Science segment has been registering robust revenues over the past few quarters, driven by sustained sales in Droplet Digital PCR and qPCR products, process chromatography and western blotting. In the last reported quarter, BIO delivered solid organic revenues from this segment, partly contributed by the reduction of back-orders. We expect this growth momentum to have continued in the first quarter of 2023. (BioRad Laboratories to Post Q1 Earnings: What's in Store?)
BioRad’s Earnings ESP of +0.16% and a Zacks Rank #2 raise the possibility of an earnings surprise in the to-be-reported quarter.
BioRad is slated to release results for the first quarter of fiscal 2023 on May 4.
Bio-Rad Laboratories, Inc. price-eps-surprise | Bio-Rad Laboratories, Inc. Quote
Henry Schein’s Dental business is likely to have gained from the acquisition of Midway Dental in the United States and Condor Dental in Switzerland in the first quarter. The company also acquired a majority stake in Unitas and completed the acquisition of a majority ownership stake in Biotech Dental S.A.S. These newly-added businesses are expected to have strengthened the company’s longstanding presence in the United States and worldwide, providing dental customers with an expanded portfolio of solutions. (Read more: Henry Schein to Report Q1 Earnings: What's in Store?)
Henry Schein is expected to release first-quarter 2023 results shortly.
Henry Schein has an Earnings ESP of +0.99% and a Zacks Rank #2.
Henry Schein, Inc. price-eps-surprise | Henry Schein, Inc. Quote
Insulet’s Q1 performance is expected to have benefited from the continued uptake of Omnipod through the U.S. pharmacy channel and strong U.S. and Total Omnipod new customer starts. This is expected to have been driven mainly by a strong start to the full market release of the Omnipod 5 automated insulin delivery system in the United States.
Insulet is scheduled to release first-quarter 2023 results on May 4.
Insulet has an Earnings ESP of +70.21% and a Zacks Rank #1.
Insulet Corporation price-eps-surprise | Insulet Corporation Quote
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: BioRad Laboratories BIO, Henry Schein HSIC, Insulet PODD, Abbott ABT and LabCorp LH. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. BioRad’s Life Science segment has been registering robust revenues over the past few quarters, driven by sustained sales in Droplet Digital PCR and qPCR products, process chromatography and western blotting. | Stocks recently featured in the blog include: BioRad Laboratories BIO, Henry Schein HSIC, Insulet PODD, Abbott ABT and LabCorp LH. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Here are highlights from Wednesday’s Analyst Blog: 3 MedTech Stocks Likely to Beat Q1 Earnings Estimates So far, the first-quarter reporting cycle has displayed a year-over-year earnings deterioration for MedTech companies within the broader Medical sector. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: BioRad Laboratories BIO, Henry Schein HSIC, Insulet PODD, Abbott ABT and LabCorp LH. Here are highlights from Wednesday’s Analyst Blog: 3 MedTech Stocks Likely to Beat Q1 Earnings Estimates So far, the first-quarter reporting cycle has displayed a year-over-year earnings deterioration for MedTech companies within the broader Medical sector. | Stocks recently featured in the blog include: BioRad Laboratories BIO, Henry Schein HSIC, Insulet PODD, Abbott ABT and LabCorp LH. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Replicating the market-wide trend, this sector’s first-quarter results are likely to be significantly dampened by the ongoing macroeconomic threat in the United States and outside. |
31032.0 | 2023-04-26 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-12 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31033.0 | 2023-04-26 00:00:00 UTC | 3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings | ABT | https://www.nasdaq.com/articles/3-medtech-stocks-likely-to-beat-estimates-in-q1-earnings | nan | nan | So far, the first-quarter reporting cycle has displayed a year-over-year earnings deterioration for MedTech companies within the broader Medical sector. The handful of MedTech stocks that have released their earnings so far showed market share gain within their base businesses through the months of the first quarter compared with 2022. However, the ongoing macroeconomic headwind in the form of a record level of inflation put pressure on the bottom line.
Even if we consider the performance on a sequential basis, the first-quarter performance of the majority of the companies is likely to have declined. Replicating the market-wide trend, this sector’s first-quarter results are likely to be significantly dampened by the ongoing macroeconomic threat in the United States and outside.
Here we talk about three stocks, BioRad Laboratories BIO, Henry Schein HSIC and Insulet PODD that are expected to beat earnings estimates in the ongoing reporting cycle.
Two Major Q1 Trends
The first-quarter reporting cycle is expected to depict a year-over-year improvement in base sales volumes. This can be attributed to a significant reduction in COVID-led severity globally. There has been a significant rebound in non-COVID and elective legacy businesses of the MedTech companies. Meanwhile, the first-quarter results of the diagnostic testing companies are expected to reflect a year-over-year decline in testing demand.
However, a contrasting trend is also evident. Considering the deteriorating trade situation, with global inflationary pressure leading to an extremely tighter situation related to raw material and labor cost as well as freight charges, we expect first-quarter results to be disappointing in comparison to the year-ago period. Through the first-quarter months, the companies, which are into international trade, are expected to have faced severe currency headwinds. During this period, the U.S. dollar strengthened compared to several foreign currencies, resulting in a slightly more unfavorable impact on sales compared to exchange rates at the time of the fourth-quarter earnings season.
In this regard, IMF, in April provided its World Economic Outlook Update. Going by the outlook, the baseline forecast is for growth to decelerate from 3.4% in 2022 to 2.8% in 2023, before settling at 3% in 2024. IMF expects developed economies to see an especially pronounced growth slowdown, from 2.7% in 2022 to 1.3% in 2023. This is expected to get reflected in the Q1 results of the MedTech companies in the form of logistical challenges and increasing unit cost in the first quarter, resulting in corporate profitability cuts.
Q1 Scorecard Thus Far
Per the latest Earnings Preview, quarterly results so far have been dull year over year, reflecting the ongoing macroeconomic headwinds and record level of inflationary pressure worldwide. Going by the sector’s scorecard, 8.8% of the companies in the Medical sector, constituting 27.5% of the sector’s market capitalization, reported earnings till Apr 19. Of these, 100% beat both earnings and revenue estimates. Earnings declined 2.4% year over year on 9.8% higher revenues.
Overall, first-quarter earnings of the Medical sector are expected to plunge 22.4% on 1% revenue growth. This compares with the fourth-quarter earnings decline of 6.7% on revenue growth of 4.9%.
Abbott ABT is one of the few companies whose base-business performance registered a strong recovery rate.
In the first quarter, Abbott’s Established Pharmaceuticals sales increased 11.1% on an organic basis on sales improvement in countries like Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management. Diabetes Care reported organic growth of 21% year over year, led by FreeStyle Libre, which contributed $1.2 billion in revenues in the reported quarter.
However, rising costs and expenses in the face of record inflationary pressure put huge pressure on margins for the company.Adjusted operating margin contracted 827 bps to 20.5% in Q1.
LabCorp’s LH revenues in the first quarter fell 3.1% year over year. The decline in revenues can be attributed to a 3.6% fall in organic revenues and a 0.7% negative impact from foreign currency translation. The downside was partially offset by 1.2% growth from acquisitions net of divestitures. The drop in organic revenues was due to an 11.6% fall in contribution from COVID-19 PCR and antibody testing (COVID-19 testing).
LabCorp’s gross margin contracted 582 basis points (bps) to 25.8% in the first quarter. Adjusted operating margin contracted 857 bps from the year-ago quarter to 11.1%.
Zacks Methodology
Given the high degree of diversity in the Medtech industry, finding the right stocks with the potential to beat estimates might be quite a daunting task.
However, our proprietary Zacks methodology makes this fairly simple.
We are focusing on stocks that have the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Our research shows that for stocks with this combination, the chances of an earnings surprise are as high as 70%.
Earnings ESP provides the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here we present three MedTech stocks that are expected to beat earnings estimates in this reporting cycle.
BioRad’s Life Science segment has been registering robust revenues over the past few quarters, driven by sustained sales in Droplet Digital PCR and qPCR products, process chromatography and western blotting. In the last reported quarter, BIO delivered solid organic revenues from this segment, partly contributed by the reduction of back-orders. We expect this growth momentum to have continued in the first quarter of 2023. (BioRad Laboratories to Post Q1 Earnings: What's in Store?)
BioRad’s Earnings ESP of +0.16% and a Zacks Rank #2 raise the possibility of an earnings surprise in the to-be-reported quarter.
BioRad is slated to release results for the first quarter of fiscal 2023 on May 4.
Bio-Rad Laboratories, Inc. Price and EPS Surprise
Bio-Rad Laboratories, Inc. price-eps-surprise | Bio-Rad Laboratories, Inc. Quote
Henry Schein’s Dental business is likely to have gained from the acquisition of Midway Dental in the United States and Condor Dental in Switzerland in the first quarter. The company also acquired a majority stake in Unitas and completed the acquisition of a majority ownership stake in Biotech Dental S.A.S. These newly-added businesses are expected to have strengthened the company’s longstanding presence in the United States and worldwide, providing dental customers with an expanded portfolio of solutions. (Read more: Henry Schein to Report Q1 Earnings: What's in Store?)
Henry Schein is expected to release first-quarter 2023 results shortly.
Henry Schein has an Earnings ESP of +0.99% and a Zacks Rank #2.
Henry Schein, Inc. Price and EPS Surprise
Henry Schein, Inc. price-eps-surprise | Henry Schein, Inc. Quote
Insulet’s Q1 performance is expected to have benefited from the continued uptake of Omnipod through the U.S. pharmacy channel and strong U.S. and Total Omnipod new customer starts. This is expected to have been driven mainly by a strong start to the full market release of the Omnipod 5 automated insulin delivery system in the United States.
Insulet is scheduled to release first-quarter 2023 results on May 4.
Insulet has an Earnings ESP of +70.21% and a Zacks Rank #1.
Insulet Corporation Price and EPS Surprise
Insulet Corporation price-eps-surprise | Insulet Corporation Quote
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT is one of the few companies whose base-business performance registered a strong recovery rate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Here we talk about three stocks, BioRad Laboratories BIO, Henry Schein HSIC and Insulet PODD that are expected to beat earnings estimates in the ongoing reporting cycle. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT is one of the few companies whose base-business performance registered a strong recovery rate. Here we talk about three stocks, BioRad Laboratories BIO, Henry Schein HSIC and Insulet PODD that are expected to beat earnings estimates in the ongoing reporting cycle. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT is one of the few companies whose base-business performance registered a strong recovery rate. Here we talk about three stocks, BioRad Laboratories BIO, Henry Schein HSIC and Insulet PODD that are expected to beat earnings estimates in the ongoing reporting cycle. | Abbott ABT is one of the few companies whose base-business performance registered a strong recovery rate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. The handful of MedTech stocks that have released their earnings so far showed market share gain within their base businesses through the months of the first quarter compared with 2022. |
31034.0 | 2023-04-25 00:00:00 UTC | Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised | ABT | https://www.nasdaq.com/articles/centene-cnc-q1-earnings-miss-estimates-23-eps-view-raised | nan | nan | Centene Corporation CNC reported first-quarter 2023 adjusted earnings per share (EPS) of $2.11, which lagged the Zacks Consensus Estimate by 5.4%. Nevertheless, the bottom line advanced 15.3% year over year.
Revenues of CNC amounted to $38,889 million, which improved 4.6% year over year. The top line outpaced the consensus mark by 7.1%.
The quarterly results took a hit from escalating medical costs. Nevertheless, the downside was partly offset by a growing premium base stemming from solid membership growth within most of its business lines and numerous contract wins.
Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation price-consensus-eps-surprise-chart | Centene Corporation Quote
Quarterly Operational Update
Revenues from Medicaid rose 5% year over year in the first quarter, while Medicare revenues grew 2% year over year. Meanwhile, commercial revenues climbed 27% year over year.
Premiums of Centene improved 6.1% year over year to $33,825 million, higher than the Zacks Consensus Estimate of $33,104 million and our estimate of $32,936.5 million. This was due to solid membership growth of 52% in the Marketplace business as well as organic Medicaid growth.
Service revenues of $1,127 million dropped 51.9% year over year in the quarter under review. Yet, the metric beat the consensus mark of $816 million.
The total membership of CNC came in at 28.5 million as of Mar 31, 2023, which increased 8.5% year over year and surpassed our estimate of 27.4 million.
Health Benefits Ratio (HBR) of 87% improved 30 basis points (bps) year over year in the first quarter, thanks to disciplined Marketplace pricing and reduced Medicare utilization.
Centene reported net earnings of $1,130 million in the quarter under review, which surged 32.6% year over year.
Total operating expenses of $37,671 million increased 4.8% year over year. Medical costs rose 5.7% year over year to $29,434 million while selling, general and administrative expenses (“SG&A”) of $3,011 million escalated 9.7% year over year.
Adjusted SG&A expense ratio deteriorated 80 bps year over year to 8.5% in the first quarter. The metric suffered a blow from an expanding Marketplace business that operates at an increased SG&A ratio.
Financial Update (as of Mar 31, 2023)
Centene exited the first quarter with cash and cash equivalents of $15,853 million, which climbed 31.3% from the 2022-end figure. Total assets of $83 billion increased 8% from the figure at 2022 end.
Long-term debt amounted to $18,223 million, up 1.6% from the level as of Dec 31, 2022. The current portion of long-term debt amounted to $97 million.
Total stockholders’ equity of $25,166 million grew 4.1% from the 2022-end figure.
In the reported quarter, net operating cash flow of $4,269 million increased almost four-fold year over year.
Share Repurchase Update
Centene bought back 4.9 million shares worth $377 million in the first quarter. As of Apr 25, 2023, CNC had a leftover share buyback capacity of $2.2 billion.
2023 Guidance Revised
Premium and service revenues are currently forecasted between $135.2 billion and $137.2 billion, higher than the prior outlook of $131.5-$133.5 billion. The mid-point of the revised outlook indicates a rise of 0.5% from the 2022 reported figure.
Revenues are estimated to lie between $144.5 billion and $146.5 billion, up from the previous guidance of $137.4-$139.4 billion. The midpoint of the revised outlook implies a 0.7% improvement from the 2022 figure.
Management anticipates adjusted EPS to register a minimum of $6.40 this year, while the earlier view called for the metric to stay between $6.25 and $6.40. The mid-point of the updated outlook suggests a minimum growth of 10.7% from the 2022 figure.
HBR is estimated in the 87.1-87.7% band, compared to the prior outlook of 87.2-87.8%. Adjusted SG&A expense ratio is expected within 8.7-9.1%, higher than the previous guidance of 8.2-8.7%. It also expects an adjusted effective tax rate of 24.1-25.1%.
Diluted shares outstanding are anticipated within 546.6-549.6 million.
2024 Outlook Trimmed
On the basis of an updated view of Medicaid redeterminations, Medicare bid strategy, and business investments, management estimates adjusted EPS to stay higher than $6.60 in 2024. The earlier view called for the metric to be a minimum of $7.15.
Long-Term Growth
Centene remains optimistic to achieve long-term adjusted earnings compound annual growth in the range of 12-15% in the second half of this decade.
Zacks Rank
Centene currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate.
Elevance Health’s first-quarter 2023 earnings of $9.46 per share beat the Zacks Consensus Estimate of $9.26 and our estimate of $9.22. Additionally, the bottom line advanced 15.5% year over year. ELV’s operating revenues improved 10.6% year over year to $41,898 million in the quarter under review. The top line beat the consensus mark by 2.5% and came higher than our estimate of $40,766.5 million. Medical membership of Elevance Health, as of Mar 31, 2023, totaled 48.1 million, which rose 2.9% year over year in the first quarter.
HCA Healthcare’s first-quarter 2023 adjusted earnings of $4.93 per share surpassed the Zacks Consensus Estimate by 23.6%. Also, the bottom line climbed 19.7% year over year. HCA’s revenues advanced 4.3% year over year to $15.6 billion. The top line beat the consensus mark by 2% and our estimate of $15.2 billion. While same-facility equivalent admissions rose 7.5% year over year in the first quarter, same-facility admissions improved 4.4% year over year.
Abbott Laboratories reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%. First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 1.1%. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Adjusted operating margin also contracted 827 bps to 20.5%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report
Centene Corporation (CNC) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31035.0 | 2023-04-25 00:00:00 UTC | NUVA vs. ABT: Which Stock Is the Better Value Option? | ABT | https://www.nasdaq.com/articles/nuva-vs.-abt%3A-which-stock-is-the-better-value-option | nan | nan | Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
NuVasive has a Zacks Rank of #2 (Buy), while Abbott has a Zacks Rank of #3 (Hold) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that NUVA is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
NUVA currently has a forward P/E ratio of 20.43, while ABT has a forward P/E of 25.20. We also note that NUVA has a PEG ratio of 1.02. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ABT currently has a PEG ratio of 4.95.
Another notable valuation metric for NUVA is its P/B ratio of 2.58. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ABT has a P/B of 5.22.
These are just a few of the metrics contributing to NUVA's Value grade of A and ABT's Value grade of C.
NUVA is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that NUVA is likely the superior value option right now.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). NUVA currently has a forward P/E ratio of 20.43, while ABT has a forward P/E of 25.20. ABT currently has a PEG ratio of 4.95. | Click to get this free report NuVasive, Inc. (NUVA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). NUVA currently has a forward P/E ratio of 20.43, while ABT has a forward P/E of 25.20. | These are just a few of the metrics contributing to NUVA's Value grade of A and ABT's Value grade of C. NUVA is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report NuVasive, Inc. (NUVA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). | Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). ABT currently has a PEG ratio of 4.95. NUVA currently has a forward P/E ratio of 20.43, while ABT has a forward P/E of 25.20. |
31036.0 | 2023-04-25 00:00:00 UTC | This Supercharged Dividend King Stock Might Soon Run Out of Steam | ABT | https://www.nasdaq.com/articles/this-supercharged-dividend-king-stock-might-soon-run-out-of-steam | nan | nan | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. Speaking to this point, the drugmaker has grown its annual revenue by a healthy 215% and its dividend payout by 270% since becoming an independent entity.
As a result of its rapid top-line growth and ever-rising dividend payout, AbbVie has been one of the best-performing Dividend King stocks over the past 10 years. To wit: The company's shares have delivered a staggering 637% total return on capital (when including dividends) over this period.
Image source: Getty Images.
As a refresher, a Dividend King is a company that has raised its payout for at least 50 consecutive years. AbbVie falls into this bucket thanks, in part, to Abbott's long track record of annual dividend increases.
AbbVie's success has centered around the anti-inflammatory biologic medicine Humira, which has topped $20 billion in annual sales each of the past three years. It accounted for 37% of the company's total net revenue in 2022.
The end of an era
Humira's sales are in sunset mode due to the therapy's recent patent expirations in both the E.U. and the United States. To overcome this headwind, the company has been rapidly expanding the approved indications for its interleukin-23 (IL-23) inhibitor Skyrizi, as well as the reversible JAK inhibitor Rinvoq.
Taken together, AbbVie expects these two next-generation immunology products to generate over $17.5 billion in annual sales by 2025. What's more, these two drugs are expected to eventually exceed Humira's peak sales in the back half of the current decade.
If true, Humira's anticipated sales decline over the next three years won't be all that big a deal for shareholders. The good news is that management has given shareholders some solid reasons to believe in its ability to maintain a top-shelf position in immunology, despite this key patent expiration.
For example, it has consistently faced fierce competitive threats in immunology from elite drugmakers such as Bristol-Myers Squibb, Johnson & Johnson, Pfizer, and Takeda Pharmaceutical. While some of these rivals have carved out a profitable niche in this $200-billion-a-year space, AbbVie has nonetheless maintained a top-shelf market share in several key indications, such as rheumatoid arthritis and inflammatory bowel disease (IBD), among others.
A new competitive threat could flip the script
AbbVie's dominance in immunology might nevertheless wane in the back half of the decade. The key reason is Merck's (NYSE: MRK) decision to lean into immunology through a $10.8 billion buyout of Prometheus Biosciences (NASDAQ: RXDX). This buyout centers around a novel anti-inflammatory medicine known as a tumor necrosis factor-like ligand 1A (TL1A). Merck's newly acquired TL1A therapeutic is currently dubbed PRA023.
This drug is presently in trials for ulcerative colitis and Crohn's disease, two common forms of IBD. However, a deeper dive shows the drug could have a best-in-class efficacy profile in several other immune-mediated diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
AbbVie, for its part, is relying on these additional indications to push its next-generation immunology meds beyond Humira's high-water point from a commercial standpoint. If Merck does indeed pursue these indications with PRA023, as most industry insiders expect, AbbVie might have to contend with a serious competitive threat to its immunology franchise in the second half of the decade.
AbbVie has other problems, too
In 2015, AbbVie paid $21 billion to acquire the groundbreaking blood-cancer medicine Imbruvica. Although the drug has indeed been a star from a growth standpoint since this deal took place, Imbruvica's sales have started to falter in response to the launch of new competitors in the space. In the most recent quarter, for instance, global Imbruvica sales fell by a worrisome 19.5%. It was originally billed as a key pillar for growth in the post-Humira environment for the drugmaker, but that thesis might no longer hold water.
And AbbVie spent a whopping $63 billion for the medical-aesthetic specialist Allergan in 2020. This deal, in many ways, centered around the wrinkle treatment Botox. Like Imbruvica, Botox has been a key growth product for AbbVie since this transaction. Again, though, it is also facing new competitive threats that could undermine its commercial opportunity in the near future.
More importantly, though, AbbVie's decision to buy additional revenue through these two high-dollar deals wasn't exactly budget friendly. At last count, the company had more than $63 billion in outstanding debt on its balance sheet.
While the drugmaker has been quickly de-leveraging in recent years, the bulk of the cash flows responsible for AbbVie's ability to do so have stemmed mainly from Humira. With Humira, Imbruvica, and Botox sales under threat, it might become harder for the company to carry out its de-leveraging plan within the next two to three years.
ABBV total long-term debt (annual) data by YCharts.
The big picture
AbbVie's management has earned a vote of confidence from shareholders. Its collective ability to shepherd Humira to the pinnacle of the immunology world in the face of enormous competition is a rare feat.
In fact, the only other two pharma companies that have maintained an overwhelmingly dominant position in their core area of expertise in the last 20 years are Gilead Sciences in HIV and Vertex Pharmaceuticals in cystic fibrosis. The reason is that rapid innovation in the space makes it nearly impossible to fend off competition forever.
Now, AbbVie has so far stayed ahead of the curve with the advent of Skyrizi and Rinvoq. But Merck and a slew of other companies do appear to have designs on wrestling market share away in the years to come. What's more, AbbVie's high debt load could limit the drugmaker's ability to pursue additional bolt-on acquisitions in the event its post-Humira growth plan starts to unravel.
All told, AbbVie's goal of returning to high levels of top-line growth by 2025 is far from a sure thing. This stated goal will heavily depend on the clinical development of rival therapies in key therapeutic areas such as immunology and oncology, as well as the company's ability to hit on additional value drivers in its earlier-stage pipeline. Since clinical trials are inherently unpredictable, AbbVie's risk-to-reward ratio could be tilting in the wrong direction. Time will tell.
10 stocks we like better than AbbVie
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Merck, Pfizer, and Vertex Pharmaceuticals. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. While some of these rivals have carved out a profitable niche in this $200-billion-a-year space, AbbVie has nonetheless maintained a top-shelf market share in several key indications, such as rheumatoid arthritis and inflammatory bowel disease (IBD), among others. In fact, the only other two pharma companies that have maintained an overwhelmingly dominant position in their core area of expertise in the last 20 years are Gilead Sciences in HIV and Vertex Pharmaceuticals in cystic fibrosis. | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. For example, it has consistently faced fierce competitive threats in immunology from elite drugmakers such as Bristol-Myers Squibb, Johnson & Johnson, Pfizer, and Takeda Pharmaceutical. While some of these rivals have carved out a profitable niche in this $200-billion-a-year space, AbbVie has nonetheless maintained a top-shelf market share in several key indications, such as rheumatoid arthritis and inflammatory bowel disease (IBD), among others. | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. As a result of its rapid top-line growth and ever-rising dividend payout, AbbVie has been one of the best-performing Dividend King stocks over the past 10 years. AbbVie's success has centered around the anti-inflammatory biologic medicine Humira, which has topped $20 billion in annual sales each of the past three years. | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. As a result of its rapid top-line growth and ever-rising dividend payout, AbbVie has been one of the best-performing Dividend King stocks over the past 10 years. Like Imbruvica, Botox has been a key growth product for AbbVie since this transaction. |
31037.0 | 2023-04-25 00:00:00 UTC | Abbott Announces Two New FDA Clearances For Life Support System | ABT | https://www.nasdaq.com/articles/abbott-announces-two-new-fda-clearances-for-life-support-system | nan | nan | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system.
With the new indication, the CentriMag Blood Pump for use with the CentriMag System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) - a type of life support for people whose heart and lungs are not working - is critical to saving their life.
Now, the clearance for longer-term support allows physicians more time to assess next steps and make critical care decisions for their patients.
Abbott also received FDA clearance for its new CentriMag Pre-connected Pack - a packaged system with several pre-connected components of the CentriMag system that can accelerate the deployment of the life support system.
Combined, the dual clearances further build out Abbott's ability to offer leading life support systems to hospitals and physicians managing critically ill patients.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. Now, the clearance for longer-term support allows physicians more time to assess next steps and make critical care decisions for their patients. Combined, the dual clearances further build out Abbott's ability to offer leading life support systems to hospitals and physicians managing critically ill patients. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. Abbott also received FDA clearance for its new CentriMag Pre-connected Pack - a packaged system with several pre-connected components of the CentriMag system that can accelerate the deployment of the life support system. Combined, the dual clearances further build out Abbott's ability to offer leading life support systems to hospitals and physicians managing critically ill patients. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) - a type of life support for people whose heart and lungs are not working - is critical to saving their life. Abbott also received FDA clearance for its new CentriMag Pre-connected Pack - a packaged system with several pre-connected components of the CentriMag system that can accelerate the deployment of the life support system. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) - a type of life support for people whose heart and lungs are not working - is critical to saving their life. Now, the clearance for longer-term support allows physicians more time to assess next steps and make critical care decisions for their patients. |
31038.0 | 2023-04-25 00:00:00 UTC | Pre-Market Most Active for Apr 25, 2023 : CSCO, FRC, TQQQ, SQQQ, INTC, INAB, BEKE, GOOGL, ABT, KO, MCD, GM | ABT | https://www.nasdaq.com/articles/pre-market-most-active-for-apr-25-2023-%3A-csco-frc-tqqq-sqqq-intc-inab-beke-googl-abt-ko | nan | nan | The NASDAQ 100 Pre-Market Indicator is down -46.26 to 12,923.5. The total Pre-Market volume is currently 54,956,198 shares traded.
The following are the most active stocks for the pre-market session:
Cisco Systems, Inc. (CSCO) is unchanged at $47.39, with 3,233,309 shares traded. CSCO's current last sale is 86.16% of the target price of $55.
FIRST REPUBLIC BANK (FRC) is -3.36 at $12.64, with 3,009,569 shares traded. FRC's current last sale is 11.29% of the target price of $112.
ProShares UltraPro QQQ (TQQQ) is -0.28 at $26.43, with 2,500,113 shares traded. This represents a 64.16% increase from its 52 Week Low.
ProShares UltraPro Short QQQ (SQQQ) is +0.33 at $31.26, with 2,388,615 shares traded. This represents a 7.13% increase from its 52 Week Low.
Intel Corporation (INTC) is -0.14 at $29.52, with 2,266,312 shares traded.INTC is scheduled to provide an earnings report on 4/27/2023, for the fiscal quarter ending Mar2023. The consensus earnings per share forecast is -0.16 per share, which represents a 87 percent increase over the EPS one Year Ago
IN8bio, Inc. (INAB) is -0.34 at $2.66, with 2,176,344 shares traded. As reported by Zacks, the current mean recommendation for INAB is in the "strong buy range".
KE Holdings Inc (BEKE) is -0.34 at $16.12, with 2,155,589 shares traded. As reported by Zacks, the current mean recommendation for BEKE is in the "buy range".
Alphabet Inc. (GOOGL) is -0.27 at $105.70, with 1,503,461 shares traded. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range".
Abbott Laboratories (ABT) is -0.53 at $109.87, with 1,151,994 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. The consensus EPS forecast is $1.2. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
Coca-Cola Company (The) (KO) is +0.11 at $64.06, with 989,633 shares traded. As reported by Zacks, the current mean recommendation for KO is in the "buy range".
McDonald's Corporation (MCD) is +2.6 at $295.80, with 863,423 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $2.31. , following a 52-week high recorded in prior regular session.
General Motors Company (GM) is +0.89 at $35.18, with 837,215 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2023. The consensus EPS forecast is $1.57. Smarter Analyst Reports: Monday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) is -0.53 at $109.87, with 1,151,994 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Intel Corporation (INTC) is -0.14 at $29.52, with 2,266,312 shares traded.INTC is scheduled to provide an earnings report on 4/27/2023, for the fiscal quarter ending Mar2023. | Abbott Laboratories (ABT) is -0.53 at $109.87, with 1,151,994 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The consensus earnings per share forecast is -0.16 per share, which represents a 87 percent increase over the EPS one Year Ago | Abbott Laboratories (ABT) is -0.53 at $109.87, with 1,151,994 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The total Pre-Market volume is currently 54,956,198 shares traded. | Abbott Laboratories (ABT) is -0.53 at $109.87, with 1,151,994 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". IN8bio, Inc. (INAB) is -0.34 at $2.66, with 2,176,344 shares traded. |
31039.0 | 2023-04-25 00:00:00 UTC | Is Abbott Laboratories Stock a Buy for Dividend Investors? | ABT | https://www.nasdaq.com/articles/is-abbott-laboratories-stock-a-buy-for-dividend-investors | nan | nan | Dividend growth investing is among the most common investing strategies around, and for good reason: Buying quality businesses and dividend growth stocks often go hand in hand. This is because a company is only able to raise its dividend for decades if its profits are also growing.
With at least 50 consecutive years of payout growth, Dividend Kings are the most reliable dividend growers in the investment universe. Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders. But is the stock a buy for income investors? Let's dive into Abbott's fundamentals and valuation to decide.
Adapting to plunging COVID-19 test demand
With 115,000 employees in over 160 countries, Abbott Laboratories maintains a truly global presence as a diversified healthcare company. The company's products enjoy market-leading positions in huge categories such as stents, continuous glucose monitoring (via its FreeStyle Libre franchise), and diagnostics (COVID-19 testing and infectious disease testing). This explains how Abbott boasts a $191 billion market capitalization, which makes it the largest medical device maker on the planet.
Abbott's total net sales dipped 18.1% over the year-ago period to $9.7 billion during the first quarter, which ended March 31. But these results aren't as bad as they look: The precipitous drop in demand for COVID-19 testing in recent months led the company's diagnostics segment revenue to be nearly cut in half (down 48.9%) in the quarter. But when factoring out COVID-19 testing sales and unfavorable foreign currency exchange for the quarter, Abbott's organic sales (nutrition, non-COVID diagnostics, established pharmaceuticals, and medical devices segments) were up 10%.
The Illinois-based company's non-GAAP (adjusted) diluted earnings per share fell 40.5% year over year to $1.03 during the first quarter. Because Abbott's total operating expenses only declined at about half the rate of its net sales, its non-GAAP net margin contracted by nearly 730 basis points to 18.6% in the quarter. This drastic reduction in profitability couldn't be offset by a lower share count stemming from Abbott's share buyback program. As a result, the company's adjusted diluted EPS plunged at twice the rate of its net sales for the quarter.
Abbott is focused on winning more market share with FreeStyle Libre and launching new products. And that's why despite the near-term headwinds from diminishing COVID-19 test volumes, the company's long-term fundamentals are arguably intact.
Image source: Getty Images.
The payout can keep moving higher
Abbott's 1.9% dividend yield is higher than the S&P 500 index's 1.7% yield. And the cherry on top is that high-single-digit annual dividend growth could continue over the long run.
The company's dividend payout ratio is expected to come in around 46% in 2023. This modest payout ratio gives Abbott flexibility to raise its dividend moderately ahead of its earnings growth in the near term as growth is uninspiring. Not to mention that the company can return to more conservative dividend growth when it returns to double-digit adjusted diluted EPS growth, as is expected as soon as 2025.
A solid long-term buy
After months of lackluster performance amid concerns of waning COVID-19 test revenue, shares of Abbott have surged 16% in just the last month. The market is finally realizing that the company is so much more than just COVID-19 testing.
Best of all, Abbott's valuation still seems to be within reason, all things considered. The stock's forward price-to-earnings (P/E) ratio of 23.1 is less than the medical devices industry average forward P/E ratio of 27.6. That's why I believe that Abbott remains a buy for investors seeking a relatively safe and growing payout.
10 stocks we like better than Abbott Laboratories
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 21, 2023
Kody Kester has positions in Abbott Laboratories. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders. Adapting to plunging COVID-19 test demand With 115,000 employees in over 160 countries, Abbott Laboratories maintains a truly global presence as a diversified healthcare company. This explains how Abbott boasts a $191 billion market capitalization, which makes it the largest medical device maker on the planet. | Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders. The Illinois-based company's non-GAAP (adjusted) diluted earnings per share fell 40.5% year over year to $1.03 during the first quarter. As a result, the company's adjusted diluted EPS plunged at twice the rate of its net sales for the quarter. | Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders. Dividend growth investing is among the most common investing strategies around, and for good reason: Buying quality businesses and dividend growth stocks often go hand in hand. This modest payout ratio gives Abbott flexibility to raise its dividend moderately ahead of its earnings growth in the near term as growth is uninspiring. | Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders. As a result, the company's adjusted diluted EPS plunged at twice the rate of its net sales for the quarter. The company's dividend payout ratio is expected to come in around 46% in 2023. |
31040.0 | 2023-04-25 00:00:00 UTC | Unusual Call Option Trade in Abbott Laboratories (ABT) Worth $292.88K | ABT | https://www.nasdaq.com/articles/unusual-call-option-trade-in-abbott-laboratories-abt-worth-%24292.88k | nan | nan | On April 25, 2023 at 11:49:44 ET an unusually large $292.88K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $115.00 / share, expiring in 52 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.40 sigmas above the mean, placing it in the 93.56th percentile of all recent large trades made in ABT options.
This trade was first picked up on Fintel's real time Options Flow tool, where unusual option trades are highlighted.
What is the Fund Sentiment?
There are 3929 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 105 owner(s) or 2.75% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.49%, a decrease of 19.02%. Total shares owned by institutions decreased in the last three months by 0.28% to 1,513,679K shares.
The put/call ratio of ABT is 1.15, indicating a bearish outlook.
Analyst Price Forecast Suggests 15.55% Upside
As of April 24, 2023, the average one-year price target for Abbott Laboratories is $127.57. The forecasts range from a low of $104.03 to a high of $151.20. The average price target represents an increase of 15.55% from its latest reported closing price of $110.40.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 4.04%. The projected annual non-GAAP EPS is $4.45.
What are Other Shareholders Doing?
Meridian Investment Counsel holds 3K shares representing 0.00% ownership of the company. No change in the last quarter.
Americana Partners holds 5K shares representing 0.00% ownership of the company. No change in the last quarter.
SEASONS SERIES TRUST - SA Multi-Managed Large Cap Growth Portfolio Class 1 holds 6K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 8K shares, representing a decrease of 22.23%. The firm decreased its portfolio allocation in ABT by 4.18% over the last quarter.
Eaton Vance Management holds 4,075K shares representing 0.23% ownership of the company. In it's prior filing, the firm reported owning 4,051K shares, representing an increase of 0.58%. The firm decreased its portfolio allocation in ABT by 5.31% over the last quarter.
St. Johns Investment Management Company holds 14K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 15K shares, representing a decrease of 2.15%. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $110.40 / share, the stock's dividend yield is 1.85%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.29 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.61. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On April 25, 2023 at 11:49:44 ET an unusually large $292.88K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $115.00 / share, expiring in 52 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.40 sigmas above the mean, placing it in the 93.56th percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.49%, a decrease of 19.02%. | On April 25, 2023 at 11:49:44 ET an unusually large $292.88K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $115.00 / share, expiring in 52 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.40 sigmas above the mean, placing it in the 93.56th percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.49%, a decrease of 19.02%. | On April 25, 2023 at 11:49:44 ET an unusually large $292.88K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $115.00 / share, expiring in 52 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.40 sigmas above the mean, placing it in the 93.56th percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.49%, a decrease of 19.02%. | On April 25, 2023 at 11:49:44 ET an unusually large $292.88K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $115.00 / share, expiring in 52 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.40 sigmas above the mean, placing it in the 93.56th percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.49%, a decrease of 19.02%. |
31041.0 | 2023-04-25 00:00:00 UTC | The Fed Predicts a Recession: Should You Still Buy Stocks Now? | ABT | https://www.nasdaq.com/articles/the-fed-predicts-a-recession%3A-should-you-still-buy-stocks-now | nan | nan | As all three major indexes touched bear territory last year, many investors hesitated to buy stocks. Rising inflation and general economic woes added to their concerns. And now, there's another element that may reinforce the worries. The Federal Reserve forecasts a recession just ahead.
Minutes from a recent Federal Open Markets Committee (FOMC) meeting predict a "mild recession" later in the year. History shows us that recessions haven't been the easiest of times for investors. So, it's very logical to ask the question you may have been asking since the start of this wave of economic troubles: Should I buy stocks right now? Let's find out.
The Fed comments
First, a bit more detail about the FOMC prediction. The body that defines U.S. monetary policy said gross domestic product growth forecasts for this year have been "subdued" for a while and some weakness in the labor market had been expected too. The addition of the recent banking-sector turmoil, though, aggravated the situation -- leading officials to predict a recession.
The good news is, as mentioned above, the expectation is for a slight downturn -- and the Fed expects recovery to begin next year. Research from International Monetary Fund economists shows recoveries tend to be strong -- and periods of expansion last longer than recessions. All of this is encouraging -- and helps us remember these difficult situations are temporary.
Now let's get back to our question: Even though these tough times won't last forever, should you really buy stocks at this point? After all, the indexes may not have reached a bottom.
It's true that, as a whole, the market may fall further. But that wouldn't stop me from buying stocks today. For a couple of reasons. First, it's impossible to time the general market or a particular stock -- and get in on the absolute lowest price. But over time, this won't matter.
Major indexes have returned to their pre-recession levels following past recessions and gone on to gain. This means even if you bought an index tracker, if you held on for the long term, you benefited from your investment.
And the same holds true if you bought individual stocks. Let's look at a handful of top consumer goods and healthcare names: Amazon (NASDAQ: AMZN), Coca-Cola (NYSE: KO), Pfizer (NYSE: PFE), and Abbott Laboratories (NYSE: ABT). All of these stocks suffered during the Great Recession -- from December 2007 through June 2009.
AMZN data by YCharts
But if you held on for five years from the start of the recession, you would have seen gains in each stock.
AMZN data by YCharts
By holding on through today, you really would have seen your portfolio grow.
AMZN data by YCharts
The importance of long term
This shows the importance of long-term investing and should lift some of your concerns about investing ahead of or during a recession.
It's also worth considering valuation. Many stocks today are trading at dirt cheap prices. Economic woes have spurred investors to turn their backs on companies most sensitive to the economy. But in many cases, these companies' long-term prospects remain very bright.
A good example is Home Depot (NYSE: HD). The stock has stagnated over the past year even after adding $40 billion to sales during the previous two years.
Even predicting flat sales this year, Home Depot still is a leader in a market set to perform over time. Today, Home Depot is trading for about 18 times trailing 12-month earnings -- compared to more than 25 in recent years.
All of this means, even with a possible recession ahead, you still can buy stocks now and win over the long haul. And buying now allows you to scoop up many quality companies for a song. That's a definite plus.
What's important when considering stocks today -- or at any time -- is focusing on the long term. That may help you stay positive during tough times -- and offer you the best path to potential wealth.
10 stocks we like better than Amazon.com
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon.com wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon.com and Home Depot. The Motley Fool has positions in and recommends Abbott Laboratories, Amazon.com, Home Depot, and Pfizer. The Motley Fool recommends the following options: long January 2024 $47.50 calls on Coca-Cola. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Let's look at a handful of top consumer goods and healthcare names: Amazon (NASDAQ: AMZN), Coca-Cola (NYSE: KO), Pfizer (NYSE: PFE), and Abbott Laboratories (NYSE: ABT). Minutes from a recent Federal Open Markets Committee (FOMC) meeting predict a "mild recession" later in the year. The body that defines U.S. monetary policy said gross domestic product growth forecasts for this year have been "subdued" for a while and some weakness in the labor market had been expected too. | Let's look at a handful of top consumer goods and healthcare names: Amazon (NASDAQ: AMZN), Coca-Cola (NYSE: KO), Pfizer (NYSE: PFE), and Abbott Laboratories (NYSE: ABT). AMZN data by YCharts The importance of long term This shows the importance of long-term investing and should lift some of your concerns about investing ahead of or during a recession. The Motley Fool has positions in and recommends Abbott Laboratories, Amazon.com, Home Depot, and Pfizer. | Let's look at a handful of top consumer goods and healthcare names: Amazon (NASDAQ: AMZN), Coca-Cola (NYSE: KO), Pfizer (NYSE: PFE), and Abbott Laboratories (NYSE: ABT). AMZN data by YCharts But if you held on for five years from the start of the recession, you would have seen gains in each stock. All of this means, even with a possible recession ahead, you still can buy stocks now and win over the long haul. | Let's look at a handful of top consumer goods and healthcare names: Amazon (NASDAQ: AMZN), Coca-Cola (NYSE: KO), Pfizer (NYSE: PFE), and Abbott Laboratories (NYSE: ABT). But that wouldn't stop me from buying stocks today. That's right -- they think these 10 stocks are even better buys. |
31042.0 | 2023-04-24 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Peter Lynch - 4/24/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-peter-lynch-4-24-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
THERMO FISHER SCIENTIFIC INC (TMO) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Thermo Fisher Scientific Inc. is engaged in serving science. The Company operates through four segments. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. Analytical Instruments segment provides an offering of instruments and the supporting consumables, software and services that are used for a range of applications. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of THERMO FISHER SCIENTIFIC INC
TMO Guru Analysis
TMO Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
GOODRX HOLDINGS INC (GDRX) is a mid-cap growth stock in the Business Services industry. The rating according to our strategy based on Peter Lynch is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: GoodRx Holdings, Inc. provides a consumer-focused digital healthcare platform in the United States. The Company offers consumers free access for branded and generic medications, medical provider consultations via telehealth, and comprehensive healthcare research and information. The Company offers information and tools to help consumers compare prices and save on their prescription drug purchases. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing and provides access to negotiated prices through its codes across the United States (the prescription transactions offering). These services are free to consumers. It also offers other healthcare products and services, including pharma manufacturer solutions, subscriptions and telehealth services. Its subscription offerings provide subscribers with added benefits and features, such as refill reminders, price alerts and other notifications.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of GOODRX HOLDINGS INC
GDRX Guru Analysis
GDRX Fundamental Analysis
SUMMIT THERAPEUTICS INC (SMMT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company's preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program, which is focused on treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its Discuva Platform.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of SUMMIT THERAPEUTICS INC
SMMT Guru Analysis
SMMT Fundamental Analysis
COGENT BIOSCIENCES INC (COGT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company's advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of COGENT BIOSCIENCES INC
COGT Guru Analysis
COGT Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of THERMO FISHER SCIENTIFIC INC TMO Guru Analysis TMO Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis GOODRX HOLDINGS INC (GDRX) is a mid-cap growth stock in the Business Services industry. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. | Detailed Analysis of THERMO FISHER SCIENTIFIC INC TMO Guru Analysis TMO Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis GOODRX HOLDINGS INC (GDRX) is a mid-cap growth stock in the Business Services industry. Detailed Analysis of GOODRX HOLDINGS INC GDRX Guru Analysis GDRX Fundamental Analysis SUMMIT THERAPEUTICS INC (SMMT) is a small-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of THERMO FISHER SCIENTIFIC INC TMO Guru Analysis TMO Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis GOODRX HOLDINGS INC (GDRX) is a mid-cap growth stock in the Business Services industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Detailed Analysis of THERMO FISHER SCIENTIFIC INC TMO Guru Analysis TMO Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis GOODRX HOLDINGS INC (GDRX) is a mid-cap growth stock in the Business Services industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
31043.0 | 2023-04-24 00:00:00 UTC | XLV, ABT, DHR, ELV: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/xlv-abt-dhr-elv%3A-etf-inflow-alert | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $530.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 295,670,000 to 299,620,000). Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Elevance Health Inc (Symbol: ELV) is up by about 2.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.87. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
BCSF shares outstanding history
UXG Videos
HASI Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Elevance Health Inc (Symbol: ELV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $530.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 295,670,000 to 299,620,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Elevance Health Inc (Symbol: ELV) is up by about 2.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.87. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Elevance Health Inc (Symbol: ELV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $530.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 295,670,000 to 299,620,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.87. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Elevance Health Inc (Symbol: ELV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $530.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 295,670,000 to 299,620,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.87. |
31044.0 | 2023-04-24 00:00:00 UTC | New Product Launches To Aid Boston Scientific's Q1 | ABT | https://www.nasdaq.com/articles/new-product-launches-to-aid-boston-scientifics-q1 | nan | nan | Boston Scientific (NYSE: BSX) is scheduled to report its Q1 2023 results on Wednesday, April 26. We expect the company to report revenues and earnings in line with the consensus estimates. A rise in elective surgeries performed and market share gains for some of its products will likely aid the company’s top-line growth. Although we expect Boston Scientific to navigate well in Q1, our forecast indicates that BSX stock is fully valued, as discussed below. Our interactive dashboard analysis of the Boston Scientific Earnings Preview has additional details.
(1) Revenues expected to align with the consensus estimates
Trefis estimates Boston Scientific’s Q1 2023 revenues to be around $3.2 billion, aligning with the consensus estimate and reflecting a mid-single-digit y-o-y growth.
The company should benefit from a continued uptick in total procedures and new products, including POLARx (Japan), Vercise, and XL valves, among others. Its recent acquisitions, including Baylis, will further bolster its top-line growth. The company has acquired a majority stake in Acotec, which will aid its future sales growth in China.
Looking back at Q4, the company reported a 4% y-o-y rise in sales to $3.2 billion, led by mid-single-digit gains across segments.
Our dashboard on Boston Scientific Revenues offers more details on the company’s segments.
(2) EPS is likely to be in line with the consensus estimates
Boston Scientific’s Q1 2023 adjusted earnings per share (EPS) is expected to be $0.44 per Trefis analysis, broadly in line with the consensus estimate of $0.43.
Boston Scientific’s adjusted net income of $642 million in Q4 2022 reflected a 2% fall from its $653 million figure in the prior-year quarter.
This can be attributed to about a 100 bps fall in net margins.
For the full-year 2023, we expect the adjusted EPS to be higher at $1.92, compared to $1.75 in 2022.
(3) BSX stock is fully valued
We estimate Boston Scientific’s Valuation to be $49 per share, about 4% below the current market price of $51.
At its current levels, BSX stock is trading at 27x forward P/E based on our earnings forecast of $1.92 for 2023, compared to the last three-year average of 24x, implying that BSX stock is fully valued.
If the company reports upbeat Q1 results and provides an outlook better than the street estimates, the P/E multiple will likely be revised upward, resulting in higher levels for BSX stock.
While BSX stock looks fully valued, it is helpful to see how Boston Scientific’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Xylem vs. Merck.
Despite higher inflation and the Fed raising interest rates, among other factors, BSX stock has risen 10% this year. Can it drop from here? See how low Boston Scientific stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Apr 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
BSX Return 2% 10% 136%
S&P 500 Return 1% 8% 85%
Trefis Multi-Strategy Portfolio 2% 10% 246%
[1] Month-to-date and year-to-date as of 4/24/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A rise in elective surgeries performed and market share gains for some of its products will likely aid the company’s top-line growth. The company should benefit from a continued uptick in total procedures and new products, including POLARx (Japan), Vercise, and XL valves, among others. (3) BSX stock is fully valued We estimate Boston Scientific’s Valuation to be $49 per share, about 4% below the current market price of $51. | (1) Revenues expected to align with the consensus estimates Trefis estimates Boston Scientific’s Q1 2023 revenues to be around $3.2 billion, aligning with the consensus estimate and reflecting a mid-single-digit y-o-y growth. (2) EPS is likely to be in line with the consensus estimates Boston Scientific’s Q1 2023 adjusted earnings per share (EPS) is expected to be $0.44 per Trefis analysis, broadly in line with the consensus estimate of $0.43. (3) BSX stock is fully valued We estimate Boston Scientific’s Valuation to be $49 per share, about 4% below the current market price of $51. | (1) Revenues expected to align with the consensus estimates Trefis estimates Boston Scientific’s Q1 2023 revenues to be around $3.2 billion, aligning with the consensus estimate and reflecting a mid-single-digit y-o-y growth. (2) EPS is likely to be in line with the consensus estimates Boston Scientific’s Q1 2023 adjusted earnings per share (EPS) is expected to be $0.44 per Trefis analysis, broadly in line with the consensus estimate of $0.43. Total [2] BSX Return 2% 10% 136% S&P 500 Return 1% 8% 85% Trefis Multi-Strategy Portfolio 2% 10% 246% [1] Month-to-date and year-to-date as of 4/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A rise in elective surgeries performed and market share gains for some of its products will likely aid the company’s top-line growth. (3) BSX stock is fully valued We estimate Boston Scientific’s Valuation to be $49 per share, about 4% below the current market price of $51. Total [2] BSX Return 2% 10% 136% S&P 500 Return 1% 8% 85% Trefis Multi-Strategy Portfolio 2% 10% 246% [1] Month-to-date and year-to-date as of 4/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31045.0 | 2023-04-22 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-11 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31046.0 | 2023-04-21 00:00:00 UTC | HCA Healthcare (HCA) Beats on Q1 Earnings, Ups '23 EPS View | ABT | https://www.nasdaq.com/articles/hca-healthcare-hca-beats-on-q1-earnings-ups-23-eps-view | nan | nan | HCA Healthcare, Inc. HCA reported first-quarter 2023 adjusted earnings of $4.93 per share, which surpassed the Zacks Consensus Estimate by 23.6%. Also, the bottom line climbed 19.7% year over year.
Its shares gained 6% in the pre-market trading session owing to the outperformance.
HCA’s revenues advanced 4.3% year over year to $15.6 billion. The top line beat the consensus mark by 2% and our estimate of $15.2 billion.
The quarterly results gained on the back of expanding patient volumes and increased surgeries which contribute a substantial amount to the top line of HCA Healthcare. However, the upside was partly offset by escalating salaries and benefits expenses.
HCA Healthcare, Inc. Price, Consensus and EPS Surprise
HCA Healthcare, Inc. price-consensus-eps-surprise-chart | HCA Healthcare, Inc. Quote
Quarterly Details
While same-facility equivalent admissions rose 7.5% year over year in the first quarter, same-facility admissions improved 4.4% year over year.
However, same-facility revenue per equivalent admission fell 2.3% year over year in the quarter under review due to greater COVID volumes and reimbursement in the previous year.
Same-facility inpatient surgeries and same-facility outpatient surgeries advanced 3.6% and 5.1%, respectively, year over year. Meanwhile, same-facility emergency room visits increased 10.3% year over year.
Salaries and benefits, supplies and other operating expenses increased 3.2% year over year to $12.4 billion and matched our estimate.
Adjusted EBITDA of $3.2 billion grew 7.7% year over year in the first quarter.
HCA Healthcare operated 180 hospitals and roughly 2,300 ambulatory sites of care across 20 states and the U.K. as of Mar 31, 2023.
Financial Update (as of Mar 31, 2023)
HCA Healthcare exited the first quarter with cash and cash equivalents of $842 million, which dropped 7.3% from the 2022-end level. It had a leftover capacity of $3.8 billion under its credit facilities at the first-quarter end.
Total assets of $52.7 billion inched up 0.5% from the figure at 2022 end.
Long-term debt, excluding debt issuance costs and discounts, amounted to $36.5 billion, down 3.3% from the figure as of Dec 31, 2022.
In the reported quarter, capital expenditures were at $1.2 billion minus acquisitions.
Cash Flows
HCA Healthcare generated cash from operations amounting to $1.8 billion in the first quarter, which surged 34.1% year over year.
Capital Deployment Update
HCA bought back shares worth $846 million in the first quarter. As of Mar 31, 2023, $3.7 billion was left under its buyback authorization.
The Board of Directors approved a quarterly cash dividend of 60 cents per share, which will be paid out on Jun 30, 2023, to its shareholders of record as of Jun 16, 2023.
2023 View Revised
Annual revenues are anticipated to stay between $62.5 billion and $64.5 billion, up from the prior view of $61.5-$63.5 billion. The midpoint of the revised outlook indicates growth of 5.5% from the 2022 reported figure.
Adjusted EBITDA is forecasted within $12.1 billion and $12.7 billion, higher than the previous guidance of $11.8-$12.4 billion. The midpoint of the updated outlook suggests 2.5% growth from the 2022 figure.
Management estimates net income attributable to HCA Healthcare to lie between $4.8 billion and $5.2 billion, up from the prior outlook of $4.5-$4.9 billion.
Earnings per share are predicted within the $17.25-$18.55 band, higher than the previous view of $16.40-$17.60. The midpoint of the revised guidance implies 6% growth from the 2022 figure.
Capital expenditures, excluding acquisitions, are expected at roughly $4.6 billion. The earlier outlook called for the metric to stay at roughly $4.3 billion.
Zacks Rank
HCA Healthcare currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Elevance Health, Inc. ELV and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate.
UnitedHealth Group reported first-quarter 2023 adjusted earnings of $6.26 per share, which beat the Zacks Consensus Estimate of $6.24 and our estimate of $6.17. The bottom line improved from the $5.49 per share reported a year ago.
Revenues of UNH were $91.9 billion for the first quarter, which climbed from $80.1 billion a year ago. The top line beat the consensus mark of $89.3 billion and our estimate of $88.9 billion. The medical care ratio deteriorated 20 basis points year over year to 82.2% in the quarter under review.
Elevance Health’s first-quarter 2023 earnings of $9.46 per share beat the Zacks Consensus Estimate of $9.26 and our estimate of $9.22. Additionally, the bottom line advanced 15.5% year over year. ELV’s operating revenues improved 10.6% year over year to $41,898 million in the quarter under review.
The top line beat the consensus mark by 2.5% and came higher than our estimate of $40,766.5 million. Medical membership of Elevance Health, as of Mar 31, 2023, totaled 48.1 million, which rose 2.9% year over year in the first quarter.
Abbott Laboratories reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%. First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis.
The top line exceeded the Zacks Consensus Estimate by 1.1%. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Adjusted operating margin also, contracted 827 bps to 20.5%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Elevance Health, Inc. ELV and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Releases Of the Medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Elevance Health, Inc. ELV and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Elevance Health, Inc. ELV and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. | ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Other Medical Sector Releases Of the Medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Elevance Health, Inc. ELV and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31047.0 | 2023-04-20 00:00:00 UTC | Noteworthy Thursday Option Activity: MTZ, ABT, TPC | ABT | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-mtz-abt-tpc | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in MasTec Inc. (Symbol: MTZ), where a total volume of 2,435 contracts has been traded thus far today, a contract volume which is representative of approximately 243,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.4% of MTZ's average daily trading volume over the past month, of 513,550 shares. Especially high volume was seen for the $85 strike put option expiring April 21, 2023, with 1,000 contracts trading so far today, representing approximately 100,000 underlying shares of MTZ. Below is a chart showing MTZ's trailing twelve month trading history, with the $85 strike highlighted in orange:
Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,957 contracts, representing approximately 2.7 million underlying shares or approximately 47% of ABT's average daily trading volume over the past month, of 5.7 million shares. Particularly high volume was seen for the $110 strike call option expiring May 19, 2023, with 2,466 contracts trading so far today, representing approximately 246,600 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange:
And Tutor Perini Corp (Symbol: TPC) saw options trading volume of 1,760 contracts, representing approximately 176,000 underlying shares or approximately 46.8% of TPC's average daily trading volume over the past month, of 376,395 shares. Particularly high volume was seen for the $5 strike put option expiring October 20, 2023, with 1,600 contracts trading so far today, representing approximately 160,000 underlying shares of TPC. Below is a chart showing TPC's trailing twelve month trading history, with the $5 strike highlighted in orange:
For the various different available expirations for MTZ options, ABT options, or TPC options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
Oversold Metals Stocks
Top Ten Hedge Funds Holding PCBK
Funds Holding ERHE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $110 strike call option expiring May 19, 2023, with 2,466 contracts trading so far today, representing approximately 246,600 underlying shares of ABT. Below is a chart showing MTZ's trailing twelve month trading history, with the $85 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,957 contracts, representing approximately 2.7 million underlying shares or approximately 47% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Tutor Perini Corp (Symbol: TPC) saw options trading volume of 1,760 contracts, representing approximately 176,000 underlying shares or approximately 46.8% of TPC's average daily trading volume over the past month, of 376,395 shares. | Below is a chart showing MTZ's trailing twelve month trading history, with the $85 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,957 contracts, representing approximately 2.7 million underlying shares or approximately 47% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Tutor Perini Corp (Symbol: TPC) saw options trading volume of 1,760 contracts, representing approximately 176,000 underlying shares or approximately 46.8% of TPC's average daily trading volume over the past month, of 376,395 shares. Particularly high volume was seen for the $110 strike call option expiring May 19, 2023, with 2,466 contracts trading so far today, representing approximately 246,600 underlying shares of ABT. | Below is a chart showing MTZ's trailing twelve month trading history, with the $85 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,957 contracts, representing approximately 2.7 million underlying shares or approximately 47% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Tutor Perini Corp (Symbol: TPC) saw options trading volume of 1,760 contracts, representing approximately 176,000 underlying shares or approximately 46.8% of TPC's average daily trading volume over the past month, of 376,395 shares. Particularly high volume was seen for the $110 strike call option expiring May 19, 2023, with 2,466 contracts trading so far today, representing approximately 246,600 underlying shares of ABT. | Below is a chart showing MTZ's trailing twelve month trading history, with the $85 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,957 contracts, representing approximately 2.7 million underlying shares or approximately 47% of ABT's average daily trading volume over the past month, of 5.7 million shares. Particularly high volume was seen for the $110 strike call option expiring May 19, 2023, with 2,466 contracts trading so far today, representing approximately 246,600 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Tutor Perini Corp (Symbol: TPC) saw options trading volume of 1,760 contracts, representing approximately 176,000 underlying shares or approximately 46.8% of TPC's average daily trading volume over the past month, of 376,395 shares. |
31048.0 | 2023-04-20 00:00:00 UTC | Barclays Maintains Abbott Laboratories (ABT) Overweight Recommendation | ABT | https://www.nasdaq.com/articles/barclays-maintains-abbott-laboratories-abt-overweight-recommendation | nan | nan | Fintel reports that on April 20, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation.
Analyst Price Forecast Suggests 11.27% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 11.27% from its latest reported closing price of $112.29.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $112.29 / share, the stock's dividend yield is 1.82%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.11 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
PJGRX - PGIM JENNISON GROWTH FUND Class R holds 258K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 504K shares, representing a decrease of 94.93%. The firm decreased its portfolio allocation in ABT by 38.81% over the last quarter.
Perkins Capital Management holds 26K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 27K shares, representing a decrease of 1.89%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
HIAGX - Hartford Disciplined Equity Hls Fund Ia holds 302K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 254K shares, representing an increase of 16.03%. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter.
PACIFIC SELECT FUND - PD Large-Cap Value Index Portfolio Class P holds 70K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 71K shares, representing a decrease of 1.30%. The firm increased its portfolio allocation in ABT by 2.44% over the last quarter.
GRSPX - Greenspring Fund retail holds 10K shares representing 0.00% ownership of the company. No change in the last quarter.
What is the Fund Sentiment?
There are 3928 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 110 owner(s) or 2.88% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.48%, a decrease of 22.01%. Total shares owned by institutions increased in the last three months by 0.05% to 1,514,436K shares.
The put/call ratio of ABT is 1.15, indicating a bearish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 20, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. The firm decreased its portfolio allocation in ABT by 38.81% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. | Fintel reports that on April 20, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. The firm decreased its portfolio allocation in ABT by 38.81% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. | Fintel reports that on April 20, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. The firm decreased its portfolio allocation in ABT by 38.81% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. | Fintel reports that on April 20, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. The firm decreased its portfolio allocation in ABT by 38.81% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. |
31049.0 | 2023-04-20 00:00:00 UTC | Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation | ABT | https://www.nasdaq.com/articles/raymond-james-maintains-abbott-laboratories-abt-outperform-recommendation-0 | nan | nan | Fintel reports that on April 20, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation.
Analyst Price Forecast Suggests 11.27% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 11.27% from its latest reported closing price of $112.29.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $112.29 / share, the stock's dividend yield is 1.82%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.11 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
SNXFX - Schwab 1000 Index Fund holds 570K shares representing 0.03% ownership of the company. In it's prior filing, the firm reported owning 572K shares, representing a decrease of 0.34%. The firm increased its portfolio allocation in ABT by 6.25% over the last quarter.
Bank Hapoalim Bm holds 10K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 10K shares, representing a decrease of 0.71%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
TQGEX - T. Rowe Price QM Global Equity Fund holds 2K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 1K shares, representing an increase of 25.42%. The firm increased its portfolio allocation in ABT by 2.08% over the last quarter.
Conning holds 327K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 331K shares, representing a decrease of 1.23%. The firm increased its portfolio allocation in ABT by 2.58% over the last quarter.
Financial Advisory Service holds 5K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 5K shares, representing a decrease of 1.22%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
What is the Fund Sentiment?
There are 3928 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 110 owner(s) or 2.88% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.48%, a decrease of 22.01%. Total shares owned by institutions increased in the last three months by 0.05% to 1,514,436K shares.
The put/call ratio of ABT is 1.15, indicating a bearish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 20, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 6.25% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm increased its portfolio allocation in ABT by 6.25% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm increased its portfolio allocation in ABT by 6.25% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm increased its portfolio allocation in ABT by 6.25% over the last quarter. |
31050.0 | 2023-04-20 00:00:00 UTC | UBS Maintains Abbott Laboratories (ABT) Buy Recommendation | ABT | https://www.nasdaq.com/articles/ubs-maintains-abbott-laboratories-abt-buy-recommendation | nan | nan | Fintel reports that on April 20, 2023, UBS maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation.
Analyst Price Forecast Suggests 11.27% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 11.27% from its latest reported closing price of $112.29.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $112.29 / share, the stock's dividend yield is 1.82%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.11 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
Hallmark Capital Management holds 5K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 5K shares, representing an increase of 0.53%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
Asset Dedication holds 21K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 21K shares, representing a decrease of 1.54%. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter.
Guggenheim Strategic Opportunities Fund holds 3K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 3K shares, representing an increase of 4.52%. The firm increased its portfolio allocation in ABT by 10.40% over the last quarter.
Axiom Investment Management holds 3K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 3K shares, representing an increase of 1.82%. The firm decreased its portfolio allocation in ABT by 59.39% over the last quarter.
Regentatlantic Capital holds 84K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 92K shares, representing a decrease of 8.44%. The firm decreased its portfolio allocation in ABT by 25.47% over the last quarter.
What is the Fund Sentiment?
There are 3928 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 110 owner(s) or 2.88% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.48%, a decrease of 22.01%. Total shares owned by institutions increased in the last three months by 0.05% to 1,514,436K shares.
The put/call ratio of ABT is 1.15, indicating a bearish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 20, 2023, UBS maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. | Fintel reports that on April 20, 2023, UBS maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. | Fintel reports that on April 20, 2023, UBS maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. | Fintel reports that on April 20, 2023, UBS maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. |
31051.0 | 2023-04-20 00:00:00 UTC | Citigroup Maintains Abbott Laboratories (ABT) Buy Recommendation | ABT | https://www.nasdaq.com/articles/citigroup-maintains-abbott-laboratories-abt-buy-recommendation | nan | nan | Fintel reports that on April 20, 2023, Citigroup maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation.
Analyst Price Forecast Suggests 11.27% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 11.27% from its latest reported closing price of $112.29.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $112.29 / share, the stock's dividend yield is 1.82%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.11 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
HIAGX - Hartford Disciplined Equity Hls Fund Ia holds 302K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 254K shares, representing an increase of 16.03%. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter.
Northern Capital Management holds 2K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 2K shares, representing an increase of 0.05%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
Ballast holds 4K shares representing 0.00% ownership of the company. No change in the last quarter.
Herold Advisors holds 13K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 17K shares, representing a decrease of 33.53%. The firm decreased its portfolio allocation in ABT by 43.62% over the last quarter.
Middleton holds 40K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 41K shares, representing a decrease of 2.25%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
What is the Fund Sentiment?
There are 3928 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 110 owner(s) or 2.88% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.48%, a decrease of 22.01%. Total shares owned by institutions increased in the last three months by 0.05% to 1,514,436K shares.
The put/call ratio of ABT is 1.15, indicating a bearish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 20, 2023, Citigroup maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Citigroup maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Citigroup maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Citigroup maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter. |
31052.0 | 2023-04-19 00:00:00 UTC | US STOCKS-S&P 500 little changed as investors digest mixed earnings | ABT | https://www.nasdaq.com/articles/us-stocks-sp-500-little-changed-as-investors-digest-mixed-earnings | nan | nan | By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas
April 19 (Reuters) - The S&P 500 was little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, while weakness in Netflix and Tesla shares weighed.
The Dow edged lower, dragged down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries.
Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results.
"Corporate results are being seen as being in large part company-specific news versusmarket news" said Art Hogan, chief market strategist at B Riley Wealth. "If that keeps us relatively calm and unchanged for now, while the sample set of reporters is still quite small, I think that's a positive."
The Dow Jones Industrial Average .DJI fell 67.89 points, or 0.2%, to 33,908.74; the S&P 500 .SPX gained 0.4 points, or 0.01%, at 4,155.27; and the Nasdaq Composite .IXIC added 16.95 points, or 0.14%, at 12,170.37.
The defensive utilities group .SPLRCU gained most among S&P 500 sectors, rising 0.7%.
The CBOE Volatility index .VIX, also known as Wall Street's fear gauge, fell to its lowest point since November 2021 during the session.
Investors are looking for signs in the corporate results that inflation may be driving up costs or hurting consumer spending, amid fears the economy may be on the cusp of a downturn.
S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES.
Netflix Inc NFLX.O shares slid 4.2% after the video-streaming pioneer offered a lighter-than-expected forecast. Shares of steaming rival Disney fell 1.8%.
Tesla Inc TSLA.O shares dropped 1% after the electric-vehicle maker's sixth U.S. price cut this year, ahead of its quarterly results due after market close on Wednesday.
Shares of Elevance Health Inc ELV.N fell 5.4% after the insurer's strong quarterly profit failed to ease investor concerns over regulatory hits to the company's government-backed insurance business. UnitedHealth shares were off 3.7%.
Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.6% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Intuitive Surgical ISRG.O shares soared 11% after its quarterly revenue and profit topped estimates.
Shares of Western Alliance Bancorp WAL.Nsurged 23% after the company posted stronger-than-expected earnings, helping lift the SPDR S&P Regional Banking ETF KRE.P 4%.
Regional banks have been in focus after the failure of Silicon Valley Bank last month prompted concerns about systemic risks.
Declining issues outnumbered advancers on the NYSE by a 1.32-to-1 ratio; on Nasdaq, a 1.07-to-1 ratio favored decliners.
The S&P 500 posted 15 new 52-week highs and one new low; the Nasdaq Composite recorded 48 new highs and 111 new lows.
(Reporting by Lewis Krauskopf in New York, Sruthi Shankar and Ankika Biswas in Bengaluru Editing by Vinay Dwivedi and Richard Chang)
((lewis.krauskopf@thomsonreuters.com; 646-223-6082; Reuters Messaging: lewis.krauskopf.thomsonreuters.com@reuters.net, Twitter: @LKrauskopf))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.6% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 was little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, while weakness in Netflix and Tesla shares weighed. Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.6% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 was little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, while weakness in Netflix and Tesla shares weighed. The Dow edged lower, dragged down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.6% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 was little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, while weakness in Netflix and Tesla shares weighed. The Dow edged lower, dragged down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.6% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. The Dow edged lower, dragged down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. The Dow Jones Industrial Average .DJI fell 67.89 points, or 0.2%, to 33,908.74; the S&P 500 .SPX gained 0.4 points, or 0.01%, at 4,155.27; and the Nasdaq Composite .IXIC added 16.95 points, or 0.14%, at 12,170.37. |
31053.0 | 2023-04-19 00:00:00 UTC | Diversified Abbott Laboratories Could Reverse And Move Higher | ABT | https://www.nasdaq.com/articles/diversified-abbott-laboratories-could-reverse-and-move-higher | nan | nan | It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook. What is surprising is that Abbott Laboratories' device growth is enough to drive a double-digit gain in organic sales. That’s enough to offset the sudden decline in COVID-related sales and keep the guidance unchanged.
This is excellent news for investors, and the stock is set up for a reversal. Another catalyst, such as an improvement in analysts' sentiment or price target, is all this market needs to move higher.
"Our first-quarter results reflect a very strong start to the year," said Robert B. Ford, chairman and chief executive officer. "Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition."
As it is, the analysts rate this stock a Moderate Buy with about 17% of upside potential. The bad news is that sentiment has softened over the last year, and the price target trended lower, but that trend may be over. Marketbeat.com hasn’t tracked any new commentary yet, but the latest, issued days before the report, includes 1 price target increase and 1 decrease in line with the broad consensus. Assuming the analysts like the cast of Abbott’s Q1 results and outlook, this should signal a bottom in sentiment, if not a rebound.
Abbott Laboratories Has Solid Quarter And Reaffirms Guidance.
Abbott Laboratories had a solid quarter despite the 18.5% decline in headline revenue. The revenue fell because of a 49% decline in the Diagnostics segment, primarily because of COVID. The revenue beat the consensus because of a 10% increase in organic sales driven by a 3.8% gain in Nutrition, a 3.7% gain in Established Pharmaceuticals and an 8.5% gain in Medical Devices. Sales were most robust in the US due to last year’s recall of baby formula and the exiting of the pediatric business in China.
The company’s margin contracted because of deleveraging related to windfall sales of COVID products but not as much as expected. The top-line strength carried through to the bottom line but was offset slightly to produce $1.03 in adjusted EPS or 510 bps better than expected compared to 620.
The takeaway is that earnings outpaced the consensus and led the company to reiterate its guidance for the year. The guidance expects $4.30 in adjusted EPS at the low end of the range, which compares well with the $4.39 consensus. The top end of $4.50 provides some room for outperformance, and both are sufficient to cover the dividend and repurchase shares.
Abbott Laboratories Is A King Of Dividend Payers
Abbott Laboratories reached Dividend King status 2 years ago and is on track to keep increasing payout for the next few years at least. The stock is yielding about 1.95%, which is better than the S&P 500 average and comes with a better track record of payments. The payout ratio is low at 50% of earnings, and the balance sheet is well-managed. Investors should expect the pace of increases to slow from the current double-digit pace to a slower one, but not for them to cease.
The chart is favorable and shows a double-bottom at the $97.50 level. The Q1 release has the stock up more than 3.5% in premarket action and is on track to test resistance at the baseline of the pattern. The baseline is near $115; if crossed, the market could move much higher.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. "Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition." Marketbeat.com hasn’t tracked any new commentary yet, but the latest, issued days before the report, includes 1 price target increase and 1 decrease in line with the broad consensus. | It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. "Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition." The revenue beat the consensus because of a 10% increase in organic sales driven by a 3.8% gain in Nutrition, a 3.7% gain in Established Pharmaceuticals and an 8.5% gain in Medical Devices. | It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook. The revenue beat the consensus because of a 10% increase in organic sales driven by a 3.8% gain in Nutrition, a 3.7% gain in Established Pharmaceuticals and an 8.5% gain in Medical Devices. | It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. What is surprising is that Abbott Laboratories' device growth is enough to drive a double-digit gain in organic sales. Another catalyst, such as an improvement in analysts' sentiment or price target, is all this market needs to move higher. |
31054.0 | 2023-04-19 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-10 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31055.0 | 2023-04-19 00:00:00 UTC | Health Care Sector Update for 04/19/2023: ABT, BBIO, LEGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-04-19-2023%3A-abt-bbio-legn | nan | nan | Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.
The iShares Biotechnology ETF (IBB) was climbing 0.4%.
In company news, Abbott Laboratories (ABT) shares rose 8% after it posted forecast-beating Q1 results.
Legend Biotech (LEGN) jumped 20%. The company plans to sell 7.66 million ordinary shares to an undisclosed institutional investor in a private placement for $26.12 per share, equivalent to $52.24 per American Depositary Share.
BridgeBio Pharma (BBIO) shares were up 11% after analysts at Evercore ISI initiated coverage of the company with an outperform rating and $40 price target.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Abbott Laboratories (ABT) shares rose 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. BridgeBio Pharma (BBIO) shares were up 11% after analysts at Evercore ISI initiated coverage of the company with an outperform rating and $40 price target. | In company news, Abbott Laboratories (ABT) shares rose 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) was climbing 0.4%. | In company news, Abbott Laboratories (ABT) shares rose 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The company plans to sell 7.66 million ordinary shares to an undisclosed institutional investor in a private placement for $26.12 per share, equivalent to $52.24 per American Depositary Share. | In company news, Abbott Laboratories (ABT) shares rose 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) was climbing 0.4%. |
31056.0 | 2023-04-19 00:00:00 UTC | US STOCKS-Dow dips, S&P 500 stable after medtech gains, Netflix drag | ABT | https://www.nasdaq.com/articles/us-stocks-dow-dips-sp-500-stable-after-medtech-gains-netflix-drag | nan | nan | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Netflix falls after downbeat forecast
Abbott Labs, Intuitive Surgical jump after earnings
Western Alliance surges as results allay deposit fears
VIX falls to lowest since November 2021
Indexes: Dow down 0.23%, S&P down 0.01%, Nasdaq up 0.03%
Updates with further market data
By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas
April 19 (Reuters) - The S&P 500 ended virtually unchanged on Wednesday while the Dow dipped as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares.
The Dow was weighed down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries.
Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results.
"Corporate results are being seen as being in large part company-specific news versusmarket news" said Art Hogan, chief market strategist at B Riley Wealth. "If that keeps us relatively calm and unchanged for now, while the sample set of reporters is still quite small, I think that's a positive."
The Dow Jones Industrial Average .DJI fell 79.62 points, or 0.23%, to 33,897.01; the S&P 500 .SPX lost 0.35 points, or 0.01%, at 4,154.52; and the Nasdaq Composite .IXIC added 3.81 points, or 0.03%, at 12,157.23.
The defensive utilities group .SPLRCU gained most among S&P 500 sectors, rising 0.8%.
The CBOE Volatility index .VIX, also known as Wall Street's fear gauge, fell to its lowest point since November 2021 during the session.
Investors are looking for signs in corporate results that inflation may be driving up costs or hurting consumer spending, amid fears the economy may be on the cusp of a downturn.
S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES.
"We seem stuck in this range, with those people who think that there is going to be a recession coming and those people who think there is going to be a soft landing," said Rick Meckler, partner at Cherry Lane Investments.
Netflix Inc NFLX.O shares slid 3.2% after the video-streaming pioneer offered a lighter-than-expected forecast. Shares of streaming rival Disney slipped 2.2%.
Tesla Inc TSLA.O shares dropped 2% after the electric-vehicle maker's sixth U.S. price cut this year. Tesla shares slid further in initial after-market trading on Wednesday following the company's quarterly report.
Shares of Elevance Health Inc ELV.N fell 5.3% after the insurer's strong quarterly profit failed to ease investor concerns over regulatory hits to the company's government-backed insurance business. UnitedHealth shares dropped 3.6%.
Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.8% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Intuitive Surgical ISRG.O shares soared 10.9% after its quarterly revenue and profit topped estimates.
Shares of Western Alliance Bancorp WAL.Nsurged 24.1% after the company posted stronger-than-expected earnings, helping lift the SPDR S&P Regional Banking ETF KRE.P 3.9%.
Regional banks have been in focus after the failure of Silicon Valley Bank last month prompted concerns about systemic risks.
Declining issues outnumbered advancers on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.11-to-1 ratio favored decliners.
The S&P 500 posted 16 new 52-week highs and one new lows; the Nasdaq Composite recorded 59 new highs and 123 new lows.
About 10 billion shares changed hands in U.S. exchanges, compared with the 10.6 billion daily average over the last 20 sessions.
(Reporting by Lewis Krauskopf in New York, Sruthi Shankar and Ankika Biswas in Bengaluru Editing by Vinay Dwivedi and Richard Chang)
((lewis.krauskopf@thomsonreuters.com; 646-223-6082; Reuters Messaging: lewis.krauskopf.thomsonreuters.com@reuters.net, Twitter: @LKrauskopf))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.8% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Netflix falls after downbeat forecast Abbott Labs, Intuitive Surgical jump after earnings Western Alliance surges as results allay deposit fears VIX falls to lowest since November 2021 Indexes: Dow down 0.23%, S&P down 0.01%, Nasdaq up 0.03% Updates with further market data By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended virtually unchanged on Wednesday while the Dow dipped as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.8% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Netflix falls after downbeat forecast Abbott Labs, Intuitive Surgical jump after earnings Western Alliance surges as results allay deposit fears VIX falls to lowest since November 2021 Indexes: Dow down 0.23%, S&P down 0.01%, Nasdaq up 0.03% Updates with further market data By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended virtually unchanged on Wednesday while the Dow dipped as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. The Dow Jones Industrial Average .DJI fell 79.62 points, or 0.23%, to 33,897.01; the S&P 500 .SPX lost 0.35 points, or 0.01%, at 4,154.52; and the Nasdaq Composite .IXIC added 3.81 points, or 0.03%, at 12,157.23. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.8% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Netflix falls after downbeat forecast Abbott Labs, Intuitive Surgical jump after earnings Western Alliance surges as results allay deposit fears VIX falls to lowest since November 2021 Indexes: Dow down 0.23%, S&P down 0.01%, Nasdaq up 0.03% Updates with further market data By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended virtually unchanged on Wednesday while the Dow dipped as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. The Dow was weighed down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.8% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Netflix falls after downbeat forecast Abbott Labs, Intuitive Surgical jump after earnings Western Alliance surges as results allay deposit fears VIX falls to lowest since November 2021 Indexes: Dow down 0.23%, S&P down 0.01%, Nasdaq up 0.03% Updates with further market data By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended virtually unchanged on Wednesday while the Dow dipped as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. The Dow was weighed down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. |
31057.0 | 2023-04-19 00:00:00 UTC | Wednesday Sector Leaders: Financial, Healthcare | ABT | https://www.nasdaq.com/articles/wednesday-sector-leaders%3A-financial-healthcare | nan | nan | Looking at the sectors faring best as of midday Wednesday, shares of Financial companies are outperforming other sectors, up 0.9%. Within that group, First Republic Bank (Symbol: FRC) and Travelers Companies Inc (Symbol: TRV) are two large stocks leading the way, showing a gain of 10.9% and 7.6%, respectively. Among financial ETFs, one ETF following the sector is the Financial Select Sector SPDR ETF (Symbol: XLF), which is up 0.3% on the day, and down 2.02% year-to-date. First Republic Bank, meanwhile, is down 88.30% year-to-date, and Travelers Companies Inc, is down 0.60% year-to-date. Combined, FRC and TRV make up approximately 1.0% of the underlying holdings of XLF.
The next best performing sector is the Healthcare sector, higher by 0.8%. Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 11.5% and 7.7%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF (XLV), which is up 0.2% in midday trading, and down 0.83% on a year-to-date basis. Intuitive Surgical Inc, meanwhile, is up 13.01% year-to-date, and Abbott Laboratories is up 3.32% year-to-date. Combined, ISRG and ABT make up approximately 5.8% of the underlying holdings of XLV.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. As you can see, three sectors are up on the day, while five sectors are down.
SECTOR % CHANGE
Financial +0.9%
Healthcare +0.8%
Utilities +0.7%
Services -0.0%
Consumer Products -0.2%
Industrial -0.2%
Materials -0.2%
Energy -0.6%
Technology & Communications -1.1%
10 ETFs With Stocks That Insiders Are Buying »
Also see:
Construction Dividend Stocks
VSTA shares outstanding history
EBS Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 11.5% and 7.7%, respectively. Combined, ISRG and ABT make up approximately 5.8% of the underlying holdings of XLV. Combined, FRC and TRV make up approximately 1.0% of the underlying holdings of XLF. | Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 11.5% and 7.7%, respectively. Combined, ISRG and ABT make up approximately 5.8% of the underlying holdings of XLV. Within that group, First Republic Bank (Symbol: FRC) and Travelers Companies Inc (Symbol: TRV) are two large stocks leading the way, showing a gain of 10.9% and 7.6%, respectively. | Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 11.5% and 7.7%, respectively. Combined, ISRG and ABT make up approximately 5.8% of the underlying holdings of XLV. Among financial ETFs, one ETF following the sector is the Financial Select Sector SPDR ETF (Symbol: XLF), which is up 0.3% on the day, and down 2.02% year-to-date. | Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 11.5% and 7.7%, respectively. Combined, ISRG and ABT make up approximately 5.8% of the underlying holdings of XLV. Looking at the sectors faring best as of midday Wednesday, shares of Financial companies are outperforming other sectors, up 0.9%. |
31058.0 | 2023-04-19 00:00:00 UTC | Health Care Sector Update for 04/19/2023: AMGN, NVS, ABT, BBIO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-04-19-2023%3A-amgn-nvs-abt-bbio | nan | nan | Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.2% and the Health Care Select Sector SPDR Fund (XLV) up by 0.3%.
The iShares Biotechnology ETF (IBB) was climbing 0.6%.
In company news, Amgen (AMGN) has won an appeal to uphold patents covering psoriasis drug Otezla and banning the proposed generic versions by Zydus Pharmaceuticals and Novartis' (NVS) Sandoz, said the US Court of Appeals for the Federal Circuit in a Wednesday filing. Amgen shares were little changed and Novartis was up 0.9%.
Abbott Laboratories (ABT) shares rose almost 8% after it posted forecast-beating Q1 results.
BridgeBio Pharma (BBIO) shares were up past 10% after analysts at Evercore ISI initiated coverage of the company with an outperform rating and a $40 price target.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) shares rose almost 8% after it posted forecast-beating Q1 results. In company news, Amgen (AMGN) has won an appeal to uphold patents covering psoriasis drug Otezla and banning the proposed generic versions by Zydus Pharmaceuticals and Novartis' (NVS) Sandoz, said the US Court of Appeals for the Federal Circuit in a Wednesday filing. BridgeBio Pharma (BBIO) shares were up past 10% after analysts at Evercore ISI initiated coverage of the company with an outperform rating and a $40 price target. | Abbott Laboratories (ABT) shares rose almost 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.2% and the Health Care Select Sector SPDR Fund (XLV) up by 0.3%. In company news, Amgen (AMGN) has won an appeal to uphold patents covering psoriasis drug Otezla and banning the proposed generic versions by Zydus Pharmaceuticals and Novartis' (NVS) Sandoz, said the US Court of Appeals for the Federal Circuit in a Wednesday filing. | Abbott Laboratories (ABT) shares rose almost 8% after it posted forecast-beating Q1 results. In company news, Amgen (AMGN) has won an appeal to uphold patents covering psoriasis drug Otezla and banning the proposed generic versions by Zydus Pharmaceuticals and Novartis' (NVS) Sandoz, said the US Court of Appeals for the Federal Circuit in a Wednesday filing. BridgeBio Pharma (BBIO) shares were up past 10% after analysts at Evercore ISI initiated coverage of the company with an outperform rating and a $40 price target. | Abbott Laboratories (ABT) shares rose almost 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.2% and the Health Care Select Sector SPDR Fund (XLV) up by 0.3%. The iShares Biotechnology ETF (IBB) was climbing 0.6%. |
31059.0 | 2023-04-19 00:00:00 UTC | S&P 500 ends little changed amid medtech gains, Netflix drag | ABT | https://www.nasdaq.com/articles/sp-500-ends-little-changed-amid-medtech-gains-netflix-drag | nan | nan | By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas
April 19 (Reuters) - The S&P 500 ended little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares.
The Dow slipped, weighed down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries.
Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results.
"Corporate results are being seen as being in large part company-specific news versusmarket news" said Art Hogan, chief market strategist at B Riley Wealth. "If that keeps us relatively calm and unchanged for now, while the sample set of reporters is still quite small, I think that's a positive."
According to preliminary data, the S&P 500 .SPX lost 0.18 points, or 0.00%, to end at 4,154.69 points, while the Nasdaq Composite .IXIC gained 4.08 points, or 0.03%, to 12,157.49. The Dow Jones Industrial Average .DJI fell 79.29 points, or 0.23%, to 33,898.92.
The CBOE Volatility index .VIX, also known as Wall Street's fear gauge, fell to its lowest point since November 2021 during the session.
Investors are looking for signs in corporate results that inflation may be driving up costs or hurting consumer spending, amid fears the economy may be on the cusp of a downturn.
S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES.
"We seem stuck in this range, with those people who think that there is going to be a recession coming and those people who think there is going to be a soft landing," said Rick Meckler, partner at Cherry Lane Investments.
Netflix Inc NFLX.O shares slid after the video-streaming pioneer offered a lighter-than-expected forecast.
Shares of Elevance Health Inc ELV.N fell after the insurer's strong quarterly profit failed to ease investor concerns over regulatory hits to the company's government-backed insurance business.
Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Intuitive Surgical ISRG.O shares soared after its quarterly revenue and profit topped estimates.
Shares of Western Alliance Bancorp WAL.Nsurged after the company posted stronger-than-expected earnings, helping lift the SPDR S&P Regional Banking ETF KRE.P.
Regional banks have been in focus after the failure of Silicon Valley Bank last month prompted concerns about systemic risks.
(Reporting by Lewis Krauskopf in New York, Sruthi Shankar and Ankika Biswas in Bengaluru Editing by Vinay Dwivedi and Richard Chang)
((lewis.krauskopf@thomsonreuters.com; 646-223-6082; Reuters Messaging: lewis.krauskopf.thomsonreuters.com@reuters.net, Twitter: @LKrauskopf))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. Shares of Elevance Health Inc ELV.N fell after the insurer's strong quarterly profit failed to ease investor concerns over regulatory hits to the company's government-backed insurance business. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. The Dow Jones Industrial Average .DJI fell 79.29 points, or 0.23%, to 33,898.92. S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES. |
31060.0 | 2023-04-19 00:00:00 UTC | Abbott Lab Climbs After Reporting Q1 Profit That Beats Estimates | ABT | https://www.nasdaq.com/articles/abbott-lab-climbs-after-reporting-q1-profit-that-beats-estimates | nan | nan | (RTTNews) - Abbott Laboratories (ABT) shares are gaining more than 5 percent on Wednesday morning trade after the company reported first-quarter profit that beat estimates.
The company reaffirmed full-year earnings per share in a range of $4.30-$4.50. Analysts are looking for $4.39 per share. Excluding COVID-19 testing sales, the company now expects full-year organic sales growth of at least high single digits.
Currently, shares are at $109.98, up 5.59 percent from the previous close of $104.15 on a volume of 2,346,928.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) shares are gaining more than 5 percent on Wednesday morning trade after the company reported first-quarter profit that beat estimates. The company reaffirmed full-year earnings per share in a range of $4.30-$4.50. Currently, shares are at $109.98, up 5.59 percent from the previous close of $104.15 on a volume of 2,346,928. | (RTTNews) - Abbott Laboratories (ABT) shares are gaining more than 5 percent on Wednesday morning trade after the company reported first-quarter profit that beat estimates. The company reaffirmed full-year earnings per share in a range of $4.30-$4.50. Excluding COVID-19 testing sales, the company now expects full-year organic sales growth of at least high single digits. | (RTTNews) - Abbott Laboratories (ABT) shares are gaining more than 5 percent on Wednesday morning trade after the company reported first-quarter profit that beat estimates. The company reaffirmed full-year earnings per share in a range of $4.30-$4.50. Excluding COVID-19 testing sales, the company now expects full-year organic sales growth of at least high single digits. | (RTTNews) - Abbott Laboratories (ABT) shares are gaining more than 5 percent on Wednesday morning trade after the company reported first-quarter profit that beat estimates. The company reaffirmed full-year earnings per share in a range of $4.30-$4.50. Analysts are looking for $4.39 per share. |
31061.0 | 2023-04-19 00:00:00 UTC | Abbott (ABT) Beats Q1 Earnings and Revenue Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-beats-q1-earnings-and-revenue-estimates | nan | nan | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $1.73 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5.10%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.90 per share when it actually produced earnings of $1.03, delivering a surprise of 14.44%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.75 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.07%. This compares to year-ago revenues of $11.9 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have lost about 5.1% since the beginning of the year versus the S&P 500's gain of 8.2%.
What's Next for Abbott?
While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.05 on $9.8 billion in revenues for the coming quarter and $4.36 on $39.62 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
SurModics (SRDX), another stock in the same industry, has yet to report results for the quarter ended March 2023.
This drug delivery technology company is expected to post quarterly loss of $0.49 per share in its upcoming report, which represents a year-over-year change of -122.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
SurModics' revenues are expected to be $25.99 million, down 0.4% from the year-ago quarter.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.75 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.07%. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.75 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.07%. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
31062.0 | 2023-04-19 00:00:00 UTC | Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say | ABT | https://www.nasdaq.com/articles/abbott-abt-reports-q1-earnings%3A-what-key-metrics-have-to-say | nan | nan | Abbott (ABT) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. EPS of $1.03 for the same period compares to $1.73 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $9.64 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +5.10%, with the consensus EPS estimate being $0.98.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net sales- Diagnostics- U.S. $1.34 billion versus $1.44 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -51.3% change.
Net sales- Nutrition- International: $1.16 billion compared to the $1.13 billion average estimate based on four analysts. The reported number represents a change of -5.1% year over year.
Net sales- Nutrition- U.S. $812 million versus $738.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.9% change.
Net sales- Diagnostics- International: $1.35 billion versus $1.58 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -46.8% change.
Net sales- Nutrition: $1.97 billion versus the five-analyst average estimate of $1.87 billion. The reported number represents a year-over-year change of +3.9%.
Net sales- Medical Devices- Diabetes Care: $1.31 billion compared to the $1.22 billion average estimate based on five analysts. The reported number represents a change of +16.6% year over year.
Net sales- Diagnostics: $2.69 billion compared to the $2.95 billion average estimate based on five analysts. The reported number represents a change of -49.2% year over year.
Net sales- Established Pharmaceuticals: $1.19 billion versus the five-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +3.7%.
Net sales- Medical Devices- Vascular- Total: $617 million versus $609.10 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
Net sales- Medical Devices- Neuromodulation- Total: $196 million compared to the $180.72 million average estimate based on four analysts. The reported number represents a change of +9.5% year over year.
Net sales- Medical Devices- Structural Heart- Total: $461 million versus the four-analyst average estimate of $433.99 million.
Net sales- Medical Devices- Heart Failure- Total: $281 million compared to the $230.94 million average estimate based on four analysts. The reported number represents a change of +27.2% year over year.
View all Key Company Metrics for Abbott here>>>
Shares of Abbott have returned +5.9% over the past month versus the Zacks S&P 500 composite's +6.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. | Abbott (ABT) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $1.34 billion versus $1.44 billion estimated by four analysts on average. | Abbott (ABT) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $1.34 billion versus $1.44 billion estimated by four analysts on average. | Abbott (ABT) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The reported revenue compares to the Zacks Consensus Estimate of $9.64 billion, representing a surprise of +1.07%. |
31063.0 | 2023-04-19 00:00:00 UTC | US STOCKS-Futures retreat as Treasury yields rise, Tesla slides | ABT | https://www.nasdaq.com/articles/us-stocks-futures-retreat-as-treasury-yields-rise-tesla-slides | nan | nan | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Futures down: Dow 0.48%, S&P 0.61%, Nasdaq 0.92%
April 19 (Reuters) - U.S. stock index futures fell on Wednesday as Treasury yields rose on expectations the Federal Reserve could keep interest rates higher for longer, while a slide in Tesla and Netflix shares was set to weigh on the tech-heavy Nasdaq.
Tesla Inc TSLA.O dropped 2.8% in premarket trading after the electric-vehicle maker cut prices on some of its Model Y and Model 3 vehicles in the United States, the sixth time it has lowered prices this year.
The company is due to report January-March quarter results after the closing bell on Wednesday.
Netflix Inc NFLX.O slipped 1.6% after the video-streaming pioneer beat Wall Street earnings estimates for the first quarter but offered a downbeat forecast.
The benchmark S&P 500 .SPX closed at a more than two-month high on Tuesday as strength in some big technology stocks countered disappointing quarterly reports from Johnson & Johnson JNJ.N and Goldman Sachs GS.N.
Wall Street bank Morgan Stanley MS.N, regional lender U.S. Bancorp USB.N, oilfield services firm Baker Hughes BKR.O and healthcare firm Abbott ABT.N are among the companies reporting results before the opening bell.
While the start of the earnings season has been largely supportive for equities, investors will be closely watching updates from market heavyweights as well as consumer companies for signs of inflation and an economic slowdown hurting margins.
Mixed economic data recently has fueled bets that the U.S. central bank will hike interest rates by 25 basis points in May, with traders giving nearly 85% odds for such a move, as per CME Group's Fedwatch tool.
The 2-year Treasury yield US2YT=RR, most reflective of short-term rate expectations, hit a one-month high of 4.27% on Wednesday and the 10-year yield US10YT=RR hit a four-week high as traders scaled back expectations of rate cuts later this year. US/
The Fed's "Beige Book", a snapshot of the health of the U.S. economy, will be released at 2:00 p.m. ET (1800 GMT), and investors will scrutinize it for impact on the recent banking crisis on economic activity. Fed Governor Michelle Bowman is set to speak later in the day.
At 05:49 a.m. ET, Dow e-minis 1YMcv1 were down 165 points, or 0.48%, S&P 500 e-minis EScv1 were down 25.5 points, or 0.61%, and Nasdaq 100 e-minis NQcv1 were down 120.75 points, or 0.92%.
Western Alliance Bancorp WAL.N rallied 15.5% after the regional bank posted stronger-than-expected earnings and said its deposits had stabilized after the March banking crisis.
Shares of banks First Republic Bank FRC.N, Zions Bancorporation ZION.O and Pacwest Bancorp PACW.O rose between 1.1% and 4.1% in premarket trade.
(Reporting by Sruthi Shankar in Bengaluru Editing by Vinay Dwivedi)
((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street bank Morgan Stanley MS.N, regional lender U.S. Bancorp USB.N, oilfield services firm Baker Hughes BKR.O and healthcare firm Abbott ABT.N are among the companies reporting results before the opening bell. Netflix Inc NFLX.O slipped 1.6% after the video-streaming pioneer beat Wall Street earnings estimates for the first quarter but offered a downbeat forecast. While the start of the earnings season has been largely supportive for equities, investors will be closely watching updates from market heavyweights as well as consumer companies for signs of inflation and an economic slowdown hurting margins. | Wall Street bank Morgan Stanley MS.N, regional lender U.S. Bancorp USB.N, oilfield services firm Baker Hughes BKR.O and healthcare firm Abbott ABT.N are among the companies reporting results before the opening bell. Futures down: Dow 0.48%, S&P 0.61%, Nasdaq 0.92% April 19 (Reuters) - U.S. stock index futures fell on Wednesday as Treasury yields rose on expectations the Federal Reserve could keep interest rates higher for longer, while a slide in Tesla and Netflix shares was set to weigh on the tech-heavy Nasdaq. The company is due to report January-March quarter results after the closing bell on Wednesday. | Wall Street bank Morgan Stanley MS.N, regional lender U.S. Bancorp USB.N, oilfield services firm Baker Hughes BKR.O and healthcare firm Abbott ABT.N are among the companies reporting results before the opening bell. Futures down: Dow 0.48%, S&P 0.61%, Nasdaq 0.92% April 19 (Reuters) - U.S. stock index futures fell on Wednesday as Treasury yields rose on expectations the Federal Reserve could keep interest rates higher for longer, while a slide in Tesla and Netflix shares was set to weigh on the tech-heavy Nasdaq. The 2-year Treasury yield US2YT=RR, most reflective of short-term rate expectations, hit a one-month high of 4.27% on Wednesday and the 10-year yield US10YT=RR hit a four-week high as traders scaled back expectations of rate cuts later this year. | Wall Street bank Morgan Stanley MS.N, regional lender U.S. Bancorp USB.N, oilfield services firm Baker Hughes BKR.O and healthcare firm Abbott ABT.N are among the companies reporting results before the opening bell. The company is due to report January-March quarter results after the closing bell on Wednesday. ET (1800 GMT), and investors will scrutinize it for impact on the recent banking crisis on economic activity. |
31064.0 | 2023-04-19 00:00:00 UTC | Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down | ABT | https://www.nasdaq.com/articles/abbotts-abt-q1-earnings-beat-estimates-margins-down | nan | nan | Abbott Laboratories ABT reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. The adjusted figure declined from the prior-year quarter’s levels by 40.5%.
The quarter’s adjustments include 28 cents of certain non-recurring items.
GAAP EPS came in at 75 cents, plunging 45.3% year on year.
First-quarter worldwide sales of $9.74 billion were down 18.1% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 1.1%.
On an organic basis (excluding the impact of foreign exchange), sales rose 10.3% year over year in the reported quarter.
Quarter in Detail
Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics.
In the first quarter, Established Pharmaceuticals sales increased 3.7% on a reported basis (up 11.1% on an organic basis) to $1.19 billion. Organic sales in key emerging markets improved 8.3% year over year. According to Abbott, organic sales improvement was backed by growth in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management.
The Medical Devices business sales rose 8.5% year over year on a reported basis (up 12.4% on an organic basis) at $3.90 billion. Sales growth was led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer Amulet, Navitor, TriClip, Aveir and CardioMEMS.
Diabetes Care reported organic growth of 21% year over year, led by FreeStyle Libre, which contributed $1.2 billion in revenues in the reported quarter. Structural Heart sales rose 16.4% and Heart Failure sales improved 13.6% year over year organically. The Vascular business recorded an organic sales growth of 3.9%% in the quarter under review. Electrophysiology, Rhythm Management and Neuromodulation recorded organic growth of 8.8%, 4% and 11.2%, respectively, in the quarter under review.
Nutrition sales rose 3.8% year over year on a reported basis (up 10.3% on an organic basis) to $1.97 billion. Pediatric Nutrition sales registered an 18.4% growth on an organic basis.
Adult Nutrition sales improved 4.2% organically. Per the company, Adult Nutrition sales benefited from strong sales performance of Abbott's complete and balanced nutrition brand, Ensure, globally.
Diagnostics sales were down 48.9% year over year on a reported basis (down 47.1% on an organic basis) to $2.69 billion. Core Laboratory Diagnostics sales were up 5.1% organically. Molecular Diagnostics declined 64% on an organic basis. Rapid Diagnostics sales declined 64.5% on an organic basis, whereas Point of Care Diagnostics sales rose 5.7% organically.
Margins
Gross profit in the reported quarter fell 21.6% year over year to $5.42 billion. Gross margin contracted 251 basis points (bps) to 55.6%.
Selling, general and administrative expenses were down 0.9% year over year to $2.76 billion. Research and development expenses declined 6.2% year over year to $654 million.
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote
The company reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Adjusted operating margin, too, contracted 827 bps to 20.5%.
2023 Guidance
Abbott provided its 2023 EPS guidance.
Full-year adjusted earnings (excluding specified items of $1.25 per share) are expected to be in the range of $4.30 to $4.50. The current Zacks Consensus Estimate is pegged at $4.36.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high-single digits and COVID testing-related sales of around $1.5 billion.
Our Take
Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. However, the figures declined on a year-over-year basis. Total sales in the first quarter were negatively impacted by a year-over-year decline in COVID testing-related sales.
The Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. Medical Device registered strong sales growth in the reported quarter led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation
Zacks Rank and Upcoming Releases
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Becton, Dickinson and Company BDX, Henry Schein, Inc. HSIC and Avanos Medical, Inc. AVNS.
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) is expected to release second quarter 2023 earnings on May 4. BDX has an estimated long-term growth of 7.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So far this year, BDX’s shares have lost 5.2% compared with the industry’s 4.2% growth.
Henry Schein, carrying a Zacks Rank #2 at present, is expected to release first quarter 2023 earnings on May 2. HSIC has an estimated long-term growth rate of 8.1%. HSIC’s earnings surpassed estimates in three of the trailing four quarters and matched the same in the other, the average beat being 2.9%.
Henry Schein has gained 22.2% compared with the industry’s 19.7% rise in the past six months.
Avanos, carrying a Zacks Rank #2 at present, is expected to release first quarter 2023 earnings on May 3. AVNS has an estimated growth rate of 1.8% for 2023. AVNS’ earnings surpassed estimates in all the trailing four quarters, the average beat being 11%.
Avanos has gained 46.3% compared with the industry’s 17.5% rise in the past six months.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. According to Abbott, organic sales improvement was backed by growth in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote The company reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote The company reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. | Abbott Laboratories ABT reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. The Medical Devices business sales rose 8.5% year over year on a reported basis (up 12.4% on an organic basis) at $3.90 billion. |
31065.0 | 2023-04-19 00:00:00 UTC | Abbott beats profit estimates on strong medical device sales | ABT | https://www.nasdaq.com/articles/abbott-beats-profit-estimates-on-strong-medical-device-sales | nan | nan | April 19 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported quarterly profit above expectations, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures.
Excluding one-off items, the company reported a profit of $1.03 per share for the first quarter ended March 31, higher than the average of analysts' estimates of 99 cents per share, according to Refinitiv IBES data.
The healthcare giant retained its adjusted profit forecast for this year at $4.30-$4.50 per share, as it expects its non-COVID-testing-related revenue to offset its testing kit sales.
Abbott cut its COVID-testing-related sales forecast to $1.5 billion from $2 billion earlier.
(Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Sherry Jacob-Phillips)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 19 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported quarterly profit above expectations, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. The healthcare giant retained its adjusted profit forecast for this year at $4.30-$4.50 per share, as it expects its non-COVID-testing-related revenue to offset its testing kit sales. (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Sherry Jacob-Phillips) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 19 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported quarterly profit above expectations, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. The healthcare giant retained its adjusted profit forecast for this year at $4.30-$4.50 per share, as it expects its non-COVID-testing-related revenue to offset its testing kit sales. Abbott cut its COVID-testing-related sales forecast to $1.5 billion from $2 billion earlier. | April 19 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported quarterly profit above expectations, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Excluding one-off items, the company reported a profit of $1.03 per share for the first quarter ended March 31, higher than the average of analysts' estimates of 99 cents per share, according to Refinitiv IBES data. (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Sherry Jacob-Phillips) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 19 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported quarterly profit above expectations, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Excluding one-off items, the company reported a profit of $1.03 per share for the first quarter ended March 31, higher than the average of analysts' estimates of 99 cents per share, according to Refinitiv IBES data. The healthcare giant retained its adjusted profit forecast for this year at $4.30-$4.50 per share, as it expects its non-COVID-testing-related revenue to offset its testing kit sales. |
31066.0 | 2023-04-19 00:00:00 UTC | Abbott Laboratories Q1 23 Earnings Conference Call At 9:00 AM ET | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q1-23-earnings-conference-call-at-9%3A00-am-et | nan | nan | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 19, 2023, to discuss Q1 23 earnings results.
To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 19, 2023, to discuss Q1 23 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 19, 2023, to discuss Q1 23 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 19, 2023, to discuss Q1 23 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 19, 2023, to discuss Q1 23 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31067.0 | 2023-04-19 00:00:00 UTC | 2 Stocks That Could Help Make You a Millionaire by Retirement | ABT | https://www.nasdaq.com/articles/2-stocks-that-could-help-make-you-a-millionaire-by-retirement | nan | nan | Most people don't want to work in their golden years. And while some programs provide financial benefits to retirees, such as Social Security, these programs are generally not meant to completely replace income from a job. That's why it's essential for individuals to save for retirement themselves and to start doing so as early as possible.
One of the best ways to do that is by investing in stocks that offer important goods or services that aren't likely to go out of style anytime soon, have long-term growth opportunities, and can provide solid returns over 20 years or more. Let's look at two companies that can deliver on that front over the long run: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V).
1. Abbott Laboratories
The healthcare industry is constantly changing, but the services companies in this sector offer never go out of style. Abbott Laboratories is a healthcare giant specializing in medical devices, although it also has a hand in pharmaceuticals, nutrition, and diagnostics. One of Abbott's greatest strengths is its ability to innovate, so it doesn't get left behind by new technologies.
One of the company's key growth drivers is its FreeStyle Libre franchise, a portfolio of continuous glucose monitoring (CGM) systems for diabetes patients to keep track of their blood glucose levels. CGM technology is a major innovation since it doesn't rely on painful fingersticks and can make more measurements throughout the day, often leading to better patient health outcomes.
Abbott Laboratories is one of the leaders in CGM, a market that will likely continue growing for years given its relatively low worldwide penetration among the 422 million diabetes patients globally. Examples of Abbott's innovative capabilities abound, and they include the company quickly developing coronavirus diagnostic tests in the heat of the pandemic.
Even though the company's operations were disrupted during much of the outbreak, leading to slightly inconsistent financial results, Abbott Laboratories continues to make headway. In 2022, the company's revenue increased by 1.3% year over year (or 6.4% in constant currency) to $43.7 billion. Abbott's earnings per share climbed by 2.5% to $5.34.
And Abbott's top and bottom lines, as well as its free cash flow, have generally been on an upward trend over the past decade.
ABT Revenue (Quarterly) data by YCharts.
The company's results should continue to improve in the long run as it develops more products and the need for healthcare services increase because of the world's population aging.
Here's one more reason why Abbott Laboratories is an excellent stock to buy and hold: The company has raised its payouts for 51 consecutive years, which makes it a Dividend King. And with a cash payout ratio of just 42.4%, there is plenty more room for increases. Opting to reinvest dividends is a great idea for those saving for retirement, since it can help significantly boost total returns.
All these factors make Abbott Laboratories an excellent stock for patient investors saving for retirement.
2. Visa
Visa operates of the largest payment networks in the world, where it helps facilitate credit card transactions. The company makes money through the various transaction fees it charges financial institutions. Several aspects of Visa's business make it an excellent stock for the long run. First, Visa's payment network is already established and boasts a vast ecosystem of financial institutions, consumers, and businesses.
That grants Visa's operations a network effect, or when the value of a service increases with use. Visa is likely to remain a top player in this field for a while, which is essentially a duopoly it shares with Mastercard. Second, Visa's revenue will grow as more transactions switch from cash and check. And although credit cards seem ubiquitous these days, there is arguably a long runway for growth here.
The company estimates that there are still trillions spent via cash and checks every year. In the first quarter of its fiscal year 2023, ending on Dec. 31, Visa's total payment volume of about $3 trillion increased by 2% year over year (7% in constant currency). The company's net revenue of $7.9 billion jumped by 12% compared to the year-ago period. And its net income came in at $4.2 billion, 6% higher than the prior year's quarter.
Visa's results have generally been solid as well when looking at a longer timeframe.
V Revenue (Quarterly) data by YCharts.
Third, Visa boasts excellent margins. With an already established payment network, additional transactions don't lead to significantly higher operational costs.
V Profit Margin data by YCharts.
Profit margins of around 50% for a company of this size are impressive. Last but not least, although not a Dividend King, Visa is also an excellent dividend-paying stock. The company has raised its payouts by 445.5% over the past decade and currently boasts a highly conservative cash payout ratio of 18.8%. Visa can perform relatively well regardless of economic conditions, so it is unlikely to suspend its dividend payments anytime soon.
That, combined with a strong competitive edge and a long runway for growth, makes Visa an excellent forever stock.
10 stocks we like better than Abbott Laboratories
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 10, 2023
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories, Mastercard, and Visa. The Motley Fool recommends the following options: long January 2025 $370 calls on Mastercard and short January 2025 $380 calls on Mastercard. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Let's look at two companies that can deliver on that front over the long run: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT Revenue (Quarterly) data by YCharts. One of the best ways to do that is by investing in stocks that offer important goods or services that aren't likely to go out of style anytime soon, have long-term growth opportunities, and can provide solid returns over 20 years or more. | Let's look at two companies that can deliver on that front over the long run: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT Revenue (Quarterly) data by YCharts. All these factors make Abbott Laboratories an excellent stock for patient investors saving for retirement. | Let's look at two companies that can deliver on that front over the long run: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT Revenue (Quarterly) data by YCharts. Here's one more reason why Abbott Laboratories is an excellent stock to buy and hold: The company has raised its payouts for 51 consecutive years, which makes it a Dividend King. | Let's look at two companies that can deliver on that front over the long run: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT Revenue (Quarterly) data by YCharts. In 2022, the company's revenue increased by 1.3% year over year (or 6.4% in constant currency) to $43.7 billion. |
31068.0 | 2023-04-19 00:00:00 UTC | Health Care Sector Update for 04/19/2023: LEGN, JNJ, GMDA, ABT, XLV, IBB | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-04-19-2023%3A-legn-jnj-gmda-abt-xlv-ibb | nan | nan | Health care stocks were steady premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was recently inactive.
Johnson & Johnson (JNJ) and Legend Biotech's (LEGN) jointly developed CAR-T cancer therapy Carvykti has shown to significantly reduce the risk of relapse in multiple myeloma patients, Stat News reported, citing leaked results. Legend Biotech was recently gaining over 13% in value.
Gamida Cell (GMDA) was down more than 20% after it priced an underwritten public offering of 17.5 million shares and warrants at $1.30 per share and warrant for gross proceeds of $22.8 million.
Abbott Laboratories (ABT) was climbing past 3% after it reported Q1 adjusted earnings of $1.03 per diluted share, down from $1.73 a year earlier but still beating the $0.98 estimate from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) was climbing past 3% after it reported Q1 adjusted earnings of $1.03 per diluted share, down from $1.73 a year earlier but still beating the $0.98 estimate from analysts polled by Capital IQ. The Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was recently inactive. Johnson & Johnson (JNJ) and Legend Biotech's (LEGN) jointly developed CAR-T cancer therapy Carvykti has shown to significantly reduce the risk of relapse in multiple myeloma patients, Stat News reported, citing leaked results. | Abbott Laboratories (ABT) was climbing past 3% after it reported Q1 adjusted earnings of $1.03 per diluted share, down from $1.73 a year earlier but still beating the $0.98 estimate from analysts polled by Capital IQ. Johnson & Johnson (JNJ) and Legend Biotech's (LEGN) jointly developed CAR-T cancer therapy Carvykti has shown to significantly reduce the risk of relapse in multiple myeloma patients, Stat News reported, citing leaked results. Legend Biotech was recently gaining over 13% in value. | Abbott Laboratories (ABT) was climbing past 3% after it reported Q1 adjusted earnings of $1.03 per diluted share, down from $1.73 a year earlier but still beating the $0.98 estimate from analysts polled by Capital IQ. The Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was recently inactive. Johnson & Johnson (JNJ) and Legend Biotech's (LEGN) jointly developed CAR-T cancer therapy Carvykti has shown to significantly reduce the risk of relapse in multiple myeloma patients, Stat News reported, citing leaked results. | Abbott Laboratories (ABT) was climbing past 3% after it reported Q1 adjusted earnings of $1.03 per diluted share, down from $1.73 a year earlier but still beating the $0.98 estimate from analysts polled by Capital IQ. Health care stocks were steady premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was recently inactive. |
31069.0 | 2023-04-19 00:00:00 UTC | Abbott beats profit estimates on strong medical device sales | ABT | https://www.nasdaq.com/articles/abbott-beats-profit-estimates-on-strong-medical-device-sales-0 | nan | nan | Adds details on medical device sales
April 19 (Reuters) - Abbott Laboratories ABT.N reported quarterly profit above expectations on Wednesday, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures.
Improvement in staffing levels at hospitals across the United States, along with the easing of pandemic restrictions in various countries were expected to aid in the recovery of procedure volumes, and in turn, help Abbott and other medical device makers generate strong sales this quarter.
Sales of medical devices - Abbott's largest segment - grew 8.5% to $3.90 billion, of which glucose monitoring device Freestyle Libre reported a revenue of $1.2 billion. Analysts had estimated the segment's sales to be $3.77 billion.
The sales of medical devices mirror a trend seen by rival Johnson & Johnson JNJ.N, which on Tuesday posted better-than-expected sales for the segment.
Excluding one-off items, the company reported a profit of $1.03 per share for the first quarter ended March 31, higher than the average of analysts' estimates of 99 cents per share, according to Refinitiv IBES data.
The healthcare giant retained its adjusted profit forecast for this year at $4.30-$4.50 per share, as it expects growth of its non-COVID-testing-related revenue to offset a decline in its testing kit sales.
Abbott cut its COVID-testing-related sales forecast to $1.5 billion from $2 billion.
(Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Sherry Jacob-Phillips)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds details on medical device sales April 19 (Reuters) - Abbott Laboratories ABT.N reported quarterly profit above expectations on Wednesday, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Improvement in staffing levels at hospitals across the United States, along with the easing of pandemic restrictions in various countries were expected to aid in the recovery of procedure volumes, and in turn, help Abbott and other medical device makers generate strong sales this quarter. The healthcare giant retained its adjusted profit forecast for this year at $4.30-$4.50 per share, as it expects growth of its non-COVID-testing-related revenue to offset a decline in its testing kit sales. | Adds details on medical device sales April 19 (Reuters) - Abbott Laboratories ABT.N reported quarterly profit above expectations on Wednesday, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Sales of medical devices - Abbott's largest segment - grew 8.5% to $3.90 billion, of which glucose monitoring device Freestyle Libre reported a revenue of $1.2 billion. Analysts had estimated the segment's sales to be $3.77 billion. | Adds details on medical device sales April 19 (Reuters) - Abbott Laboratories ABT.N reported quarterly profit above expectations on Wednesday, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Sales of medical devices - Abbott's largest segment - grew 8.5% to $3.90 billion, of which glucose monitoring device Freestyle Libre reported a revenue of $1.2 billion. The sales of medical devices mirror a trend seen by rival Johnson & Johnson JNJ.N, which on Tuesday posted better-than-expected sales for the segment. | Adds details on medical device sales April 19 (Reuters) - Abbott Laboratories ABT.N reported quarterly profit above expectations on Wednesday, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Sales of medical devices - Abbott's largest segment - grew 8.5% to $3.90 billion, of which glucose monitoring device Freestyle Libre reported a revenue of $1.2 billion. Analysts had estimated the segment's sales to be $3.77 billion. |
31070.0 | 2023-04-18 00:00:00 UTC | Pre-Market Earnings Report for April 19, 2023 : ASML, ABT, MS, ELV, USB, TRV, BKR, NDAQ, CFG, SYF, ALLY, LAD | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-for-april-19-2023-%3A-asml-abt-ms-elv-usb-trv-bkr-ndaq-cfg-syf | nan | nan | The following companies are expected to report earnings prior to market open on 04/19/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
ASML Holding N.V. (ASML)is reporting for the quarter ending March 31, 2023. The capital goods company's consensus earnings per share forecast from the 1 analyst that follows the stock is $4.59. This value represents a 27.86% increase compared to the same quarter last year. In the past year ASML and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ASML is 31.20 vs. an industry ratio of 21.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2023. The medical products company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.98. This value represents a 43.35% decrease compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 14.44%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 23.97 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Morgan Stanley (MS)is reporting for the quarter ending March 31, 2023. The investment bankers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.67. This value represents a 18.93% decrease compared to the same quarter last year. MS missed the consensus earnings per share in the 2nd calendar quarter of 2022 by -7.1%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MS is 13.00 vs. an industry ratio of 12.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Elevance Health, Inc. (ELV)is reporting for the quarter ending March 31, 2023. The medical services company's consensus earnings per share forecast from the 16 analysts that follow the stock is $9.30. This value represents a 12.73% increase compared to the same quarter last year. In the past year ELV has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 0.58%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ELV is 14.80 vs. an industry ratio of 11.30, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp (USB)is reporting for the quarter ending March 31, 2023. The bank company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.13. This value represents a 14.14% increase compared to the same quarter last year. In the past year USB has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 8.11%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for USB is 7.40 vs. an industry ratio of 8.30.
The Travelers Companies, Inc. (TRV)is reporting for the quarter ending March 31, 2023. The insurance (property & casualty) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $3.64. This value represents a 13.74% decrease compared to the same quarter last year. In the past year TRV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for TRV is 12.17 vs. an industry ratio of 15.00.
Baker Hughes Company (BKR)is reporting for the quarter ending March 31, 2023. The oil (field services) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.26. This value represents a 73.33% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for BKR is 18.57 vs. an industry ratio of 14.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Nasdaq, Inc. (NDAQ)is reporting for the quarter ending March 31, 2023. The securities exchange company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.65. This value represents a 1.52% decrease compared to the same quarter last year. NDAQ missed the consensus earnings per share in the 4th calendar quarter of 2022 by -1.54%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NDAQ is 20.81 vs. an industry ratio of 18.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Citizens Financial Group, Inc. (CFG)is reporting for the quarter ending March 31, 2023. The savings & loan company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.11. This value represents a 3.74% increase compared to the same quarter last year. CFG missed the consensus earnings per share in the 4th calendar quarter of 2022 by -3.85%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CFG is 6.42 vs. an industry ratio of 10.60.
Synchrony Financial (SYF)is reporting for the quarter ending March 31, 2023. The financial services company's consensus earnings per share forecast from the 13 analysts that follow the stock is $1.49. This value represents a 13.87% decrease compared to the same quarter last year. In the past year SYF has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 12.5%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SYF is 5.94 vs. an industry ratio of 12.70.
Ally Financial Inc. (ALLY)is reporting for the quarter ending March 31, 2023. The financial services company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.88. This value represents a 56.65% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ALLY is 7.74 vs. an industry ratio of 9.60.
Lithia Motors, Inc. (LAD)is reporting for the quarter ending March 31, 2023. The retail company's consensus earnings per share forecast from the 6 analysts that follow the stock is $8.77. This value represents a 26.67% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for LAD is 6.55 vs. an industry ratio of 8.70.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2023. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 23.97 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 23.97 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2023. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 23.97 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2023. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 23.97 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry. |
31071.0 | 2023-04-17 00:00:00 UTC | Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation | ABT | https://www.nasdaq.com/articles/raymond-james-maintains-abbott-laboratories-abt-outperform-recommendation | nan | nan | Fintel reports that on April 17, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation.
Analyst Price Forecast Suggests 20.18% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 20.18% from its latest reported closing price of $103.96.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $103.96 / share, the stock's dividend yield is 1.96%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.91 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
Summit Place Financial Advisors holds 22K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 20K shares, representing an increase of 8.83%. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter.
PLPIX - LargeCap S&P 500 Index Fund R-1 holds 289K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 294K shares, representing a decrease of 1.87%. The firm increased its portfolio allocation in ABT by 5.71% over the last quarter.
Phocas Financial holds 3K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 4K shares, representing a decrease of 7.25%. The firm increased its portfolio allocation in ABT by 85,484.54% over the last quarter.
GCAEX - The Gabelli Equity Income Fund holds 4K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 4K shares, representing an increase of 9.09%. The firm increased its portfolio allocation in ABT by 11.15% over the last quarter.
Coastal Bridge Advisors holds 2K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 2K shares, representing an increase of 3.06%. The firm decreased its portfolio allocation in ABT by 99.88% over the last quarter.
What is the Fund Sentiment?
There are 3938 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 144 owner(s) or 3.80% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.46%, a decrease of 21.97%. Total shares owned by institutions increased in the last three months by 0.05% to 1,513,897K shares.
The put/call ratio of ABT is 1.13, indicating a bearish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 17, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 5.71% over the last quarter. | Fintel reports that on April 17, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 5.71% over the last quarter. | Fintel reports that on April 17, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 5.71% over the last quarter. | Fintel reports that on April 17, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 5.71% over the last quarter. |
31072.0 | 2023-04-17 00:00:00 UTC | BTIG Maintains Abbott Laboratories (ABT) Buy Recommendation | ABT | https://www.nasdaq.com/articles/btig-maintains-abbott-laboratories-abt-buy-recommendation | nan | nan | Fintel reports that on April 17, 2023, BTIG maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation.
Analyst Price Forecast Suggests 20.18% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 20.18% from its latest reported closing price of $103.96.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $103.96 / share, the stock's dividend yield is 1.96%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.91 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
Waldron Private Wealth holds 22K shares representing 0.00% ownership of the company. No change in the last quarter.
First National Bank & Trust Co Of Newtown holds 13K shares representing 0.00% ownership of the company. No change in the last quarter.
LDVCX - AXS Thomson Reuters Venture Capital Return Tracker Fund Class C Shares holds 7K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 7K shares, representing a decrease of 0.29%. The firm increased its portfolio allocation in ABT by 17.57% over the last quarter.
Connors Funds - Connors Hedged Equity Fund Institutional Class holds 4K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 3K shares, representing an increase of 28.66%. The firm decreased its portfolio allocation in ABT by 0.39% over the last quarter.
Wellington Management Group Llp holds 14,816K shares representing 0.85% ownership of the company. In it's prior filing, the firm reported owning 1,708K shares, representing an increase of 88.47%. The firm increased its portfolio allocation in ABT by 826.48% over the last quarter.
What is the Fund Sentiment?
There are 3938 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 144 owner(s) or 3.80% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.46%, a decrease of 21.97%. Total shares owned by institutions increased in the last three months by 0.05% to 1,513,897K shares.
The put/call ratio of ABT is 1.13, indicating a bearish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 17, 2023, BTIG maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 17.57% over the last quarter. The firm decreased its portfolio allocation in ABT by 0.39% over the last quarter. | Fintel reports that on April 17, 2023, BTIG maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 17.57% over the last quarter. The firm decreased its portfolio allocation in ABT by 0.39% over the last quarter. | Fintel reports that on April 17, 2023, BTIG maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 17.57% over the last quarter. The firm decreased its portfolio allocation in ABT by 0.39% over the last quarter. | Fintel reports that on April 17, 2023, BTIG maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 17.57% over the last quarter. The firm decreased its portfolio allocation in ABT by 0.39% over the last quarter. |
31073.0 | 2023-04-17 00:00:00 UTC | Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader | ABT | https://www.nasdaq.com/articles/abbott-abt-gets-fda-clearance-for-freestyle-libre-3-reader | nan | nan | Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Through the reader, diabetes patients can have access to lifesaving technology that is smaller and easier to use without bearing the high-cost burdens of other systems.
The newest development uplifts the company’s efforts to add the FreeStyle Libre 3 system to Medicare's list of covered systems at the earliest.
Significance of Freestyle Libre 3
Abbott’s FreeStyle Libre 3 is currently the most prescribed and affordable iCGM system in the United States. The latest in the FreeStyle Libre portfolio features a glucose sensor, which is noted as the world's smallest, thinnest and most discreet.
Image Source: Zacks Investment Research
The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm. This allows the patient to manage diabetes quickly and easily by viewing glucose readings on a large, bright and easy-to-see screen.
The reader uses a rechargeable lithium-ion battery, which is commonly found in many other electronic devices like mobile phones. The reader comes with the user manual, which provides details on how to safely store, charge and use the device through the Abbott-provided USB cable and power adapter.
People who use the FreeStyle Libre 3 system will also have the option to use the current FreeStyle Libre 3 smartphone apps. However, these apps are only compatible with certain mobile devices and operating systems.
Industry Prospects
Per a Research report, the global blood glucose monitoring device market was valued at $11.71 billion in 2021. It is expected to witness a CAGR of 8% up to 2030.
The rising incidence of diabetes and the increasing awareness regarding diabetes preventive care and new products are expected to fuel market growth.
Recent Developments
In March 2023, Abbott’s latest addition to the Epic surgical valve platform, the Epi Max stented tissue valve, received FDA approval. The design of the device is optimized to improve valve blood flow and will be used in the treatment of aortic regurgitation or stenosis.
In the same month, ABT also announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. The studies revealed that the remote monitoring of patients with hemodynamic pressure sensing technology, such as its CardioMEMS HF System, can significantly improve survival in heart failure patients with reduced ejection fraction.
Price Performance
In the past six months, Abbott’s shares have declined 0.9% compared to the industry’s rise of 6.9%.
Zacks Rank and Key Picks
Abbott Laboratories currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Lantheus LNTH, Avanos Medical AVNS and Insulet PODD. Lantheus sports a Zacks Rank #1 (Strong Buy), while Avanos Medical and Insulet each carry a Zack Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lantheus’ stock has risen 45.9% in the past year. Earnings estimates for Lantheus have remained constant at $4.79 per share for 2023 and $5.32 for 2024 in the past 30 days.
LNTH’s earnings beat estimates in all the last four quarters, delivering an average surprise of 50%. In the last reported quarter, it posted an earnings surprise of 42.71%.
Estimates for Avanos Medical in 2023 have remained constant at $1.68 per share in the past 30 days. Shares of the company have declined 3.7% in the past year compared with the industry’s fall of 10.8%.
Avanos Medical’s earnings beat estimates in all the trailing four quarters, the average surprise being 11.01%. In the last reported quarter, AVNS delivered an earnings surprise of 25%.
Insulet’s stock has increased 24.1% in the past year. The company has an estimated earnings growth rate of 56.59% for the next year.
Insulet’s earnings beat estimates in three of the trailing four quarters and missed the same in one, the average surprise being 59.81%. In the last reported quarter, PODD delivered an earnings surprise of 129.17%.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). In the same month, ABT also announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). In the same month, ABT also announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. | Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. In the same month, ABT also announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. | Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. In the same month, ABT also announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. |
31074.0 | 2023-04-17 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABT | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-79 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Abbott Laboratories (Symbol: ABT) $103.96 $121.60 16.97%
Brown & Brown Inc (Symbol: BRO) $58.77 $66.75 13.58%
Lincoln Electric Holdings, Inc. (Symbol: LECO) $159.00 $177.67 11.74%
Johnson & Johnson (Symbol: JNJ) $165.84 $183.69 10.76%
Nucor Corp. (Symbol: NUE) $146.19 $161.67 10.59%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
Abbott Laboratories (Symbol: ABT) 1.96% 16.97% 18.93%
Brown & Brown Inc (Symbol: BRO) 0.78% 13.58% 14.36%
Lincoln Electric Holdings, Inc. (Symbol: LECO) 1.61% 11.74% 13.35%
Johnson & Johnson (Symbol: JNJ) 2.73% 10.76% 13.49%
Nucor Corp. (Symbol: NUE) 1.40% 10.59% 11.99%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52%
Brown & Brown Inc (Symbol: BRO) $0.392 $0.436 11.22%
Lincoln Electric Holdings, Inc. (Symbol: LECO) $2.14 $2.4 12.15%
Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60%
Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on JNJ — FREE
Get the latest Zacks research report on NUE — FREE
Dividend Growth Stocks: 25 Aristocrats »
Also see:
Institutional Holders of KLAC
CBIN Split History
Devon Energy Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT) $103.96 $121.60 16.97% Brown & Brown Inc (Symbol: BRO) $58.77 $66.75 13.58% Lincoln Electric Holdings, Inc. (Symbol: LECO) $159.00 $177.67 11.74% Johnson & Johnson (Symbol: JNJ) $165.84 $183.69 10.76% Nucor Corp. (Symbol: NUE) $146.19 $161.67 10.59% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.96% 16.97% 18.93% Brown & Brown Inc (Symbol: BRO) 0.78% 13.58% 14.36% Lincoln Electric Holdings, Inc. (Symbol: LECO) 1.61% 11.74% 13.35% Johnson & Johnson (Symbol: JNJ) 2.73% 10.76% 13.49% Nucor Corp. (Symbol: NUE) 1.40% 10.59% 11.99% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Brown & Brown Inc (Symbol: BRO) $0.392 $0.436 11.22% Lincoln Electric Holdings, Inc. (Symbol: LECO) $2.14 $2.4 12.15% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% These five stocks are part of our full Dividend Aristocrats List. | Abbott Laboratories (Symbol: ABT) $103.96 $121.60 16.97% Brown & Brown Inc (Symbol: BRO) $58.77 $66.75 13.58% Lincoln Electric Holdings, Inc. (Symbol: LECO) $159.00 $177.67 11.74% Johnson & Johnson (Symbol: JNJ) $165.84 $183.69 10.76% Nucor Corp. (Symbol: NUE) $146.19 $161.67 10.59% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.96% 16.97% 18.93% Brown & Brown Inc (Symbol: BRO) 0.78% 13.58% 14.36% Lincoln Electric Holdings, Inc. (Symbol: LECO) 1.61% 11.74% 13.35% Johnson & Johnson (Symbol: JNJ) 2.73% 10.76% 13.49% Nucor Corp. (Symbol: NUE) 1.40% 10.59% 11.99% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Brown & Brown Inc (Symbol: BRO) $0.392 $0.436 11.22% Lincoln Electric Holdings, Inc. (Symbol: LECO) $2.14 $2.4 12.15% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% These five stocks are part of our full Dividend Aristocrats List. | Abbott Laboratories (Symbol: ABT) $103.96 $121.60 16.97% Brown & Brown Inc (Symbol: BRO) $58.77 $66.75 13.58% Lincoln Electric Holdings, Inc. (Symbol: LECO) $159.00 $177.67 11.74% Johnson & Johnson (Symbol: JNJ) $165.84 $183.69 10.76% Nucor Corp. (Symbol: NUE) $146.19 $161.67 10.59% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.96% 16.97% 18.93% Brown & Brown Inc (Symbol: BRO) 0.78% 13.58% 14.36% Lincoln Electric Holdings, Inc. (Symbol: LECO) 1.61% 11.74% 13.35% Johnson & Johnson (Symbol: JNJ) 2.73% 10.76% 13.49% Nucor Corp. (Symbol: NUE) 1.40% 10.59% 11.99% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Brown & Brown Inc (Symbol: BRO) $0.392 $0.436 11.22% Lincoln Electric Holdings, Inc. (Symbol: LECO) $2.14 $2.4 12.15% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% These five stocks are part of our full Dividend Aristocrats List. | Abbott Laboratories (Symbol: ABT) $103.96 $121.60 16.97% Brown & Brown Inc (Symbol: BRO) $58.77 $66.75 13.58% Lincoln Electric Holdings, Inc. (Symbol: LECO) $159.00 $177.67 11.74% Johnson & Johnson (Symbol: JNJ) $165.84 $183.69 10.76% Nucor Corp. (Symbol: NUE) $146.19 $161.67 10.59% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.96% 16.97% 18.93% Brown & Brown Inc (Symbol: BRO) 0.78% 13.58% 14.36% Lincoln Electric Holdings, Inc. (Symbol: LECO) 1.61% 11.74% 13.35% Johnson & Johnson (Symbol: JNJ) 2.73% 10.76% 13.49% Nucor Corp. (Symbol: NUE) 1.40% 10.59% 11.99% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Brown & Brown Inc (Symbol: BRO) $0.392 $0.436 11.22% Lincoln Electric Holdings, Inc. (Symbol: LECO) $2.14 $2.4 12.15% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% These five stocks are part of our full Dividend Aristocrats List. |
31075.0 | 2023-04-14 00:00:00 UTC | Noteworthy ETF Outflows: XLV, ABT, ELV, MDT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-xlv-abt-elv-mdt | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $101.7 million dollar outflow -- that's a 0.3% decrease week over week (from 297,070,000 to 296,320,000). Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is down about 2.2%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.57. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
LSAK Stock Predictions
Institutional Holders of VSAT
CIU YTD Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is down about 2.2%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $101.7 million dollar outflow -- that's a 0.3% decrease week over week (from 297,070,000 to 296,320,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is down about 2.2%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.57. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is down about 2.2%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $101.7 million dollar outflow -- that's a 0.3% decrease week over week (from 297,070,000 to 296,320,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.57. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is down about 2.2%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $101.7 million dollar outflow -- that's a 0.3% decrease week over week (from 297,070,000 to 296,320,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.57. |
31076.0 | 2023-04-14 00:00:00 UTC | Abbott: FDA Clears Reader For FreeStyle Libre 3 Integrated Continuous Glucose Monitoring System | ABT | https://www.nasdaq.com/articles/abbott%3A-fda-clears-reader-for-freestyle-libre-3-integrated-continuous-glucose-monitoring | nan | nan | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system.
Abbott noted that it is working to get the FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible.
The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm, allowing them to manage their diabetes quickly and easily by viewing their glucose readings6 on a large, bright and easy-to-see screen.
People who use the FreeStyle Libre 3 system will still have the option to use the current FreeStyle Libre 3 smartphone apps, the company said.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system. The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm, allowing them to manage their diabetes quickly and easily by viewing their glucose readings6 on a large, bright and easy-to-see screen. For More Such Health News, visit rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system. Abbott noted that it is working to get the FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible. The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm, allowing them to manage their diabetes quickly and easily by viewing their glucose readings6 on a large, bright and easy-to-see screen. | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system. The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm, allowing them to manage their diabetes quickly and easily by viewing their glucose readings6 on a large, bright and easy-to-see screen. People who use the FreeStyle Libre 3 system will still have the option to use the current FreeStyle Libre 3 smartphone apps, the company said. | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system. Abbott noted that it is working to get the FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible. The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm, allowing them to manage their diabetes quickly and easily by viewing their glucose readings6 on a large, bright and easy-to-see screen. |
31077.0 | 2023-04-14 00:00:00 UTC | Intuitive Surgical Stock To See Higher Levels Post Q1? | ABT | https://www.nasdaq.com/articles/intuitive-surgical-stock-to-see-higher-levels-post-q1 | nan | nan | Intuitive Surgical (NASDAQ: ISRG) is scheduled to report its Q1 2023 results on Tuesday, April 18. We expect Intuitive Surgical to report revenue and earnings slightly above the street estimates, driven by a rise in total procedures volume. Although we believe the company will navigate well during the quarter, the stock has little room for growth, as discussed below. Our interactive dashboard analysis on Intuitive Surgical Earnings Preview has additional details.
(1) A rise in procedure volume to drive revenue growth
Trefis estimates Intuitive Surgical’s Q1 2023 revenues to be around $1.61 billion, marginally above the $1.59 billion consensus estimate.
The overall procedure volume will likely drive the sales growth for Intuitive Surgical. This has been the trend over the recent quarters, and we expect it to continue in the near term.
Looking at Q3 2022, the company saw its sales rise 7% (y-o-y) to $1.66 billion. This can be attributed to a higher demand for consumables. The overall procedure volume grew 18% during the quarter. All three segments – Instruments & Accessories, System, and Services saw sales rise during the quarter. However, Intuitive Surgical placed 369 da Vinci Surgical systems in the previous quarter, vs. 385 in Q4 2021.
Our dashboard on Intuitive Surgical Revenues has more details on the company’s segments.
(2) EPS likely to be slightly above the consensus estimates
Intuitive Surgical’s Q1 2023 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the $1.20 consensus estimate.
The company’s adjusted net income of $439 million in Q4 2022 reflected a 7% fall from its $473 million figure in the prior-year quarter, as the 7% sales growth was more than offset by a nearly 385 bps drop in adjusted net margins. This can primarily be attributed to higher fixed costs.
With elevated inflation, the costs may remain high for the company in the near term. Our Intuitive Surgical Operating Income Comparison dashboard has more details.
For the full-year 2023, we expect the adjusted EPS to be higher at $5.35 compared to $4.68 in 2022.
(3) ISRG stock has little room for growth
We estimate Intuitive Surgical’s Valuation to be around $278 per share, which is 5% above the current market price of $263.
This represents a 52x P/E multiple based on our forward adjusted earnings expectation of $5.35.
ISRG stock enjoys a higher valuation multiple, given the substantial revenue and earnings growth over the past years.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Abbott vs. Amerco.
With inflation rising and the Fed raising interest rates, among other factors, ISRG stock fell 1% this year. Can it drop more? See how low Intuitive Surgical stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Apr 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ISRG Return 3% -1% 273%
S&P 500 Return 0% 7% 84%
Trefis Multi-Strategy Portfolio 1% 9% 242%
[1] Month-to-date and year-to-date as of 4/12/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We expect Intuitive Surgical to report revenue and earnings slightly above the street estimates, driven by a rise in total procedures volume. (3) ISRG stock has little room for growth We estimate Intuitive Surgical’s Valuation to be around $278 per share, which is 5% above the current market price of $263. ISRG stock enjoys a higher valuation multiple, given the substantial revenue and earnings growth over the past years. | (1) A rise in procedure volume to drive revenue growth Trefis estimates Intuitive Surgical’s Q1 2023 revenues to be around $1.61 billion, marginally above the $1.59 billion consensus estimate. (2) EPS likely to be slightly above the consensus estimates Intuitive Surgical’s Q1 2023 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the $1.20 consensus estimate. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. | (1) A rise in procedure volume to drive revenue growth Trefis estimates Intuitive Surgical’s Q1 2023 revenues to be around $1.61 billion, marginally above the $1.59 billion consensus estimate. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return 3% -1% 273% S&P 500 Return 0% 7% 84% Trefis Multi-Strategy Portfolio 1% 9% 242% [1] Month-to-date and year-to-date as of 4/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (3) ISRG stock has little room for growth We estimate Intuitive Surgical’s Valuation to be around $278 per share, which is 5% above the current market price of $263. ISRG stock enjoys a higher valuation multiple, given the substantial revenue and earnings growth over the past years. Total [2] ISRG Return 3% -1% 273% S&P 500 Return 0% 7% 84% Trefis Multi-Strategy Portfolio 1% 9% 242% [1] Month-to-date and year-to-date as of 4/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31078.0 | 2023-04-14 00:00:00 UTC | What To Expect From Abbott's Q1? | ABT | https://www.nasdaq.com/articles/what-to-expect-from-abbotts-q1 | nan | nan | Abbott (NYSE: ABT) will report its Q1 2023 results on Wednesday, April 19. We expect the company to post revenue and earnings in line with the street expectations. Abbott will see a decline in sales given the forex headwinds and lower Covid-19-related testing demand. Although we expect Abbott to post an in-line Q1, our forecast indicates that ABT stock has some room for growth, as discussed below. Our interactive dashboard analysis of Abbott Earnings Preview has additional details.
(1) Revenues are expected to be lower compared to the prior-year quarter
Trefis estimates Abbott’s Q1 2023 revenues to be around $9.6 billion, reflecting a 19% y-o-y decline and aligning with the consensus estimate.
The revenue decline can primarily be attributed to lower demand for Covid-19 testing and forex headwinds.
For perspective, Abbott expects total Covid-19-related sales of $2.0 billion in 2023, compared to $8.4 billion last year.
Looking at Q4, the company reported total revenue of $10.1 billion, down 12% y-o-y, primarily due to a 26% decline in diagnostics sales.
Our dashboard on Abbott Revenues offers more details on the company’s segments.
(2) EPS likely to be in line with the consensus estimates
Abbott’s Q1 2023 adjusted earnings per share (EPS) is expected to be $0.99 per Trefis analysis, aligning with the consensus estimate.
Abbott’s adjusted net income of $1.8 billion in Q4 2022 reflected a 23% fall from its $2.4 billion figure in the prior-year quarter. This can be attributed to lower revenues and about 780 bps operating margin contraction due to higher costs. Our Abbott Operating Income Comparison dashboard has more details.
For the full-year 2023, we expect the adjusted EPS to be lower at $4.44, compared to $5.34 in 2022.
(3) ABT stock looks like it has more room for growth
We estimate Abbott’s Valuation to be around $119 per share, about 15% above the current market price of $103.
At its current levels, ABT stock is trading at a forward P/E multiple of 23x based on our EPS estimate of $4.44 for 2023, compared to the last three-year average of 24x.
If the company reports upbeat Q1 results and provides a 2023 outlook better than the street estimates, the P/E multiple will likely be revised upward, resulting in higher levels for ABT stock.
While ABT stock looks like it has more room for growth, it is helpful to see how Abbott’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Cintas vs. Merck.
With inflation rising and the Fed raising interest rates, among other factors, ABT stock has fallen 6% this year. Can it drop more? See how low Abbott stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Apr 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ABT Return 2% -6% 169%
S&P 500 Return 0% 7% 84%
Trefis Multi-Strategy Portfolio 1% 9% 242%
[1] Month-to-date and year-to-date as of 4/12/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (3) ABT stock looks like it has more room for growth We estimate Abbott’s Valuation to be around $119 per share, about 15% above the current market price of $103. At its current levels, ABT stock is trading at a forward P/E multiple of 23x based on our EPS estimate of $4.44 for 2023, compared to the last three-year average of 24x. With inflation rising and the Fed raising interest rates, among other factors, ABT stock has fallen 6% this year. | Abbott (NYSE: ABT) will report its Q1 2023 results on Wednesday, April 19. Although we expect Abbott to post an in-line Q1, our forecast indicates that ABT stock has some room for growth, as discussed below. (3) ABT stock looks like it has more room for growth We estimate Abbott’s Valuation to be around $119 per share, about 15% above the current market price of $103. | Total [2] ABT Return 2% -6% 169% S&P 500 Return 0% 7% 84% Trefis Multi-Strategy Portfolio 1% 9% 242% [1] Month-to-date and year-to-date as of 4/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE: ABT) will report its Q1 2023 results on Wednesday, April 19. Although we expect Abbott to post an in-line Q1, our forecast indicates that ABT stock has some room for growth, as discussed below. | (3) ABT stock looks like it has more room for growth We estimate Abbott’s Valuation to be around $119 per share, about 15% above the current market price of $103. Abbott (NYSE: ABT) will report its Q1 2023 results on Wednesday, April 19. Although we expect Abbott to post an in-line Q1, our forecast indicates that ABT stock has some room for growth, as discussed below. |
31079.0 | 2023-04-13 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-13 | nan | nan | Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session. The stock lagged the S&P 500's daily gain of 1.33%. At the same time, the Dow added 1.14%, and the tech-heavy Nasdaq gained 2.94%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 4.87% in the past month. In that same time, the Medical sector gained 7.14%, while the S&P 500 gained 6.11%.
Investors will be hoping for strength from Abbott as it approaches its next earnings release, which is expected to be April 19, 2023. The company is expected to report EPS of $0.98, down 43.35% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.64 billion, down 18.98% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.36 per share and revenue of $39.74 billion. These results would represent year-over-year changes of -18.35% and -8.97%, respectively.
It is also important to note the recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.41% lower. Abbott is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 23.5. Its industry sports an average Forward P/E of 22.15, so we one might conclude that Abbott is trading at a premium comparatively.
Also, we should mention that ABT has a PEG ratio of 4.62. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.41 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.36 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.62. | Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.36 per share and revenue of $39.74 billion. | Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.36 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.62. | Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.36 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.62. |
31080.0 | 2023-04-12 00:00:00 UTC | Notable Wednesday Option Activity: PTON, ABT, LULU | ABT | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-pton-abt-lulu | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Peloton Interactive Inc (Symbol: PTON), where a total of 62,338 contracts have traded so far, representing approximately 6.2 million underlying shares. That amounts to about 70.2% of PTON's average daily trading volume over the past month of 8.9 million shares. Especially high volume was seen for the $11 strike put option expiring April 14, 2023, with 6,095 contracts trading so far today, representing approximately 609,500 underlying shares of PTON. Below is a chart showing PTON's trailing twelve month trading history, with the $11 strike highlighted in orange:
Abbott Laboratories (Symbol: ABT) saw options trading volume of 39,635 contracts, representing approximately 4.0 million underlying shares or approximately 69.5% of ABT's average daily trading volume over the past month, of 5.7 million shares. Especially high volume was seen for the $95 strike put option expiring May 19, 2023, with 18,741 contracts trading so far today, representing approximately 1.9 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange:
And lululemon athletica inc (Symbol: LULU) saw options trading volume of 16,968 contracts, representing approximately 1.7 million underlying shares or approximately 66.3% of LULU's average daily trading volume over the past month, of 2.6 million shares. Especially high volume was seen for the $360 strike put option expiring April 21, 2023, with 1,295 contracts trading so far today, representing approximately 129,500 underlying shares of LULU. Below is a chart showing LULU's trailing twelve month trading history, with the $360 strike highlighted in orange:
For the various different available expirations for PTON options, ABT options, or LULU options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
Cheap Stocks To Watch
Funds Holding DCGO
Funds Holding FINX
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $95 strike put option expiring May 19, 2023, with 18,741 contracts trading so far today, representing approximately 1.9 million underlying shares of ABT. Below is a chart showing PTON's trailing twelve month trading history, with the $11 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 39,635 contracts, representing approximately 4.0 million underlying shares or approximately 69.5% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And lululemon athletica inc (Symbol: LULU) saw options trading volume of 16,968 contracts, representing approximately 1.7 million underlying shares or approximately 66.3% of LULU's average daily trading volume over the past month, of 2.6 million shares. | Below is a chart showing PTON's trailing twelve month trading history, with the $11 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 39,635 contracts, representing approximately 4.0 million underlying shares or approximately 69.5% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And lululemon athletica inc (Symbol: LULU) saw options trading volume of 16,968 contracts, representing approximately 1.7 million underlying shares or approximately 66.3% of LULU's average daily trading volume over the past month, of 2.6 million shares. Especially high volume was seen for the $95 strike put option expiring May 19, 2023, with 18,741 contracts trading so far today, representing approximately 1.9 million underlying shares of ABT. | Below is a chart showing PTON's trailing twelve month trading history, with the $11 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 39,635 contracts, representing approximately 4.0 million underlying shares or approximately 69.5% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And lululemon athletica inc (Symbol: LULU) saw options trading volume of 16,968 contracts, representing approximately 1.7 million underlying shares or approximately 66.3% of LULU's average daily trading volume over the past month, of 2.6 million shares. Especially high volume was seen for the $95 strike put option expiring May 19, 2023, with 18,741 contracts trading so far today, representing approximately 1.9 million underlying shares of ABT. | Below is a chart showing PTON's trailing twelve month trading history, with the $11 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 39,635 contracts, representing approximately 4.0 million underlying shares or approximately 69.5% of ABT's average daily trading volume over the past month, of 5.7 million shares. Especially high volume was seen for the $95 strike put option expiring May 19, 2023, with 18,741 contracts trading so far today, representing approximately 1.9 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And lululemon athletica inc (Symbol: LULU) saw options trading volume of 16,968 contracts, representing approximately 1.7 million underlying shares or approximately 66.3% of LULU's average daily trading volume over the past month, of 2.6 million shares. |
31081.0 | 2023-04-12 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-8 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31082.0 | 2023-04-12 00:00:00 UTC | What's in Store for Abbott Laboratories (ABT) in Q1 Earnings? | ABT | https://www.nasdaq.com/articles/whats-in-store-for-abbott-laboratories-abt-in-q1-earnings-0 | nan | nan | Abbott Laboratories ABT is slated to report first-quarter 2023 results on Apr 19 before market open.
In the last reported quarter, the company delivered an earnings surprise of 14.4%. Over the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all the occasions, the average beat being 22.42%.
Let's see how things have shaped up prior to this announcement.
Factors at Play
Persistent healthcare staffing challenges and diminishing demand for COVID-testing products are expected to have affected Abbott’s first-quarter performance. The decline in U.S. infant formula sales due to manufacturing disruptions and stubborn inflationary pressure, record strengthening of the U.S. dollar and supply chain issues in certain areas of business are expected to have weighed heavily on the company through the first quarter. The lockdown issues in limited geographies, including China (where the company has an extensive base), are expected to have impacted business during the first quarter.
On a positive note, within Established Pharmaceuticals Division (EPD), the company has been witnessing sequential improvement banking on the successful execution of its Branded Generic operating model. The first-quarter performance is likely to have been driven by growing customer demand for core therapeutic lines, including cardiometabolic, respiratory and central nervous system/pain management.
In Diagnostics, we expect the company to report a year-over-year decline in COVID test sales due to lower demand for laboratory-based tests. Excluding COVID testing revenues, sales of routine diagnostic tests are expected to have improved on the continuous rollout of Alinity — Abbott’s suite of diagnostic instruments — and expanding menus across testing platforms of immunoassay, clinical chemistry and molecular testing. In March 2023, the company received FDA approval for the Alinity i laboratory traumatic brain injury (TBI) blood test. This will be the first commercially available TBI blood test widely available to hospitals in the United States. We believe this development to have contributed to the company’s Q1 performance.
Abbott’s other consumer-facing businesses, which include diabetes care, have been catching up, backed by new product instructions. During the fourth quarter of 2022, ABT initiated the full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. This is likely to have contributed to first-quarter performance on strong consumer adoption.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote
The recent U.S. regulatory approvals of Aveir — the highly-innovative leadless pacemaker used to treat people with slow heart rhythms — and Eterna — the smallest implantable rechargeable spinal cord stimulation system available in the market for chronic pain — are expected to have contributed to the first-quarter performance on the back on strong market adoption.
Within Nutrition, total worldwide Nutrition and Pediatric Nutrition sales are expected to have declined in the quarter to be reported, thanks to the voluntary recall and manufacturing shutdown of certain infant formula products manufactured at one of Abbott's U.S. plants since last February. These include the company’s market-leading Similac and Elecare.
Estimates
For first-quarter 2023, the Zacks Consensus Estimate for total revenues is pegged at $9.64 billion, indicating an 18.9% decline from the prior-year comparable quarter’s reported figure. The consensus mark for earnings is pegged at 98 cents, suggesting a 43.4% decline year on year.
Earnings Whispers
Per our proven model, a stock with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a higher chance of beating estimates. That is not the case here, as you can see:
Earnings ESP: Abbott has an Earnings ESP of -1.92%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: It currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories BIO has an Earnings ESP of +0.16% and a Zacks Rank of #1. The company is expected to release first-quarter 2023 results on Apr 27. You can see the complete list of today’s Zacks #1 Rank stocks here.
Bio-Rad has a 2023 expected earnings growth rate of 10.3%. BIO’s earnings yield of 3.38% compares favorably with the industry’s (2.78%).
Masimo Corporation MASI has an Earnings ESP of +0.72% and a Zacks Rank of #1. Masimo is expected to release first-quarter fiscal 2023 results on May 2.
Masimo’s return on equity ratio of 18.84% compares favorably with the industry’s (34.98%). MASI has a debt/capital ratio of 41.29% compared with the industry’s 8.07%.
Teva Pharmaceutical Industries Limited TEVA currently has an Earnings ESP of +14.97% and a Zacks Rank of #2. TEVA is expected to release first-quarter 2023 results on May 2.
TEVA’s 2024 growth rate is estimated at 4.4%. TEVA’s earnings yield of 25.50% compares favorably with the industry’s (34.35%).
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | During the fourth quarter of 2022, ABT initiated the full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. Abbott Laboratories ABT is slated to report first-quarter 2023 results on Apr 19 before market open. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report first-quarter 2023 results on Apr 19 before market open. During the fourth quarter of 2022, ABT initiated the full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report first-quarter 2023 results on Apr 19 before market open. During the fourth quarter of 2022, ABT initiated the full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. | Abbott Laboratories ABT is slated to report first-quarter 2023 results on Apr 19 before market open. During the fourth quarter of 2022, ABT initiated the full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31083.0 | 2023-04-12 00:00:00 UTC | Earnings Preview: Abbott (ABT) Q1 Earnings Expected to Decline | ABT | https://www.nasdaq.com/articles/earnings-preview%3A-abbott-abt-q1-earnings-expected-to-decline | nan | nan | The market expects Abbott (ABT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on April 19, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $0.98 per share in its upcoming report, which represents a year-over-year change of -43.4%.
Revenues are expected to be $9.64 billion, down 19% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Abbott?
For Abbott, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.92%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Abbott will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Abbott would post earnings of $0.90 per share when it actually produced earnings of $1.03, delivering a surprise of +14.44%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Abbott doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The market expects Abbott (ABT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. | The market expects Abbott (ABT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. | The market expects Abbott (ABT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | The market expects Abbott (ABT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. For Abbott, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. |
31084.0 | 2023-04-11 00:00:00 UTC | Unusual Call Option Trade in Abbott Laboratories (ABT) Worth $316.32K | ABT | https://www.nasdaq.com/articles/unusual-call-option-trade-in-abbott-laboratories-abt-worth-%24316.32k | nan | nan | On April 11, 2023 at 10:35:12 ET an unusually large $316.32K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $110.00 / share, expiring in 66 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.29 sigmas above the mean, placing it in the 98.05 percentile of all recent large trades made in ABT options.
This trade was first picked up on Fintel's real time Unusual Option Trades tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 20.48% Upside
As of April 6, 2023, the average one-year price target for Abbott Laboratories is $124.94. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 20.48% from its latest reported closing price of $103.70.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
What is the Fund Sentiment?
There are 3951 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 148 owner(s) or 3.89% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.44%, a decrease of 28.50%. Total shares owned by institutions increased in the last three months by 0.06% to 1,513,995K shares. The put/call ratio of ABT is 0.95, indicating a bullish outlook.
What are Large Shareholders Doing?
Capital Research Global Investors holds 76,785K shares representing 4.42% ownership of the company. In it's prior filing, the firm reported owning 78,807K shares, representing a decrease of 2.63%. The firm increased its portfolio allocation in ABT by 1.70% over the last quarter.
Capital International Investors holds 53,026K shares representing 3.05% ownership of the company. In it's prior filing, the firm reported owning 52,232K shares, representing an increase of 1.50%. The firm increased its portfolio allocation in ABT by 6.00% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 53,002K shares representing 3.05% ownership of the company. In it's prior filing, the firm reported owning 52,252K shares, representing an increase of 1.41%. The firm increased its portfolio allocation in ABT by 6.29% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 40,307K shares representing 2.32% ownership of the company. In it's prior filing, the firm reported owning 39,698K shares, representing an increase of 1.51%. The firm increased its portfolio allocation in ABT by 6.14% over the last quarter.
Geode Capital Management holds 30,599K shares representing 1.76% ownership of the company. In it's prior filing, the firm reported owning 30,061K shares, representing an increase of 1.76%. The firm increased its portfolio allocation in ABT by 6.77% over the last quarter.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $103.70 / share, the stock's dividend yield is 1.97%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 1.94 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On April 11, 2023 at 10:35:12 ET an unusually large $316.32K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $110.00 / share, expiring in 66 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.29 sigmas above the mean, placing it in the 98.05 percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.44%, a decrease of 28.50%. | On April 11, 2023 at 10:35:12 ET an unusually large $316.32K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $110.00 / share, expiring in 66 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.29 sigmas above the mean, placing it in the 98.05 percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.44%, a decrease of 28.50%. | On April 11, 2023 at 10:35:12 ET an unusually large $316.32K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $110.00 / share, expiring in 66 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.29 sigmas above the mean, placing it in the 98.05 percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.44%, a decrease of 28.50%. | On April 11, 2023 at 10:35:12 ET an unusually large $316.32K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $110.00 / share, expiring in 66 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.29 sigmas above the mean, placing it in the 98.05 percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.44%, a decrease of 28.50%. |
31085.0 | 2023-04-11 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Mid-America Apartment Communities | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-abbott-laboratories-and-mid-america-apartment-communities-0 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.48 on 5/15/23, Abbott Laboratories will pay its quarterly dividend of $0.51 on 5/15/23, and Mid-America Apartment Communities Inc will pay its quarterly dividend of $1.40 on 4/28/23. As a percentage of ABBV's recent stock price of $161.65, this dividend works out to approximately 0.92%, so look for shares of AbbVie Inc to trade 0.92% lower — all else being equal — when ABBV shares open for trading on 4/13/23. Similarly, investors should look for ABT to open 0.49% lower in price and for MAA to open 0.94% lower, all else being equal.
Below are dividend history charts for ABBV, ABT, and MAA, showing historical dividends prior to the most recent ones declared.
AbbVie Inc (Symbol: ABBV):
Abbott Laboratories (Symbol: ABT):
Mid-America Apartment Communities Inc (Symbol: MAA):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 3.66% for AbbVie Inc, 1.96% for Abbott Laboratories, and 3.74% for Mid-America Apartment Communities Inc.
In Tuesday trading, AbbVie Inc shares are currently up about 0.2%, Abbott Laboratories shares are up about 0.2%, and Mid-America Apartment Communities Inc shares are off about 0.1% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
UGE shares outstanding history
Top Ten Hedge Funds Holding CEPU
Top Ten Hedge Funds Holding CMK
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABT to open 0.49% lower in price and for MAA to open 0.94% lower, all else being equal. Below are dividend history charts for ABBV, ABT, and MAA, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): Mid-America Apartment Communities Inc (Symbol: MAA): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.49% lower in price and for MAA to open 0.94% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): Mid-America Apartment Communities Inc (Symbol: MAA): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.49% lower in price and for MAA to open 0.94% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABT to open 0.49% lower in price and for MAA to open 0.94% lower, all else being equal. Below are dividend history charts for ABBV, ABT, and MAA, showing historical dividends prior to the most recent ones declared. |
31086.0 | 2023-04-11 00:00:00 UTC | TG Therapeutics (TGTX) Surges 22.8%: Is This an Indication of Further Gains? | ABT | https://www.nasdaq.com/articles/tg-therapeutics-tgtx-surges-22.8%3A-is-this-an-indication-of-further-gains | nan | nan | TG Therapeutics TGTX shares rallied 22.8% in the last trading session to close at $19.01. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.9% gain over the past four weeks.
TG Therapeutics recorded a strong price increase after American financial services firm, Cantor Fitzgerald, cited strong sales data for TG Therapeutics’ newly approved multiple sclerosis therapy Briumvi and argued that the biotech would likely meet or exceed the current consensus for the monoclonal antibody. Also, the latest Zacks Consensus Estimate shows significant upward revision for its quarterly revenues compared to the year-ago reported number. The company is expected to release its first-quarter 2023 earnings on May 9.
This biopharmaceutical company is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of +29.4%. Revenues are expected to be $5.41 million, up 168% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For TG Therapeutics, the consensus EPS estimate for the quarter has been revised 5.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TGTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
TG Therapeutics is a member of the Zacks Medical - Products industry. One other stock in the same industry, Abbott ABT, finished the last trading session 1.2% lower at $103.70. ABT has returned 8.2% over the past month.
Abbott's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.98. Compared to the company's year-ago EPS, this represents a change of -43.4%. Abbott currently boasts a Zacks Rank of #3 (Hold).
Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom
It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They’re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation.
>>Show me how I could profit from the metaverse!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock in the same industry, Abbott ABT, finished the last trading session 1.2% lower at $103.70. ABT has returned 8.2% over the past month. Click to get this free report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock in the same industry, Abbott ABT, finished the last trading session 1.2% lower at $103.70. ABT has returned 8.2% over the past month. | Click to get this free report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock in the same industry, Abbott ABT, finished the last trading session 1.2% lower at $103.70. ABT has returned 8.2% over the past month. | One other stock in the same industry, Abbott ABT, finished the last trading session 1.2% lower at $103.70. ABT has returned 8.2% over the past month. Click to get this free report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31087.0 | 2023-04-08 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-7 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31088.0 | 2023-04-07 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABT | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-6 | nan | nan | Making its debut on 10/09/2013, smart beta exchange traded fund ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, a strategy created to reflect the market or a particular market segment.
Investors who believe in market efficiency should consider market cap indexes, as they replicate market returns in a low-cost, convenient, and transparent way.
But, there are some investors who would rather invest in smart beta funds; these funds track non-cap weighted strategies, and are a strong option for those who prefer choosing great stocks in order to beat the market.
By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such.
Methodologies like equal-weighting, one of the simplest options out there, fundamental weighting, and volatility/momentum based weighting are all choices offered to investors in this space, but not all of them can deliver superior returns.
Fund Sponsor & Index
Managed by Proshares, NOBL has amassed assets over $11.09 billion, making it one of the larger ETFs in the Style Box - Large Cap Value. Before fees and expenses, this particular fund seeks to match the performance of the S&P 500 DividendAristocrats Index.
The S&P 500 Dividend Aristocrats Index targets companies that are currently members of the S&P 500, have increased dividend payments each year for at least 25 years & meet certain market capitalization & liquidity requirements.
Cost & Other Expenses
For ETF investors, expense ratios are an important factor when considering a fund's return; in the long-term, cheaper funds actually have the ability to outperform their more expensive cousins if all other things remain the same.
Annual operating expenses for this ETF are 0.35%, making it on par with most peer products in the space.
It's 12-month trailing dividend yield comes in at 1.93%.
Performance and Risk
So far this year, NOBL has gained about 0.89%, and is down about -3.68% in the last one year (as of 04/07/2023). During this past 52-week period, the fund has traded between $79.96 and $97.74.
The fund has a beta of 0.89 and standard deviation of 18.53% for the trailing three-year period, which makes NOBL a medium risk choice in this particular space. With about 67 holdings, it effectively diversifies company-specific risk.
Alternatives
ProShares S&P 500 Dividend Aristocrats ETF is an excellent option for investors seeking to outperform the Style Box - Large Cap Value segment of the market. There are other ETFs in the space which investors could consider as well.
IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. IShares Core Dividend Growth ETF has $23.27 billion in assets, Vanguard Dividend Appreciation ETF has $65.49 billion. DGRO has an expense ratio of 0.08% and VIG charges 0.06%.
Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Style Box - Large Cap Value.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports
Abbott Laboratories (ABT) : Free Stock Analysis Report
Aflac Incorporated (AFL) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports
iShares Core Dividend Growth ETF (DGRO): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Making its debut on 10/09/2013, smart beta exchange traded fund ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides investors broad exposure to the Style Box - Large Cap Value category of the market. Fund Sponsor & Index Managed by Proshares, NOBL has amassed assets over $11.09 billion, making it one of the larger ETFs in the Style Box - Large Cap Value. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. IShares Core Dividend Growth ETF has $23.27 billion in assets, Vanguard Dividend Appreciation ETF has $65.49 billion. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Making its debut on 10/09/2013, smart beta exchange traded fund ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides investors broad exposure to the Style Box - Large Cap Value category of the market. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Making its debut on 10/09/2013, smart beta exchange traded fund ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides investors broad exposure to the Style Box - Large Cap Value category of the market. The fund has a beta of 0.89 and standard deviation of 18.53% for the trailing three-year period, which makes NOBL a medium risk choice in this particular space. |
31089.0 | 2023-04-06 00:00:00 UTC | 3 No-Brainer Medical Device Stocks to Buy Right Now | ABT | https://www.nasdaq.com/articles/3-no-brainer-medical-device-stocks-to-buy-right-now | nan | nan | The COVID-19 pandemic slowed business for many healthcare companies because the number of elective surgeries fell. On top of that, labor shortages for hospital staff, tightened hospital spending, and supply chain issues slowed sales of medical equipment.
However, as elective procedures gradually return to where they were before the pandemic, medical equipment makers are seeing a surge in sales. Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time.
Let's see why investors should consider them now.
Edwards has its pulse on growth
Edwards Lifesciences focuses on devices for critical care monitoring and to treat structural heart disease.
About 10 years ago, the company pioneered transcatheter heart valves (TAVR) that don't require open-heart surgery. It's looking forward to a boost this year thanks to the launch late last year of its next-generation TAVR, the Sapien 3 Ultra Resilia. The valve is made from cow heart tissue and has anti-calcification technology.
The company's other big seller has been its HemoSphere system to monitor patients' heart functions and fluid status. Edwards should benefit as the population ages. Heart disease is the No. 1 cause of death in the U.S., according to the Centers for Disease Control and Prevention.
The need for heart valves and heart monitoring is expected to grow, with Edwards saying in its latest quarterly report that it expects low double-digit growth in business between now and 2028.
The company reported fourth-quarter and full-year earnings on Jan. 31. Fourth-quarter sales were up 1% year over year to $1.35 billion while yearly revenue grew 3% to $5.38 billion. Earnings also grew. In the fourth quarter, Edwards reported earnings per share (EPS) of $0.65, up 22.6% over the fourth quarter of 2021. Yearly EPS was up 2.5% to $2.44.
Edwards said it expects 2023 sales of $5.6 billion to $6 billion, up 9% to 12%, and adjusted EPS between $2.45 and $2.60, compared to $2.48 in 2022.
ABT EPS Diluted (Annual) data by YCharts
Abbott is keeping the FDA busy
Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. On Jan. 6, the FDA cleared Abbott's Navitor, its latest transcatheter aortic valve implantation (TAVI) system, to treat people with severe aortic stenosis (when a heart valve doesn't open properly) who are at high risk for open-heart surgery.
Then on Jan. 26, it received FDA approval for another indication for its Proclaim XR SCS (spinal-cord stimulation) system as a non-medication pain therapy for diabetic peripheral neuropathy.
Finally, on March 30, Abbott received FDA approval of its Epic Max stented tissue valve to treat patients with aortic regurgitation (when a heart valve doesn't close properly) or stenosis. Epic Max is designed for patients who can't take blood thinners but need heart valve replacements.
On the financial front, Abbott reported revenue of $43.6 billion last year, up 1.3%, though EPS was down to $3.91 compared to $3.94 a year earlier. Abbott's diabetes care sales spiked by 34.8% in the U.S. last year and 9.9% overall to $4.8 billion, thanks to the introduction of the Freestyle Libre 3, the world's smallest and thinnest continuous glucose monitoring (CGM) device.
One advantage Abbott has over the other two stocks here is its dividend, which it has increased for 51 consecutive years. The current quarterly dividend pays $0.51 per share, equal to an above-average yield of about 2%. The payout ratio is a conservative 42%, meaning it is well-covered by the company's cash flows.
G7 launch will drive DexCom sales this year
DexCom focuses on CGM systems for diabetic care -- a need that is increasing due to an aging population and increasing obesity. According to the International Diabetes Foundation, there were 537 million adults with diabetes in 2021, and that number is expected to grow to 783 million by 2045. The number could be even higher, the foundation said, because nearly one in two adults who have diabetes are undiagnosed.
The company launched its latest -- and smallest -- CGM device, the G7, in February and is looking forward to another year of growth.
DexCom reported fourth-quarter and full-year 2022 numbers on Feb. 9. Fourth-quarter revenue was up 17% year over year to $815 million while full-year revenue was up 19% to $2.9 billion.
Net income for the year was $341 million, up about 45%, with 2023 EPS coming in at $0.82, up almost 55%. Fourth-quarter net income was $91.8 million, compared to a loss of $5.3 million in the same quarter a year ago, while EPS this quarter was $0.22 compared to an EPS loss of $0.01 in the same period a year ago.
This year, thanks to the launch of the G7, the company's guidance points to revenue of between $3.35 billion and $3.49 billion, growth of 15% to 20%.
10 stocks we like better than Edwards Lifesciences
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Edwards Lifesciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 8, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Edwards Lifesciences. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time. ABT EPS Diluted (Annual) data by YCharts Abbott is keeping the FDA busy Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. About 10 years ago, the company pioneered transcatheter heart valves (TAVR) that don't require open-heart surgery. | Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time. ABT EPS Diluted (Annual) data by YCharts Abbott is keeping the FDA busy Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. Finally, on March 30, Abbott received FDA approval of its Epic Max stented tissue valve to treat patients with aortic regurgitation (when a heart valve doesn't close properly) or stenosis. | Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time. ABT EPS Diluted (Annual) data by YCharts Abbott is keeping the FDA busy Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. Fourth-quarter sales were up 1% year over year to $1.35 billion while yearly revenue grew 3% to $5.38 billion. | Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time. ABT EPS Diluted (Annual) data by YCharts Abbott is keeping the FDA busy Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. The need for heart valves and heart monitoring is expected to grow, with Edwards saying in its latest quarterly report that it expects low double-digit growth in business between now and 2028. |
31090.0 | 2023-04-06 00:00:00 UTC | 3 Discounted Dividend Stocks With Combined 150+ Years Of Dividend Growth | ABT | https://www.nasdaq.com/articles/3-discounted-dividend-stocks-with-combined-150-years-of-dividend-growth | nan | nan | All three of these dividend stocks are both S&P 500 stocks and they have grown their individual dividends for more than 25 consecutive years. Two of the stocks have increased their dividend every year for at least 50 years, technically making them a dividend king. One of these dividend stocks for passive income include: Lowe's Companies (NYSE: LOW).
Check out this video to learn more, consider subscribing to the channel, and check out the special offer in the link below.
*Stock prices used were end-of-day prices of March 31, 2023. The video was published on April 3, 2023.
10 stocks we like better than Lowe's Companies
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Lowe's Companies wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 8, 2023
Mark Roussin, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Lowe's Companies. The Motley Fool has a disclosure policy.
Mark Roussin is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Lowe's Companies wasn't one of them! If you choose to subscribe through their link they will earn some extra money that supports their channel. | After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has no position in any of the stocks mentioned. The Motley Fool recommends Lowe's Companies. | All three of these dividend stocks are both S&P 500 stocks and they have grown their individual dividends for more than 25 consecutive years. Check out this video to learn more, consider subscribing to the channel, and check out the special offer in the link below. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has no position in any of the stocks mentioned. | One of these dividend stocks for passive income include: Lowe's Companies (NYSE: LOW). See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has no position in any of the stocks mentioned. The Motley Fool recommends Lowe's Companies. |
31091.0 | 2023-04-05 00:00:00 UTC | Wells Fargo Maintains Abbott Laboratories (ABT) Overweight Recommendation | ABT | https://www.nasdaq.com/articles/wells-fargo-maintains-abbott-laboratories-abt-overweight-recommendation | nan | nan | On April 5, 2023, Wells Fargo maintained coverage of Abbott Laboratories with a Overweight recommendation.
Analyst Price Forecast Suggests 23.00% Upside
As of March 30, 2023, the average one-year price target for Abbott Laboratories is $126.45. The forecasts range from a low of $108.07 to a high of $151.20. The average price target represents an increase of 23.00% from its latest reported closing price of $102.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Abbott Laboratories is $39,830MM, a decrease of 8.76%. The projected annual non-GAAP EPS is $4.45.
Abbott Laboratories Declares $0.51 Dividend
On February 17, 2023 the company declared a regular quarterly dividend of $0.51 per share ($2.04 annualized). Shareholders of record as of April 14, 2023 will receive the payment on May 15, 2023. Previously, the company paid $0.51 per share.
At the current share price of $102.80 / share, the stock's dividend yield is 1.98%. Looking back five years and taking a sample every week, the average dividend yield has been 1.61%, the lowest has been 1.26%, and the highest has been 2.29%. The standard deviation of yields is 0.18 (n=237).
The current dividend yield is 2.04 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.51. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.42%, demonstrating that it has increased its dividend over time.
What are Other Shareholders Doing?
Trustcore Financial Services holds 10K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 11K shares, representing a decrease of 4.79%. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter.
Taddei, Ludwig & Associates holds 3K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 2K shares, representing an increase of 7.55%. The firm increased its portfolio allocation in ABT by 14.98% over the last quarter.
PIONEER VARIABLE CONTRACTS TRUST holds 13K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 14K shares, representing a decrease of 2.40%. The firm increased its portfolio allocation in ABT by 2.03% over the last quarter.
Goodwin Investment Advisory holds 1K shares representing 0.00% ownership of the company. No change in the last quarter.
DAVENPORT & Co holds 813K shares representing 0.05% ownership of the company. In it's prior filing, the firm reported owning 662K shares, representing an increase of 18.61%. The firm increased its portfolio allocation in ABT by 30.68% over the last quarter.
What is the Fund Sentiment?
There are 3959 funds or institutions reporting positions in Abbott Laboratories. This is an increase of 162 owner(s) or 4.27% in the last quarter. Average portfolio weight of all funds dedicated to ABT is 0.54%, a decrease of 11.55%. Total shares owned by institutions decreased in the last three months by 0.06% to 1,515,548K shares. The put/call ratio of ABT is 0.94, indicating a bullish outlook.
Abbott Laboratories Background Information
(This description is provided by the company.)
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
See all Abbott Laboratories regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. The firm increased its portfolio allocation in ABT by 14.98% over the last quarter. The firm increased its portfolio allocation in ABT by 2.03% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. The firm increased its portfolio allocation in ABT by 14.98% over the last quarter. The firm increased its portfolio allocation in ABT by 2.03% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. The firm increased its portfolio allocation in ABT by 14.98% over the last quarter. The firm increased its portfolio allocation in ABT by 2.03% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. The firm increased its portfolio allocation in ABT by 14.98% over the last quarter. The firm increased its portfolio allocation in ABT by 2.03% over the last quarter. |
31092.0 | 2023-04-05 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-6 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31093.0 | 2023-04-05 00:00:00 UTC | Better Dividend Stock: AbbVie vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-dividend-stock%3A-abbvie-vs.-johnson-johnson | nan | nan | The pharmaceutical industry is a great place to look for dividend stocks, and AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are among the best. Both drugmakers generally grow their dividends at a good clip, and both are part of the highly exclusive group of Dividend Kings, having raised their payouts for more than 50 years straight. But which of these pharmaceutical giants is the better dividend stock? Let's look into both companies and decide.
The case for AbbVie: It has an answer to the loss of Humira's patent exclusivity
AbbVie is going through a bit of a difficult period. In January, it started facing biosimilar competition in the U.S. for its blockbuster immunology medicine, Humira. The drugmaker expects its top line to decrease this year and the next as a result. But AbbVie's dividend is safe, and its prospects remain attractive. The company's lineup of medicines is vast, with several products that will help supplement Humira's sales drop gaining momentum.
One of them is the migraine treatment Qulipta. There is also cancer medicine Venclexta and AbbVie's Botox franchise. But AbbVie's most important growth drivers will be Skyrizi and Rinvoq, two immunology drugs taking over many of Humira's indications. For instance, Skyrizi proved more effective than Humira at clearing skin in plaque psoriasis patients. Skyrizi and Rinvoq are expected to surpass Humira's peak annual sales by 2027 and maintain their momentum thereafter.
So there is a long road of growth ahead for these medicines. Last year, AbbVie's net revenue increased by 3.3% year over year to $58.1 billion. The company's adjusted earnings per share (EPS) of $13.77 increased by about 16.4% year over year. As a Dividend King, AbbVie has raised its payouts for 51 consecutive years when taking into consideration that it used to be under the banner of medical device giant Abbott Laboratories. But since it split from its former parent company in 2013, AbbVie has increased its payouts by 270%.
Its current yield of 3.71% is higher than the S&P 500 average of 1.74%, and its cash payout ratio of 41.42% leaves plenty of room for further hikes. AbbVie looks strong enough to overcome the challenges to Humira and come out with a stronger company that still routinely rewards its shareholders with dividend increases.
The case for Johnson & Johnson: Its upcoming consumer health spinoff should boost revenue growth
Johnson & Johnson has a diversified business. The company is a leader in the pharmaceutical industry, with a presence in oncology, immunology, neuroscience, infectious diseases, and more. But the company also boasts a prominent medical device unit that recently got even stronger with the acquisition of Abiomed, which most notably provides oxygenation support medical technology.
There is another important way in which Johnson & Johnson is changing. The company is still splitting up its consumer health segment. The transaction should boost Johnson & Johnson's revenue growth as this segment has been trailing the company's two other units on this front. Regardless of all these changes, Johnson & Johnson will continue to generate solid revenue and earnings, just as it has in the past.
Last year, the drugmaker's top line increased by 1.3% to $94.9 billion. Johnson & Johnson's adjusted EPS came in at $10.15, rising by 3.6% compared to 2021. The healthcare giant does face some issues, most notably a barrage of lawsuits related to its talcum powder products. However, Johnson & Johnson has a robust balance sheet -- with an AAA rating from Standard & Poor's -- and it is more than capable of taking care of its obligations.
Johnson & Johnson has raised its dividend for 60 years straight, including by 71.2% in the past 10 years; its dividend yield is at 2.95%, also higher than that of the S&P 500. The company's cash payout ratio of almost 68% looks a bit high. But Johnson & Johnson's impeccable dividend record is unlikely to come to a halt anytime soon.
The verdict: Both are great, but AbbVie has a higher yield
Both companies are solid dividend stocks. They even have comparable forward price-to-earning (P/E) ratios, with AbbVie's 14.3 slightly lower than Johnson & Johnson's 14.7. So income-seeking investors can't go wrong with either. But which one is better for dividends? My vote goes to AbbVie, but only by a very slight margin. The company has a higher dividend per share ($1.41 vs. $1.13) and has raised its dividends much faster than its peer in recent years.
AbbVie's lower cash payout ratio shows that it can still afford to do so more than Johnson & Johnson, and what's more, AbbVie has a more attractive yield. Although the loss of patent exclusivity for Humira will be a challenge, AbbVie's revenue growth should pick back up in 2025. The company's business will be just fine over the long run and can support sustained dividend growth for a long time.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 8, 2023
Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a Dividend King, AbbVie has raised its payouts for 51 consecutive years when taking into consideration that it used to be under the banner of medical device giant Abbott Laboratories. Its current yield of 3.71% is higher than the S&P 500 average of 1.74%, and its cash payout ratio of 41.42% leaves plenty of room for further hikes. AbbVie looks strong enough to overcome the challenges to Humira and come out with a stronger company that still routinely rewards its shareholders with dividend increases. | As a Dividend King, AbbVie has raised its payouts for 51 consecutive years when taking into consideration that it used to be under the banner of medical device giant Abbott Laboratories. The case for Johnson & Johnson: Its upcoming consumer health spinoff should boost revenue growth Johnson & Johnson has a diversified business. AbbVie's lower cash payout ratio shows that it can still afford to do so more than Johnson & Johnson, and what's more, AbbVie has a more attractive yield. | The case for Johnson & Johnson: Its upcoming consumer health spinoff should boost revenue growth Johnson & Johnson has a diversified business. Johnson & Johnson has raised its dividend for 60 years straight, including by 71.2% in the past 10 years; its dividend yield is at 2.95%, also higher than that of the S&P 500. AbbVie's lower cash payout ratio shows that it can still afford to do so more than Johnson & Johnson, and what's more, AbbVie has a more attractive yield. | But which of these pharmaceutical giants is the better dividend stock? The case for Johnson & Johnson: Its upcoming consumer health spinoff should boost revenue growth Johnson & Johnson has a diversified business. Johnson & Johnson has raised its dividend for 60 years straight, including by 71.2% in the past 10 years; its dividend yield is at 2.95%, also higher than that of the S&P 500. |
31094.0 | 2023-04-04 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-9 | nan | nan | Abbott (ABT) closed at $102.80 in the latest trading session, marking a +1.19% move from the prior day. This move outpaced the S&P 500's daily loss of 0.58%. Elsewhere, the Dow lost 0.59%, while the tech-heavy Nasdaq lost 1.54%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 1.13% over the past month. This has lagged the Medical sector's gain of 0.22% and the S&P 500's gain of 2% in that time.
Abbott will be looking to display strength as it nears its next earnings release, which is expected to be April 19, 2023. On that day, Abbott is projected to report earnings of $0.98 per share, which would represent a year-over-year decline of 43.35%. Meanwhile, our latest consensus estimate is calling for revenue of $9.64 billion, down 18.98% from the prior-year quarter.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. These results would represent year-over-year changes of -17.98% and -8.97%, respectively.
Investors might also notice recent changes to analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% lower. Abbott is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.2. Its industry sports an average Forward P/E of 21.21, so we one might conclude that Abbott is trading at a premium comparatively.
Also, we should mention that ABT has a PEG ratio of 4.56. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.34 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 154, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $102.80 in the latest trading session, marking a +1.19% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.56. | Abbott (ABT) closed at $102.80 in the latest trading session, marking a +1.19% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.56. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed at $102.80 in the latest trading session, marking a +1.19% move from the prior day. | Abbott (ABT) closed at $102.80 in the latest trading session, marking a +1.19% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.56. |
31095.0 | 2023-04-04 00:00:00 UTC | Top Stock Reports for T-Mobile US, Abbott Laboratories & AMD | ABT | https://www.nasdaq.com/articles/top-stock-reports-for-t-mobile-us-abbott-laboratories-amd | nan | nan | Tuesday, April 4, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of T-Mobile US have outperformed the Zacks Wireless National industry over the past year (+11.2% vs. -3.4%). The company's industry-leading growth in postpaid and broadband customers is driven by superior 5G network and focus on customers. The company has augmented its 5G footprint by introducing 5G Home Internet services in several states.
T-Mobile plans to reach 300 million people within 2023. It intends to bring more competition to home broadband, especially in underserved rural markets. T-Mobile is on track to complete the Sprint customer network decommissioning. However, T-Mobile operates in a fiercely competitive and almost saturated U.S. telecom market, which lowers its growth potential to some extent.
Several promotional activities to lure additional customers are further eroding its profitability. Importantly, the costs incurred to gain customers and enhance revenues have not rewarded its shareholders yet. Debt obligation woes also persist.
(You can read the full research report on T-Mobile US here >>>)
Abbott Laboratories shares have declined -13.4% over the past year against the Zacks Medical - Products industry’s decline of -37.8%. The company’s total sales were negatively impacted by a decline in COVID testing-related sales. Moreover, the decline in U.S. infant formula sales due to manufacturing disruptions dented the quarter’s sales further.
However, on a positive note, excluding COVID testing sales, worldwide Diagnostics sales grew over 11% led by rapid diagnostics. Within EPD, sales increased 8% organically in the fourth quarter led by double-digit growth across several countries.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. Abbott outperformed the industry over the past year.
(You can read the full research report on Abbott Laboratories here >>>)
Shares of AMD have outperformed the Zacks Electronics - Semiconductors industry over the past six months (+42.1% vs. +38.5%). The company expects to witness continued growth in embedded and data Center segments, partially offset by a decline in the client and gaming segments for first quarter of 2023. Sequentially, embedded segment revenues are expected to increase.
Client and Gaming segment revenues are expected to decline, largely consistent with seasonality. Data Center segment revenues are expected to decline due to elevated levels of inventory with some cloud customers.
However, AMD is benefiting from strong product portfolio and acquisitions including Xilinx and Pensando, which has diversified its business. Robust adoption of EPYC processors by North American hyperscalers has been a tailwind.
(You can read the full research report on AMD here >>>)
Other noteworthy reports we are featuring today include Intuit Inc. (INTU), S&P Global Inc. (SPGI) and Cintas Corporation (CTAS).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
T-Mobile (TMUS) Poised to Gain from Nationwide 5G Footprint
EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues
AMD Rides on Strong Adoption of EPYC & Ryzen Processors
Featured Reports
Intuit (INTU) Rides on Product Refresh, Higher Subscriptions
Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Moreover, increase in subscriptions is driving stable revenue growth for the company.
S&P Global's (SPGI) ChartIQ Acquisition to Act as a Tailwind
Per the Zacks analyst, S&P Global's Market Intelligence segment is likely to benefit from the acquisition of ChartIQ. High operational cost remains a concern.
Uniform Rental Unit Aids Cintas (CTAS), High Costs Ail
The Zacks analyst is encouraged by strength in Cintas' Uniform Rental unit due to increased volumes. However, escalating cost of sales pose a threat to the company's bottom line.
Life-Science Assets, Strategic Buyouts Aid Alexandria (ARE)
Per the Zacks Analyst, Alexandria to benefit from the healthy demand for its life-science assets and strategic acquisitions. However, rising interest rates remain a key concern.
Expanding Customer Base, Steady Investment Aid Atmos (ATO)
Per the Zacks analyst Atmos Energy is gaining from demand from increasing customer base. Long-term investments will fortify infrastructure enabling it to serve more customer and boosts profits.
Five Below (FIVE) Gains From Robust Store Expansion Effort
Per the Zacks analyst, Five Below's focus on expanding its reach by increasing store base across different locations bodes well. The store count rose 12.6% in fiscal 2022 compared to year ago period.
CRISPR's (CRSP) Dependence on Collaboration Revenues A Woe
While CRISPR Therapeutics' pipeline progress is impressive, the Zacks Analyst is concerned about a lack of stable stream of income as the company has no marketed drugs in its portfolio.
New Upgrades
Solid Equipment Rental Business Aids United Rentals (URI)
Per the Zacks analyst, United Rentals benefits from solid end markets for equipment rental business in North America.
New Products & Acquisitions Aid Blackbaud's (BLKB) Performance
Per the Zacks analyst, Blackbaud's performance is gaining from frequent product launches and increasing customer renewal rates. Synergies from recent acquisitions also bode well.
Brighthouse (BHF) Continues to Gain From Life & Annuity Products
Per the Zacks analyst, Brighthouse is set to grow on compelling suite of life and annuity products, growing insurance market. New sales of life insurance products, wide distribution network bode well.
New Downgrades
APA Corporation (APA) Wrecked by Massive Debt Burden
The Zacks analyst believes that APA Corporation's high debt-to-capitalization of 80.2% is a concern, as it restricts the firm's financial freedom to tap into growth opportunities.
Low Liquidity & Supply Chain Disruptions Hurt Trinity (TRN)
The Zacks analyst is pessimistic about TRN's low current ratio. Also, its operations are being hurt by supply chain disruptions and labor shortages.
Forex Woes Impede Charles River's (CRL) International Sales
The strengthening of Euro and some other developed market currencies has been constantly hampering Charles River's performance in the international markets.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
Cintas Corporation (CTAS) : Free Stock Analysis Report
Intuit Inc. (INTU) : Free Stock Analysis Report
T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report
S&P Global Inc. (SPGI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD). Today's Must Read T-Mobile (TMUS) Poised to Gain from Nationwide 5G Footprint EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues AMD Rides on Strong Adoption of EPYC & Ryzen Processors Featured Reports Intuit (INTU) Rides on Product Refresh, Higher Subscriptions Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Today's Must Read T-Mobile (TMUS) Poised to Gain from Nationwide 5G Footprint EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues AMD Rides on Strong Adoption of EPYC & Ryzen Processors Featured Reports Intuit (INTU) Rides on Product Refresh, Higher Subscriptions Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD). | Today's Must Read T-Mobile (TMUS) Poised to Gain from Nationwide 5G Footprint EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues AMD Rides on Strong Adoption of EPYC & Ryzen Processors Featured Reports Intuit (INTU) Rides on Product Refresh, Higher Subscriptions Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD). | Today's Must Read T-Mobile (TMUS) Poised to Gain from Nationwide 5G Footprint EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues AMD Rides on Strong Adoption of EPYC & Ryzen Processors Featured Reports Intuit (INTU) Rides on Product Refresh, Higher Subscriptions Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31096.0 | 2023-04-03 00:00:00 UTC | Invesco S&P 500 QVM Multi-factor ETF Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/invesco-sp-500-qvm-multi-factor-etf-experiences-big-outflow | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 QVM Multi-factor ETF (Symbol: QVML) where we have detected an approximate $141.8 million dollar outflow -- that's a 13.9% decrease week over week (from 42,050,000 to 36,200,000). Among the largest underlying components of QVML, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Standard and Poors Global Inc (Symbol: SPGI) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is higher by about 1.6%. For a complete list of holdings, visit the QVML Holdings page » The chart below shows the one year price performance of QVML, versus its 200 day moving average:
Looking at the chart above, QVML's low point in its 52 week range is $21.3219 per share, with $26.8318 as the 52 week high point — that compares with a last trade of $24.33. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
Cheap Healthcare Shares
TROW Stock Predictions
CDN Split History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of QVML, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Standard and Poors Global Inc (Symbol: SPGI) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is higher by about 1.6%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of QVML, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Standard and Poors Global Inc (Symbol: SPGI) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is higher by about 1.6%. For a complete list of holdings, visit the QVML Holdings page » The chart below shows the one year price performance of QVML, versus its 200 day moving average: Looking at the chart above, QVML's low point in its 52 week range is $21.3219 per share, with $26.8318 as the 52 week high point — that compares with a last trade of $24.33. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of QVML, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Standard and Poors Global Inc (Symbol: SPGI) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 QVM Multi-factor ETF (Symbol: QVML) where we have detected an approximate $141.8 million dollar outflow -- that's a 13.9% decrease week over week (from 42,050,000 to 36,200,000). For a complete list of holdings, visit the QVML Holdings page » The chart below shows the one year price performance of QVML, versus its 200 day moving average: Looking at the chart above, QVML's low point in its 52 week range is $21.3219 per share, with $26.8318 as the 52 week high point — that compares with a last trade of $24.33. | Among the largest underlying components of QVML, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Standard and Poors Global Inc (Symbol: SPGI) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 QVM Multi-factor ETF (Symbol: QVML) where we have detected an approximate $141.8 million dollar outflow -- that's a 13.9% decrease week over week (from 42,050,000 to 36,200,000). For a complete list of holdings, visit the QVML Holdings page » The chart below shows the one year price performance of QVML, versus its 200 day moving average: Looking at the chart above, QVML's low point in its 52 week range is $21.3219 per share, with $26.8318 as the 52 week high point — that compares with a last trade of $24.33. |
31097.0 | 2023-04-02 00:00:00 UTC | 3 Dividend-Growth Stocks to Buy in April That Can Crush Inflation | ABT | https://www.nasdaq.com/articles/3-dividend-growth-stocks-to-buy-in-april-that-can-crush-inflation | nan | nan | It isn't just your imagination: Day-to-day expenses are climbing. In February, the Consumer Price Index was up 6% over the previous year.
You don't need to be an economist to understand inflation's effect on income-generating stock portfolios. If prices consistently rise faster than the dividends you receive, your passive income stream could get squeezed down to a tiny trickle by the time you retire.
If you're worried about how inflation could affect your future stream of passive income, consider these healthcare stocks.
COMPANY DIVIDEND YIELD DIVIDEND GROWTH (5 YEARS) DIVIDEND GROWTH (10 YEARS)
CVS Health 3.2% 21% 169%
Abbott Laboratories 2.1% 82% 264%
UnitedHealth Group 1.4% 83% 489%
Data source: Yahoo! Finance.
All three have a history of meeting and raising their payouts much faster than inflation. Read on to see why there's a good chance they can keep cranking their dividends higher in the years ahead.
CVS Health
You're probably familiar with CVS Health's (NYSE: CVS) enormous chain of retail pharmacies, but there's a lot more to this business. In 2018, it pulled off a $78 billion merger with health insurance benefits provider Aetna.
Aetna wasn't CVS Health's first foray into benefits management, either. The company's pharmacy benefits management business is America's largest, with 110 million plan members.
CVS Health probably doesn't show up when you screen for dividend growth stocks because it froze its payout for a few years to help pay down debt from the Aetna merger. Clearly, the merger has been successful. The company has raised its dividend commitment by 21% since Dec. 10, 2021.
Americans spent $4.3 trillion on healthcare in 2021. While high prescription drug prices get a lot of attention, CVS Health understands that spending on physician and clinical services is more than double prescription drug spending.
To help retain a larger portion of the monthly premiums it collects from around 35 million people, it's becoming a leading provider of the health insurance benefits it's paid to manage. The recent acquisition of Signify Health will add 10,000 clinicians to its employee roster. With the ability to provide more of the benefits it is also paid to manage, shareholders can look forward to big dividend raises for many years.
UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is America's largest manager of health insurance benefits. It receives premiums from around 48 million Americans each month and is improving at managing healthcare expenses by pursuing a vertical integration plan very similar to CVS Health.
UnitedHealth Group's Optum Health segment is one of the country's largest employers of health practitioners. Around 70,000 physicians working in more than 2,200 locations are currently employed by or aligned with Optum Health.
Despite rapidly raising its payout, the company needed just 25.6% of the free cash flow it generated over the past year to meet its dividend obligation. There are no guarantees that UnitedHealth will be able to raise its payout another 489% in the coming decade, but we can reasonably expect some big bumps in the right direction over the next few years.
Abbott Laboratories
If health insurance benefits managers aren't your style, consider Abbott Laboratories (NYSE: ABT). This healthcare conglomerate has raised its dividend payout for 60 consecutive years with help from increasing sales of tangible products and diagnostics.
Abbott's nutrition segment gained a lot of attention last year after the temporary closure of a single manufacturing site led to a national baby formula shortage. Diagnostics sales declined in the fourth quarter due to rapidly receding demand for COVID tests, too. Despite unprecedented challenges for two of its operating segments, annual revenue climbed 6.4% last year once adjusted for the negative effects of a stronger U.S. dollar.
Abbott's raised its payout at a pace that crushes inflation, with help from a medical device segment that keeps launching successful new products. Last May, the U.S. Food and Drug Administration (FDA) cleared FreeStyle Libre 3, the company's next-generation constant blood-glucose monitor. In January, the FDA approved Abbott's new replacement heart valve system.
With plenty of new growth drivers to push profits in the right direction, patient investors can look forward to many more years of rapidly growing dividends from this stock.
10 stocks we like better than CVS Health
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and CVS Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 8, 2023
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories If health insurance benefits managers aren't your style, consider Abbott Laboratories (NYSE: ABT). To help retain a larger portion of the monthly premiums it collects from around 35 million people, it's becoming a leading provider of the health insurance benefits it's paid to manage. It receives premiums from around 48 million Americans each month and is improving at managing healthcare expenses by pursuing a vertical integration plan very similar to CVS Health. | Abbott Laboratories If health insurance benefits managers aren't your style, consider Abbott Laboratories (NYSE: ABT). The company's pharmacy benefits management business is America's largest, with 110 million plan members. While high prescription drug prices get a lot of attention, CVS Health understands that spending on physician and clinical services is more than double prescription drug spending. | Abbott Laboratories If health insurance benefits managers aren't your style, consider Abbott Laboratories (NYSE: ABT). CVS Health You're probably familiar with CVS Health's (NYSE: CVS) enormous chain of retail pharmacies, but there's a lot more to this business. CVS Health probably doesn't show up when you screen for dividend growth stocks because it froze its payout for a few years to help pay down debt from the Aetna merger. | Abbott Laboratories If health insurance benefits managers aren't your style, consider Abbott Laboratories (NYSE: ABT). All three have a history of meeting and raising their payouts much faster than inflation. Aetna wasn't CVS Health's first foray into benefits management, either. |
31098.0 | 2023-04-01 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-5 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31099.0 | 2023-03-31 00:00:00 UTC | Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval | ABT | https://www.nasdaq.com/articles/abbotts-abt-epic-max-tissue-valve-receives-fda-approval | nan | nan | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. The new valve is intended to preserve and simplify future options for patients to manage their heart valve disease.
The latest regulatory clearance is expected to significantly boost Abbott’s structural heart business of the broader Medical Devices segment.
About Epic Max Tissue Valve
Epic Max is developed to achieve excellent hemodynamics or blood flow. Its low-profile frame enables potential future transcatheter interventions for patients. This new valve is built on the Epic surgical valve platform, utilizing its long-term performance and durability.
This device is the newest addition to Abbott's Epic surgical valve platform, which has trusted safety and strong clinical outcomes, with an optimized design to enhance valve blood flow.
Benefits of Epic Max Tissue Valve
The aortic valve is one of the heart valves most commonly impacted by cardiovascular disease, frequently requiring replacement. Per management, Abbott's Epic Max design optimizes blood flow for patients and has a low profile that makes future cardiac interventions simpler.
Image Source: Zacks Investment Research
It is worth mentioning that when the aortic valve doesn't close properly or fails to fully open, the heart doesn’t pump blood efficiently and flow to the body is reduced. If left untreated, aortic valve disease can lead to heart failure, stroke, blood clots or death. Bioprosthetic valves like Epic Max are suggested for patients who require valve replacement and aren't suitable for taking blood-thinning medication.
Progress Within Structural Heart Space
This month, Abbott announced favorable findings on remote pressure monitoring. This study result was presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. The data revealed that monitoring patients remotely with hemodynamic pressure sensing technology can significantly improve the survival rate of heart failure patients with reduced ejection fraction (HFrEF).
The same month, Abbott announced significant progress with Navitor, the company’s latest-generation transcatheter aortic valve implantation (TAVI) system. The company announced late-breaking data for Navitor during presentations at the annual Cardiovascular Research Technologies (CRT) meeting held in Washington, D.C. (Feb 25-28, 2023).
Results from this study supported Navitor's recent FDA approval to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Industry Prospects
Per a report by Allied Market Research, the global TAVI market was valued at $4,559 million in 2020 and is anticipated to reach $16,937 million by 2030 at a CAGR of 14%. Factors like the increase in the prevalence of aortic stenosis, rise in demand for various TAVI procedures and rise in the elderly population are likely to drive the market.
Given the market potential, the latest regulatory clearance is expected to strengthen Abbott's global structural heart business.
Price Performance
Shares of the company have gained 4.2% in a year against the industry’s fall of 9.6%.
Zacks Rank and Key Picks
Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hologic, Inc. HOLX, Henry Schein, Inc. HSIC and Avanos Medical, Inc. AVNS.
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 15.2%. HOLX’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 30.6%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has gained 1.7% against the industry’s 17.5% growth in the past year.
Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 8.1%. HSIC’s earnings surpassed estimates in three of the trailing four quarters and matched the same in the other, the average beat being 2.9%.
Henry Schein has lost 12.4% compared with the industry’s 10.9% decline in the past year.
Avanos, carrying a Zacks Rank #2 at present, has an estimated growth rate of 1.8% for 2023. AVNS’ earnings surpassed estimates in all the trailing four quarters, the average beat being 11%.
Avanos has lost 13.7% compared with the industry’s 17.5% decline in the past year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research It is worth mentioning that when the aortic valve doesn't close properly or fails to fully open, the heart doesn’t pump blood efficiently and flow to the body is reduced. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. Per management, Abbott's Epic Max design optimizes blood flow for patients and has a low profile that makes future cardiac interventions simpler. | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Benefits of Epic Max Tissue Valve The aortic valve is one of the heart valves most commonly impacted by cardiovascular disease, frequently requiring replacement. | Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Price Performance Shares of the company have gained 4.2% in a year against the industry’s fall of 9.6%. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.